The effect of antiretroviral treatment on HIV associated tuberculosis incidence and outcomes in the Free State Province, South Africa. by Timmerman, Venessa
 
 
 
 
 
The Effect of Antiretroviral Treatment on  
HIV Associated Tuberculosis Incidence  
and Outcomes in the Free State Province, 
 South Africa 
 
 
Venessa Timmerman 
(TMMVAN001) 
 
 
Supervisors 
Dr. LR Fairall 
Prof. MO Bachmann 
 
 
Thesis Presented for the Degree of  
DOCTOR OF PHILOSOPHY 
in the Department of Medicine, Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
February 2013 
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
2 
ABSTRACT 
Background:  Of people co-infected with HIV and tuberculosis (TB) globally, 79% are in Sub-
Saharan Africa. While scale-up of antiretroviral treatment (ART) is reducing mortality in the 
region, there is little direct evidence of the magnitude of its effect on mortality in people co-
infected with TB, or on TB treatment outcomes.  There is little evidence on the effect of ART on 
TB incidence in HIV positive people in South Africa, which has most HIV-TB cases in the 
region. 
Methods:  The study population was a cohort of all patients aged ≥16 years enrolled with the 
public-sector ART programme in the Free State province of South Africa during the first six 
years (2004-2010). Cohort data were linked between the HIV and TB programmes, laboratory 
and hospital services and the national population register. Various multiple regression models 
estimated the effects of ART on time to TB and incidence of TB episodes in all HIV-positive 
patients (n=74 075) and, in subsets of co-infected patients, estimated the effects of ART on 
mortality (n=10 498) and TB treatment outcomes (n=9 276). The analyses compared outcomes 
during person-time with and without ART, adjusting for patient-level confounders, with multiple 
imputation of missing CD4 counts and weights. 
Results:  ART was independently associated with a lower hazard of time to TB (sub-distribution 
hazard ratio 0.64, 95% confidence interval (CI) 0.61-0.67), lower incidence of TB episodes 
(incidence rate ratio 0.66, 95% CI 0.64-0.69), lower  hazard of time to death after TB diagnosis 
(hazard ratio 0.53, 95% CI 0.47-0.61), and higher odds of successful TB treatment outcome 
(odds ratio 3.25, 95% CI 2.62-4.06). 
Conclusion:  ART was effective at reducing the risk of TB in HIV-positive adults and is thus an 
important part of TB control. It also reduced mortality in co-infected adults, supporting recent 
policy changes to make it available to all irrespective of CD4 counts.  However more research is 
needed to understand better the causes of high mortality in co-infected patients. 
 
V. Timmerman        February 2013  
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1. INTRODUCTION 
1.1. Background: The “Syndemic” of infection with HIV and tuberculosis in South 
Africa 
The work reported in this thesis focuses on the “syndemic” of Tuberculosis (TB) and human 
immunodeficiency virus (HIV) infection in South Africa, a health disaster of major proportions 
that over the last three decades has dominated the medical agendas for the countries of Sub-
Saharan Africa and overwhelmed the health resources of these countries.  The term “syndemic” 
highlights the fact that their combined negative effects on the health of nations is not additive but 
synergistic.  The presence of HIV has reversed gains made in combating TB over the previous 
half century (since the introduction of effective TB therapy) and resulted in dramatic increases in 
the incidence and mortality from this disease.  TB, in turn, has greatly increased the pace of 
development, morbidity and mortality of infection with HIV.  The mechanisms of interaction of 
these “terrible twins” have been extensively studied.  But, perhaps more importantly, their 
interaction has demanded a scrutiny of TB control programmes, and the need for reorganisation 
of health services at every level to jointly address these problems through systems of integrated 
care.  Central to such programmes is understanding the impact of effective treatment of each on 
the prognosis of patients with co-infection, and on the spread of disease in communities.  This 
thesis provides insights on these and other questions through analysis of a dataset from carefully 
documented cohorts of patients receiving care for TB or HIV (or both) in the state-run health 
services in the Free State province of South Africa for a 6-year period, from the time of the 
antiretroviral (ART) roll-out (2004).  However, in order to appreciate the importance of this 
work, it is appropriate to review the nature, size and historical health system responses to this 
“syndemic”.  
1.1.1. HIV in Sub-Saharan Africa. 
As the world enters the 30th year of the Acquired Immunodeficiency Syndrome (AIDS) epidemic, 
figures are still alarmingly high;  34 million people were living with HIV at the end of 2011, an 
overall global prevalence of 0.8%, and 2.5 million people were newly infected with HIV during 
that year (UNAIDS Global report 2012).  In recent years, most high burden countries have seen 
a decline in new HIV infections, but in the Middle East, North Africa, Eastern Europe and 
Central Asia an increase in HIV incidence has been reported.  The rapid large-scale rollout of 
17 
antiretroviral therapy (ART) has saved an estimated 14 million life years in low and middle 
income countries.   By 2011, more than 8 million HIV positive patients had started ART and 1.7 
million deaths from AIDS related causes were reported globally - 24 % fewer than in 2005 
(UNAIDS Global report 2012).   
Sub-Saharan Africa is the most heavily affected region, representing 69% of all HIV positive 
people (23.5 million in 2011), 92% of HIV positive pregnant women, and 90% of children 
diagnosed with HIV.   Concerted efforts to prevent infection has led to a 25% decline in new 
HIV infections between 2001 and 2011, which numbered 1.8 million in 2011 (Figure 1).  ART 
coverage has also improved substantially since 2005 (Figure 2).  An estimated 56% of eligible 
patients were receiving ART by 2011, ranging from countries who achieved ART initiation in 
more than 80% of eligible patients (including five countries in the Sub-Saharan Africa  
Botswana, Namibia, Rwanda, Swaziland, Zambia) to suboptimal performers (40% to 79% ART 
coverage for other Africa countries like Lesotho, Mosambique, Malawi, Uganda, South Africa 
and Democratic Republic of Congo).   Although 70% of all people dying from AIDS-related 
causes are from the Sub-Saharan region, deaths declined by 32%, from 3.2 million in 2001 to 1.2 
million in 2011  (UNAIDS Global report 2012).  
 
Figure 1: Number of people newly infected with HIV, 2001–2011 (UNAIDS Global report, 2012) 
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Figure 2: Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 
2002–2011 (UNAIDS Global report, 2012) 
1.1.2. HIV/AIDS and South Africa 
South Africa is one of the most affected countries worldwide.  In 2011, it accounted for 16% 
(5.36 million) of the worldwide HIV burden while its population represented only 0.7% of the 
world’s population (UNAIDS global report 2012; Stats SA July 2007).  Fifty eight percent 
(approximately 3 million) of affected persons were women and 6% were children, aged 0-14 
years (334 000).  The national prevalence was estimated in 2011 by an UNAIDS SPECTRUM 
model to be 17.3% in the general adult population (15-49 years), while the National Antenatal 
Sentinel Survey Report of 2012 estimated prevalence at 29% among antenatal women, with 
significant regional differences ranging from 4.75% in the Western Cape to 24.1% in KwaZulu-
Natal.  In the Free State Province, from where data for this thesis were drawn, the antenatal 
prevalence in 2011 was found to be 19.58%.  (National Department of Health (NDOH) 2012 
Antenatal Sentinel Survey Report; UNGASS Global AIDS Response Progress Response 2012: 
Republic of South Africa).  Although the HIV prevalence rate has plateaued, it is at a high level 
of nearly 30% and the HIV epidemic is continuing.  It was estimated that the number of new 
infections in 2011 was 1.43%, which is slightly lower than the 1.63% new infections in 2008.  
HIV incidence is exceptionally high compared to other Sub-Saharan countries.  (National 
Department of Health 2011 National Antenatal prevalence survey; NDOH National Strategic 
Plan 2012-2016; UNAIDS HIV epidemic report. 2010). 
South Africa has implemented one of the world’s largest HIV treatment programmes during the 
past few years, with treatment access scaled-up by 75% between 2009 and 2011 as displayed in 
Figure 3 (UNAIDS global report, 2012).  This rapid scale up made it possible to treat 2 million 
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people by October 2012, which is 80% of all those in need of treatment, reaching the target of 
universal access to treatment (Irin News 9 October 2012, Report 94365: ‘SOUTH AFRICA: 
Revamped AIDS council makes its debut’).  One of the benefits of good ART coverage in 
communities was shown by a prospective cohort study from Hlabisa sub-district in KwaZulu-
Natal which found that the risk of acquiring HIV infection was 38% lower (aHR = 0.62, CI: 
0.50-0.76)  in communities with high ART coverage (30-40%) compared to low ART coverage 
(<10%) communities (Tanser F et al., 2013).   Mortality is also starting to decrease due to 
improved ART coverage.  An estimated 270 190 South Africans died of AIDS related causes in 
2011, placing South Africa in the 25-49% death reduction category of deaths that occurred 
between 2005 and 2011, and increased the country’s life expectancy by five years. (UNAIDS 
global report 2012; Mayosi BM et al., 2012). 
 
Figure 3: ART scale-up vs. AIDS deaths for South Africa (From UNAIDS 2012 country specific report) 
1.1.3. Expansion of ART services in South Africa 
Staging of HIV infection and patients’ need for ART is based on both clinical manifestations of 
infection, and an assessment of state of immuno-compromisation, for which measurement of 
CD4 lymphocytes is the most useful marker. 
In November 2003 the South African cabinet approved a national plan for HIV/AIDS prevention, 
care and treatment.  ART guidelines were based on the World Health Organisation (WHO) 
recommendations (National ART Guidelines, National Department of Health 2004; National 
Department of Health Strategic Plan 2000-2005).  Adults were eligible for ART when their CD4 
count fell below 200 cells/µL and/or they presented with WHO Stage 4 disease. The cabinet 
originally estimated that 53 000 people would be using ART by the end of March 2004.  The 
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target was revised in March 2005, owing to delays in the rollout.  In July 2004, some eight 
months after the rollout started, the Treatment Action Campaign (TAC) organised a symposium 
to establish a review of the current state of the rollout in South Africa and strategies for 
increasing access to treatment.  It was established that only 6 000 patients were on ART (of the 
estimated 53 000 who required it).  The major reasons for the slow progress in the early phases 
of the roll out included shortage of qualified doctors, nurses, pharmacists, and counsellors 
(human resources problem), high prices of drugs and difficulties with their procurement, lack of 
transparency of government in informing stake-holders of issues requiring attention, logistical 
problems for example adequate safe storage for drugs, and lack of electronic systems at sites for 
monitoring treatment and outcomes (Schneider H et al., 2006;  Steyn F et al., 2006). 
The HIV treatment programme was also affected by structural problems within the government 
health sector; care in clinics being organized in “vertical” programmes, and overly strict 
accreditation system for clinics and hospitals to provide ART.  Consequently HIV treatment and 
care was only accessible at certain clinics, and it was not integrated into primary health care 
facilities (referred to as horizontal or integrated approach) and only a small proportion of doctors 
were authorised to prescribe ART.  HIV positive patients had to be referred to an ART facility 
where a registered ART nurse or doctor would assess their eligibility for ART.  This vertical 
model placed pressure on an already straining health care system, diverting staff from other 
primary care facilities (Steyn F. et al., 2006), and causing heavy additional workloads since 
patients on ART need close monitoring and frequent visits.   
Between 2007 and 2011, a revised National Strategic Plan for HIV/AIDS and sexually 
transmitted infections (National Strategic plan 2007, released by National Department of Health 
on 14 March 2007) was in operation.  Three specific goals were to reduce the number of HIV 
infections, to reduce the impact of the epidemic on individuals, families, and communities by 
expanding access to individuals for treatment care and support, and to reduce mother-to-child 
transmission.  In addition, in 2010,  the new national minister of health, Dr. Aaron Motsoaledi, 
usher in several key changes to further accelerate access to treatment including, a mass 
campaign to test 15 million South Africans for HIV, the scrapping of stringent accreditation 
criteria for sites providing treatment, the extension of prescribing authority to trained nurses, and 
the revision of eligibility criteria for starting treatment.  These revised criteria made it possible 
for all TB patients and pregnant women with a CD4 count of less than 350 cells/µl to receive 
ART.  In 2011 eligibility criteria were expanded again, making provision for ART for TB 
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patients regardless of CD4 count and raising the CD4 count threshold to350 cells/µl for all other 
HIV positive adults.  
Despite all these efforts, the targets for the number of people on ART have not been met during 
the first few years of the programme.  After the initial stumbling blocks the HIV programme had 
to overcome, the programme is still faced with a number of significant limitations; high staff 
vacancies in clinics, inadequate budget allocation for primary care, the vertical service model 
(Uebel KE et al., 2010), and long patient waiting times for initiation of ART (Ingle SM et al., 
2010).  The slow pace of rollout has not kept pace with targets or the demand for ART resulting 
in accumulation of the number of patients waiting for ART initiation.  This is illustrated by the 
figures from the Free State Province as seen in the graph below (Figure 4). 
 
Figure 4: Monthly new enrolments (2004-2007) plotted against need and goals as envisaged in the National 
Strategic Plan 2008 and 2009 (From Uebel KE et al., 2010) 
A new National Strategic Plan (NSP) for the period 2012-2016 was released in November 2011 
(NDOH: National Strategic Plan 2012-2016) and raised the treatment target from 80% to 90% of 
those that need ART, addressing Target 6B (Achieve universal access to treatment for 
HIV/AIDS for all those who need it by 2015) of the Millennium Development Goals number 6 
(WHO Millennium Development Goals, 2012, see Figure 5).  
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Figure 5: Millennium Development Goals (MDG) and the details of MDG 6, Stop TB targets, and WHO 
health strategy and targets launched in 2010. 
In a further attempt to address target 6A, which is to have reduce mortality related to HIV by 
25%, and halted and reversed the spread of HIV/AIDS by 2015, some of the National Strategic 
plan’s goals include the following: to reduce new HIV infections in children by 90% by 2016, 
improve life expectancy by five years for men and women by 2016.  Some of the key 
interventions proposed in the NSP 2012-2016 include: HIV testing and TB screening for all 
The Millennium Development Goals (MDGs) are eight international development goals that were 
officially established following the Millennium Summit of the United Nations in 2000, whereby all 193 
United Nations member states have agreed to achieve these goals by the year 2015.  MDG number 6 is 
to Combat HIV/AIDS, malaria, and other diseases. 
 
The targets set for 2015 by this goal include:  
 
Target 6A: Halt and begin to reverse the spread of HIV/AIDS 
Target 6B: Achieve, by 2010, universal access to treatment for HIV/AIDS for all those in need. 
Target 6C: Halt and begin to reverse the incidence of malaria and other major diseases 
  
Stop TB partnership targets set for 2015 and 2050:  
By 2015:  Reduce prevalence and death rates by 50%,compared with their levels in 1990  
By 2050: Reduce the global incidence of active TB cases to <1 case per 1 million population 
per year 
WHO Health Strategy on HIV launched in 2010: 
• Optimise HIV prevention, treatment and care outcomes. 
• Leverage broader health outcomes through HIV responses: Strengthen links between HIV 
programmes and other health programmes 
• Build stronger and sustainable systems. 
• Reduce vulnerabilities and remove structural barriers to accessing services. 
 
 WHO 2015 Targets 
• Reduce new infections: reduce by 50% the percentage of young people aged 15–24 years who 
are infected (compared with a 2009 baseline) 
• Eliminate new HIV infections in children: reduce new HIV infections in children by 90% 
(compared with a 2009 baseline) 
• Reduce HIV-related mortality: reduce HIV-related deaths by 25% (compared with a 2009 
baseline) 
• Reduce tuberculosis-related mortality: reduce tuberculosis deaths by 50% (compared with a 
2004 baseline). 
 
Source:  WHO Global TB report, 2012;  UN Millennium goals; WHO Health Strategy 
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South Africans (12 and older) on an annual basis for those with unknown status, or previously 
tested HIV negative (improved case finding), early diagnosis of HIV and TB, early treatment for 
HIV and TB, and taking biomedical and behavioural prevention interventions.   
The 2012-2016 NSP recognised that the centralised ART model, where only selected facilities 
provided ART, made it difficult to refer co-infected patients from decentralised TB services 
when they required concomitant treatment for both conditions.  Since 2010 the Department of 
Health started to decentralise ART initiation to primary health care, which was also supported by 
a randomised trial in the Free State to assess task shifting of ART prescription to nurses (Fairall 
LR et al., 2012, Uebel KE et al., 2010; DOH NSP 2012-2016) 
1.2. Tuberculosis in South Africa and co-infection with HIV 
WHO reports major progress in the reduction of TB cases and deaths in the past two decades 
(WHO Global TB report, 2012 and WHO TB fact sheet, 2012).  Although the MDG to halt and 
reverse the TB epidemic by 2015 has been achieved (new cases of TB have been falling and fell 
at a rate of 2.2% in 2011), they caution that the global burden of TB remains enormous.  It is 
estimated that there were 8.7 million people who fell ill with TB in 2011, of which 13% 
(1.1 million) were co-infected with HIV and 5.8 million were newly diagnosed cases (two thirds).  
It remains the second highest global killer due to a single infectious agent (second to HIV/AIDS), 
with an estimated 1.4 million deaths reported in 2011, 990 000 deaths among HIV-negative and 
430 000 among HIV-positive patients.  Geographically the burden of TB is highest in Asia and 
Africa.  Approximately one quarter of the world’s cases occur in the African region (Figure 6), 
and Africa shows the highest rates of cases and deaths relative to population, presumably as part 
of its HIV epidemic. 
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Figure 6: Global  trends in estimated rates of TB incidence.  Global trends in estimated incidence rate 
including HIV-positive TB (Green) and estimated incidence rate of HIV-postive TB (Red).  From WHO 
Global TB report, 2012. 
The risk of developing TB is estimated to be 20-37 times greater in people living with HIV than 
among those without HIV infection (WHO TB and HIV).  It is well-known that HIV positive 
patients have a dramatically increased risk of TB infection, either as a result of primary 
progression or reactivation of latent infection (Manosuthi W et al., 2006) although the 
importance of re-infection in high prevalence settings is now recognised.  The association 
between HIV and TB has been shown to be strongly associated with CD4 cell recovery during 
ART in South Africa (Lawn SD et al., 2009a).  The incidence of TB is markedly reduced in 
persons receiving ART (Girardi E et al., 2012), and delaying ART increases the risk of both TB 
and also other opportunistic infections. The HPTN 052 trial done in sero-discordant couples to 
evaluate HIV-1 transmission to a HIV negative partner, reported that early ART (started when 
CD4 count was between 350 and 500) vs. delayed ART (CD4<250) reduced the risk by 89% 
(HR 0.11 CI: 0.04-0.32), and early ART was also associated with a 41% (HR 0.59 CI: 0.40-0.88) 
reduction in clinical events (mainly due to extra-pulmonary TB) in the HIV-infected partner 
(Cohen MS et al., 2011).  A mathematical model based on data from nine countries in Sub-
Saharan Africa showed that the earlier ART is started after sero-conversion the more TB 
incidence will be reduced, e.g. when ART is started 5 years after HIV sero-conversion TB 
incidence in 2050 will be reduced by 66% while ART started 1 year after HIV sero-conversion 
will reduce TB incidence by 97% (Williams BG et al., 2010).   The proportion of TB patients 
co-infected with TB was overall 39% for the Sub-Saharan Africa region, contributing 79% of 
global TB-HIV co-infection cases due to its high HIV prevalence (WHO TB fact sheet, 2012).  
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The HIV epidemic is  stabilising in terms of the number of new cases reported, and TB incidence 
rate was 3.1% lower in 2011 than in 2010 for the Africa region.  However, the decline is still 
slow.  This is attributable to the fact that the risk of TB is high even in the early stages of HIV 
infection, when the risk of other opportunistic infections is still low (i.e. CD4 counts of 350 to 
500 cells/µl) (Houlihan CF et al., 2009).  Peak ages for TB are the same as for HIV; women in 
their twenties and men in their thirties (Lawn S.D. et al, 2006).  Patients contracting both TB and 
HIV (TB-HIV co-infection) are a major concern for South Africa with an incidence rate of 650 
TB cases/100 000 for co-infected HIV-TB patients in 2011 (WHO TB South Africa, 2012). 
In 2006 WHO ranked South Africa’s TB burden as fourth highest in the world (WHO Global TB 
Report, 2009).  By 2011 it still remained among the top five countries with the largest number of 
incident cases (WHO Global TB report, 2012).  The TB notification rate increased fourfold 
between 1986 and 2006 from 163 cases/100 000 population to 628 cases/100 000 population 
(NDOH Report 2007: TB Strategic Plan for South Africa, 2007–2011).  By 2011, over 900 cases 
per 100 000 population were reported (WHO TB South Africa, 2012).  This dramatic increase in 
South Africa’s TB caseload is shown in Figure 7.  
 
Figure 7: Incidence of TB (per hundred thousand people) in South Africa (from World Bank report, 2012) 
In 2011, new cases of TB in South Africa approximated 325 321 (343 715 is the total) of which 
only 40% were smear positive cases (Table 1).  The relatively low percentage of smear positive 
patients can potentially be attributed to co-infection of TB and HIV due to the atypical 
presentation of TB in co-infected patients (Jayasundera CI et al., 1993; Mahajan V et al., 2008).  
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Table 1: TB case notifications 2011 from the WHO global TB report, 2012 
 
Due to concerns about the high pill burden, IRIS (immune reconstitution inflammatory 
syndrome), drug-drug interactions and co-toxicities (Dean GL et al., 2002; Niemie M et al., 2003; 
Manosuthi W et al., 2010), earlier guidelines recommended that co-infected adults complete 
their TB treatment before starting ART (National Department of Health Antiretroviral Treatment 
Guidelines 2004), often resulting in delayed referral to ART programmes.  This delay left the 
large proportion of TB patients co-infected with HIV in the TB programme, without ready 
access to ART (66% not receiving ART, Table 2), contributing to mortality.   
The new NSP (2012-2016) aims at addressing the problem of delayed and small numbers of co-
infected patients initiated on ART in support of MDG 6 - Target 6c.  The NSP has set the 
country’s targets to increase TB cure rate to 85% by 2016, to reduce TB infections to 2010 levels 
by 2016, and to reduce mortality due to TB by 50%.  Interventions are planned to improve early 
diagnosis and treatment of TB and reducing vulnerability to TB infection.  These interventions 
to prevent TB infection through intensified case-finding of TB are critical to have reduced and 
reversed the spread of TB and TB related mortality by 50% in 2015 (WHO Global Health 
Observatory).  Restructuring of the primary health care service platform is a priority to ensure 
that HIV and TB services are fully integrated at all levels of responsibility and implementation, 
and that the TB and HIV programmes are incorporated integrated development plans (NDOH 
NSP 2012-2016). 
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Table 2: Co-infected HIV/TB patients during 2011 from WHO global TB report, 2012 
 
Despite all the difficulties in implementing ART and delayed treatment in co-infected HIV-TB 
patients, the WHO Global TB report shows that since 2002, ART coverage has increased, 
incidence and prevalence have stabilised, mortality is stabilising (unfortunately excluding 
figures on HIV positive patients with TB), and treatment success rate has increased (Figure 8). 
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Figure 8: Graphical presentation of ART coverage, incidence and prevalence of TB, mortality (excluding 
HIV positive and TB), and treatment success in South Africa during 2011 (from WHO Country specific 
report, 2012) 
1.3. Management of HIV and TB 
Despite the potential availability of affordable medications, there remains a large number of 
avoidable deaths and co-morbidity in co-infected HIV-TB patients, especially in Africa 
(UNAIDS global report, 2010).  Only 42% of the nine million people in need of ART treatment 
globally were receiving it in 2010 (UNAIDS, Aids at 30, 2011). WHO has recognised that the 
DOT (directly observed treatment) strategy alone is not able to reduce the prevalence and 
incidence of TB in high HIV burden settings  (De Cock KM and Chaisson RE, 1999), and in 
2008 recommended the Three I’s strategy: intensified case-finding, isoniazid preventive therapy 
(IPT) and TB infection control (WHO for IPT, 2011). 
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Since 1993 WHO has recommended the use of isoniazid as a therapy for preventing TB in adults 
with HIV (WHO preventative therapy policy, 1998).  Yet, only a small proportion of patients 
received IPT according to the WHO Global TB control report, 2012.  South Africa was the top 
country in prescribing IPT during 2011, with 373 000 HIV positive patients without active TB 
receiving IPT (WHO global TB report, 2012). The reasons for poor implementation of IPT are 
complex (Lawn SD et al., 2010).  IPT should only be prescribed in patients without active TB 
therefore one of the main reasons for the low uptake of IPT is the process of IPT screening, 
tuberculin skin test (TST), to assess eligibility for IPT (Kerkhoff AD et al., 2012). The WHO 
revised their  IPT guidelines  in 2011 and made an explicit recommendation that TST is not a 
requirement for initiation of IPT in HIV positive people (WHO for IPT, 2011).  A meta-analysis 
of placebo-controlled trials reported that IPT was effective in reducing the risk of active TB by 
32% (RR 0.68 CI: 0.54-0.85), however IPT was not associated with a reduction in all-cause 
mortality (Akolo C et al., 2010).  Observational studies (Fenner L et al., 2011; Charalambous S 
et al., 2010; Golub JE et al., 2009) and a clinical trial (Durovni B et al., 2010) have shown that 
the risk of TB and mortality was reduced with the combined effect of IPT and ART, while the 
results from two ongoing trials are eagerly awaited (NCT00495651 and NCT00463086) to 
assess the synergy between ART and IPT. 
Cotrimoxazole can be used as a prophylactic treatment due to its wide range of action against 
common infectious agents.  It is cheap and widely available but there are concerns about the 
possibility of increased drug resistance since it is shares a component with drugs commonly used 
for Malaria.  Since patients co-infected with TB-HIV have higher death rates than those infected 
with either TB or HIV on its own (Colebunders RL et al., 1989; De Cock KM et al., 1992; 
Perriens JH et al., 1995), information on the effect of cotrimoxazole prophylaxis in patients with 
both infections are needed.  A Cochrane review published in 2009 (Grimwade K and 
Swindler GH, 2009) identified four placebo controlled trials and reported that cotrimoxazole 
appears to be effective in preventing death and illnesses in HIV infected patients.  However, 
insufficient evidence existed in people without TB and they recommended that studies needs to 
be conducted to evaluate the cost-effectiveness of this intervention.  A systematic review and 
meta analysis by Suthar and colleagues (2012a) found that cotrimoxazole therapy, an additional 
preventative therapy, also increased survival significantly in HIV-infected adults on ART, not 
limited to co-infected HIV-TB patients.  There was no publication bias but high heterogeneity in 
study results, and most of the studies followed patients for less than one year.  Therefore more 
research is needed to determine the optimal duration of treatment, which is currently evaluated 
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by a trial in Uganda, testing the hypothesis of stopping cotrimoxazole in adults on ART will not 
increase morbidity or mortality and decrease haematological adverse events (Suthar AB et al., 
2012a; Trial ISRCTN44723643). 
1.3.1. The effect of ART on TB incidence in people with HIV 
The most comprehensive meta-analysis to date examining the impact of ART on TB incidence 
included eleven studies from developing country settings, of which four were from Sub-Saharan 
Africa, and one from a combination of regions including Sub-Saharan Africa (Suthar AB et al., 
2012b).  The main finding of this analysis was that ART is strongly associated with reducing 
risk of TB in adults living with HIV (HR 0.35, 95% CI 0.28 to 0.44).  The meta-analysis was 
also the first to examine the effect of ART on TB incidence in categories defined by the CD4 
count at the time of ART initiation.  It reported dramatic reductions in all CD4 strata: HR 0.16, 
(95% CI 0.07 to 0.36) in patients with CD4 less than 200 cells/µL at initiation; HR 0.34, 95% 
(CI 0.19 to 0.60) in patients with CD4 between 200 and 350 cells/µL at initiation, and in those 
with CD4 counts of more than 350 cells/µL at initiation HR 0.43 (95% CI 0.30 to 0.63).  This 
meta-analysis is important because it highlights the role ART could play in TB control in high 
HIV burden settings.  Further, the finding of a preventative effect of ART on TB incidence in 
patients with CD4 counts of more than 350 cells/µl lends weight to arguments supporting earlier 
initiation of ART.  
One multi-cohort study that missed the date cut-off for inclusion in the Suthar review, analysed 
the incidence of TB during pre-ART and ART periods from eight large HIV programmes in six 
countries in the Sub-Saharan region (Nicholas S et al., 2011).  The incidence rates reported were 
consistent with other studies which also showed that the incidence of TB decreases with starting 
ART (Brinkhof MW et al., 2007; Moore D et al., 2007).  These findings were consistent with 
previously published studies that found that immuno-compromised patients were more at risk 
(Lawn SD et al., 2005a & 2006).   Importantly, a study by Pettit and colleagues (2011) in low 
TB incidence setting found that ART reduced the risk of TB, especially when ART was initiated 
during first six months of ART compared to later.  However, after they adjusted for the most 
recent CD4 count with marginal structural models, the risk of TB did not remain elevated during 
the first six months of ART compared to not receiving ART, as it was in the crude model.  This 
suggested that the elevated risk of TB during the six month period was related (at least in part) to 
low CD4 cell counts (Pettit AC et al., 2011). 
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In a collaborative study between researchers in Europe and the United States, data from 12 
cohorts were evaluated for the effect of ART on TB incidence in high income countries (HIV 
Causal Collaboration, 2012).  A total of 65 112 patients started ART between 1997 and 2006 of 
which 712 (1.09%) were diagnosed with TB (the incidence rate was 0.3/100 py).  Marginal 
structural models were used to compare patients receiving ART and those not yet receiving ART.  
ART was effective in reducing the risk of TB by 44% (HR 0.56 CI: 0.44-0.72) when compared 
to patients not receiving ART.  However, the risk of TB was not reduced by ART in patients 
with a CD4<50 cells/µl. 
Data from a South African cohort also showed dramatic reductions in the risk of TB associated 
with starting ART (Fairall LR et al., 2008).  In that study, patients  (n=14 267) from the Free 
State HIV programme were followed up for 20 months by the end of 2005.  The incidence of TB 
15.08/100 py for patients with a CD4 count below 200 cells/µl and not receiving ART and 
5.85/100 py for those receiving ART.  Crude incidence rate ratios indicated that ART was highly 
effective in preventing TB in the CD4<200 cells/µl stratum, IRR 0.39 CI: 0.31-0.48, while the 
overall crude incidence rate ratio associated with ART was IRR 0.61 CI: 0.49-0.75.  Using a 
marginal structural model and adjusting for baseline variables and time-varying covariates 
(months on ART, CD4 and weight results), the risk of developing TB was reduced by 39% (HR 
0.61 CI: 0.46-0.81) overall, and by 33% in the CD4<200 cells/µl stratum (HR 0.67 CI: 0.50-
0.89).  
There is consistent evidence from observational studies that TB incidence during the first few 
months of ART is higher than in later years of treatment (Girarde E et al., 2005; Lawn SD et al., 
2005a; Bonnet MM et al., 2006; Brinkhof MW et al., 2007; Rajesekaran S et al., 2009; 
Dembele M et al., 2010; Van Rie A et al., 2011).  Higher incidence during the first few months 
of treatment has been attributed to Immune Reconstitution Inflammatory Syndrome (IRIS) and 
the unmasking of subclinical TB during initial restoration of the immune system (Dhasmana DJ 
et al., 2008; Meintjies G et al., 2008; Lawn SD et al., 2008 and 2009c), and also the increased 
risk of infection before the CD4 count rises.   
While the risk of TB declines with cumulative time on ART, it never reaches the normal 
background rate of TB.  A cohort study at Thembalethu clinic in Johannesburg assessed TB 
incidence in patients receiving ART between 2004 and 2007 (Van Rie A et al., 2011).  The 
cumulative probability of TB on ART was a 10% risk of TB by the end of the fourth year, 
whereas the estimated lifetime risk of TB in HIV uninfected individuals is only 10% (Styblo K, 
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1985).  This is consistent with other studies which also found that TB incidence rate in ART 
patients stabilises above the estimated background levels of TB incidence (Gupta A et al., 2012, 
Hermans SM et al., 2010; Eshun-Wilson I et al., 2012), suggesting that ART is not able to 
restore the immune system completely (Jones JL et al., 2000; Brinkhof MW et al., 2007; Lawn 
SD et al 2009c; Lawn SD et al., 2005). 
While many studies have by now reported an association between ART and a reduction in TB 
incidence, relatively few have included a comparison of ART (3 drugs) vs. no drugs, which is 
necessary for a more reliable estimate of the effect of ART on TB incidence. The absence of a 
comparator group is a serious limitation of many studies, and is the reason given for why as 
many of 40 studies, or two thirds of studies identified, were not included in the Suthar meta-
analysis (Suthar AB et al., 2012b).  Further limitations in these analyses include failure to 
account for the competing risk of death and the effect of ART on multiple TB episodes.  
1.3.2. Effect of ART on mortality in people with HIV and TB 
Several studies have shown that HIV positive patients are more likely to die from TB than HIV 
uninfected TB patients (El Soni AI et al., 2002; Sarder N et al., 2006; Moolphate S et al., 2011).  
A recent study in Ethiopia evaluating the effect of HIV status on survival in TB patients 
attending a health centre between 2006 and 2010, confirmed that co-infected HIV positive TB 
patients were 60% more likely to die than un-infected HIV patients with TB (Shaweno D et al., 
2012).  A significant difference in the death rate was seen during the continuation phase, 
7.5 / 1 000 person months for HIV positive vs. 1.7 / 1 000 person months for HIV negative 
patients (p=0.003).  It was hypothesized that late presentation of patients might be a critical 
factor for early death in this cohort instead of just HIV infection itself since no difference in 
death was seen during the intensive phase of TB treatment.   
TB is a leading reported cause of death among HIV positive patients worldwide (WHO Interim 
policy 2004; Lopez-Gatell H et  al., 2008; Saraceni V et  al., 2008; Cain KP et  al., 2007; 
Etard JF et  al., 2006).  The impact of TB on HIV associated mortality may even be 
underestimated. The atypical clinical presentations of TB in HIV positive patients results in 
diagnostic challenges and delays in diagnosis (Jayasundera CI et  al., 1993; Mohan A and 
Sharma SK , 2008).  A high frequency of undiagnosed disseminated TB at post mortem in HIV 
patients has been reported in several studies (Lucas SB et al., 1993; Rana  FS et al., 2000; 
Ansari  NA et al., 2002; Cohen  T et al., 2010a; Wong  EB et al., 2010). 
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Cohorts from both high, low and middle income countries suggest that ART is associated with 
reduced the risk of mortality in co-infected HIV-TB. (Lawn SD et al., 2009b).  In the 
Netherlands co-infection of HIV and TB was associated with increased risk of death and that the 
decrease in mortality was due the more widespread use of ART (Haar CH et al., 2007).  In Spain 
mortality was also shown to be reduced in co-infected TB patients who received ART (Velasco 
M et al., 2009).  Some studies in Malawi (Makombe SD et al., 2007; Bong CM et al., 2007) and 
Thailand (Manosuthi W et al., 2006) have shown improved mortality in TB patients on ART 
compared with non-TB patients (receiving ART).  Surprisingly, a study from Malawi (Makombe 
D et al., 2007) showed that the six month cohort outcome of co-infected HIV-TB patients on 
ART had better survival than HIV positive patients on ART without TB (77% vs. 71%, p<0.001).   
In a study from Thailand, the impact of ART on the survival of HIV positive TB patients 
compared patients who received ART during TB treatment with those who did not. 
(Sanguanwonse N et al., 2008).  There was an 83% risk reduction (HR 0.17 CI: 0.12-0.24) in 
mortality.  Since this study required a large sample size (n=1 269) patients from health care 
facilities across the country in both public and private health facilities in 5 provinces were 
included.  Sophisticated analyses (propensity score analysis) were used to adjust for an important 
survivor bias, i.e. physicians’ potentially avoiding commencement of ART in patients with high 
risk of death (Akksilp S et al., 2007).  A smaller study from Thailand published a year earlier by 
Akksilp et al (2007) involved patients from the same setting in the population-based TB 
surveillance system in one province only (n=329).  ART given before or during TB treatment 
(compared with no ART) reduced deaths by 80% (OR 0.2 CI: 0.1-0.5).  Both of these studies 
monitored death during the course of TB treatment and excluded patients who defaulted or 
transferred as the vital status of such patients was not known.   
Although these studies suggest a strong association between ART and reduction in mortality in 
co-infected patients, early treatment guidelines advised that ART treatment be delayed.  Reasons 
included concerns about adherence (the high pill burden), (Dean GL et al., 2002; Manosuthi W 
et al., 2010), potential pharmacologic interactions or drug-drug interactions  (Niemie M et al., 
2003), higher likelihood of side-effects or drug toxicities, and the risk of IRIS precipitated by 
mycobacterial products from dying organisms evoking an overwhelming inflammatory response, 
triggered by a rapidly recovering immune system (Cohen K et al., 2010b; Kwara A et al., 2010; 
McIlleron H et al., 2007; Lawn SD et al., 2007a; Shelburne SA et al., 2005).  However, although 
real, these risks need to balanced with the risks associated with delaying ART too long  (Lawn 
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SD et al., 2005c and 2007b,c; Violari A et al., 2008; Basset IV et al., 2009; Abdool Karim SS et 
al., 2011). 
During the past decade several studies, clinical trials and observational studies have been 
undertaken to establish the optimal time to commence ART during TB treatment in co-infected 
patients (Manosuthi W et al., 2006; Dheda K et al., 2004; Lawn SD et al., 2006 and 2011a).  
Some observational studies found that early initiation of ART initiation was not associated with 
better survival (Andia I et al., 2010; Yotebien M et al, 2010), but a study from five hospitals in 
Spain which compared survival when ART was administered within two months of TB 
treatment with ART administered after two months of TB treatment suggested benefit from 
earlier administration (Velasco M et al., 2009).  Only nine percent (9%) of patients died in the 
early ART group compared with 20% of patients in the later ART group, a reduction in the risk 
of death of 63% (HR 0.37 CI: 0.17-0.66).  However, results from observational studies like this 
must be regarded with caution as they do not account for deaths in patients before they started 
ART or biases inherent in ART allocation (Lawn SD et al., 2011a). 
Fortunately this question has been the subject of five randomised trials the results of which have 
most recently been summarised by Naidoo and colleagues (2013, Table 3). Overall, the trials 
found that only severely immuno-compromised patients (CD4<50 cells/µl) experienced a 
survival benefit with early ART, except for patients with TB meningitis.  Whether ART was 
initiated within two months or after two months of TB treatment, no difference in AIDS or 
mortality was found.  The Camelia trial reported an advantage of starting ART early (after two 
weeks of TB) compared to starting ART later (after eight weeks) in patients with a CD4 count 
below 200cells/µl (Blanc FX et al., 2010).  Interestingly although the risk and severity of IRIS 
was increased with early ART, the overall IRIS-associated mortality was lower. 
Table 3: Summary of randomised trials evaluating the optimal to start ART in co-infected HIV-TB patients. 
Study  Country and 
Enrolment 
Sample size and 
basic cohort 
description 
Comparison Outcome 
SAPIT  
Abdool 
Karim S et 
al., 2010 
South Africa 
(Durban), one 
facility 
 
Enrolment:  
28 June 2005 
to 11 July 
2008 
n=429 
HIV positive 
Smear positive 
pulmonary TB 
>= 18 years 
Median CD4: 150  
Median age: 34 years 
Males: 48% 
Early arm: started 
ART within 4 weeks 
after start of TB 
(n=214) 
Late arm: started 
ART during first 4 
weeks of continuation 
phase of TB (n=215) 
Early ART for patients with 
CD4<50 increased AIDS 
free survival. 
Deferred ART in patients 
with CD4>50 reduced risk 
of IRIS without increasing 
risk of AIDS or death. 
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Study  Country and 
Enrolment 
Sample size and 
basic cohort 
description 
Comparison Outcome 
STRIDE 
(ACTG5221) 
Havlir DV et 
al., 2011 
4 Continents, 
26 sites 
 
Enrolment: 
Sep 2006 to 
Aug 2009 
n=809 
HIV positive 
suspected TB 
>= 18 years 
Median CD4: 77 
cells/µl 
Early arm: started 
ART within 2 weeks 
of TB treatment 
(n=332) 
Late arm: started 
ART after 8-12 
weeks of TB 
treatment (n=329) 
Overall, early ART did not 
reduce AIDS-defining 
illnesses and death 
compared to early ART. 
For CD4<50, early ART 
had 42% less AIDS defining 
illnesses and death 
compared to late ART 
(p=0.02). 
CAMELIA 
Blanc FX et 
al., 2010 
Cambodia, 5 
hospitals 
 
Enrolment: 
31 Jan 2006 to 
27 May 2009 
n=661 
HIV positive 
Newly diagnosed 
acid-fast bacilli 
positive TB 
>= 18 years 
Median CD4: 25 
Median age: 35 years 
Males: 64% 
Early arm: started 
ART 2 weeks after 
start of TB treatment 
(n=332) 
Late arm: started 
ART after 8 weeks of 
TB treatment (n=329) 
Early ART significantly 
improved survival in 
patients with CD4<=200 
HR 0.62 CI: 0.44-0.86) 
IRIS significantly increased 
in early ARM (HR 2.51; CI: 
1.78-3.59) 
Median gain in CD4 was 
144 cells/µl irrespective of 
arm 
OXTREC 
023-04 
Vietnam  n=253 
HIV positive 
TB meningitis  
Mean CD4: 41  
Early arm: 
Immediate, within 7 
days. 
Late arm: Deferred 
within 2 months 
High overall mortality 
No difference in time to 
new AIDS event or death 
(HR 1.16 CI: 0.87-1.55  
p=5.31) 
Degu WA et 
al., 2012 
Ethiopia  n=512 
HIV positive 
TB 
Median CD4: 78 
cells/µl 
 
 
 
ART after TB was 
started: 
Arm: 1 week  
Arm 2: 4 weeks 
Arm 3: 8 weeks after  
Overall incidence of 
mortality:  
1 week:  36.4/100 py  
4 weeks: 26/100 py  
8 weeks: 20.8/100py 
( p=0.4) 
 
Relative risk of mortality 
CD4<=50 vs. CD4>50   
Wk 1: RR 1.5 CI: 0.6-0.9 
Wk 4: RR 2.0 CI: 0.7-5.2 
Wk 8: RR 2.9 CI: 0.8-9.9  
(NS)  
 
Early ART did not reduce 
risk of mortality and rate of 
AIDS-defining illnesses, 
rate of IRIS was increased.  
Better survival trend seen in 
patients with CD4<50 
cells/µl. 
CD4: cells/µl 
The reasons for and mechanisms underlying the excess mortality in co-infected patients remains 
controversial.  A 2010 review on the effect of TB on mortality in HIV positive people concluded 
36 
that there is insufficient data to support the causal effect of TB on mortality in co-infected people 
on ART (Straetemans M et al., 2010).  The role of advanced immuno-suppression warrants 
further research (Lawn SD et al., 2009b).  While it has been shown that TB is strongly 
associated with mortality in co-infected patients, a direct causal effect has not yet been 
established as an independent predictor of mortality.  Mortality data from ART services in 
Uganda, Malawi and South Africa have confirmed an associated risk with low baseline CD4 cell 
counts, increasing age, body mass index, and clinical staging (Moore D et al., 2007;  Zacharia R 
et al., 2006, Westreich D et al., 2009) . 
1.3.3. Effect of ART on TB treatment outcomes 
Despite long-established TB reporting systems, there are few studies evaluating the effect of 
ART on TB treatment outcomes. A recently published study from Malawi (Kanyerere HS et al., 
2012) evaluated outcomes in 1 190 co-infected patients in whom cotrimoxazole was initiated in 
88% and ART in 58%.  ART was initiated within the first two months in 61% of patients, even 
though the national guidelines during the study period recommended that ART should be started 
during the continuation phase of TB treatment.  A significant improvement in successful 
(cured/completed) TB treatment outcomes was found for patients who started ART early 
(<2 months) compared to late ART (>=2 months); the likelihood of a successful outcome was 60% 
higher (RR 1.6 CI: 1.4-1.8).  They also reported that the risk of death was reduced by 75% (RR 
0.25 CI: 0.19-0.35).  No comparison was made between patients who received ART and those 
who did not. 
A multi-centre study in Italy evaluated TB treatment outcomes of co-infected patients and the 
effect of ART on death as recorded in a TB register (Girardi E et al., 2012). The use of ART 
during TB treatment was associated with a reduction in the hazard of death (IRR 0.12 CI: 0.06-
0.30) while lower CD4 cell count, age more than 40 years and MDR increased the risk of death. 
A study by Hermans and co-workers (2012) showed that in an integrated HIV-TB setting, 
successful TB treatment outcomes (cured or completed) increased from 62% to 68% and 
unfavourable outcomes (died and defaulted) decreased from 33% to 25%.  More patients in the 
CD4<100 cells/µl category started ART during TB treatment in 2009 (94% vs. 78%, p<0.001), 
and the median time between TB treatment and initiation of ART decreased from 103 days to 45 
days.  Patient’s data from 2007 (n=346, before integrated service started) were compared with 
data from 2009 (n=366, after integration).  In addition more patients were diagnosed with extra-
37 
pulmonary TB and started on ART in 2009.  The results of this supported integration of TB and 
HIV services (Hermans SM et al., 2012). Similar conclusions were reached by studies in Cape 
Town which found that a non-integrated HIV-TB service was associated with a delay in 
initiating ART in co-infected patients (Kerschberger B et al., 2012; Lawn SD et al., 2011b). 
With small sample size studies it is possible to collect data manually from non-integrated HIV 
and TB services and to combine the data in a research database.  Often these research facilities 
are equipped for such a data collection process with specific data collection forms since principal 
investigators are guiding the process for research purposes.  For a province wide programme 
surveillance dataset, like the Free State province, collecting HIV and TB information from more 
than 200 facilities spread across the province was not feasible and another approach had to be 
taken.   
1.4. Data linkage 
Access to accurate, complete, timely patient - and organisational data is needed for research on 
current health systems services and problems (Roos LL et al., 1985; Qauad MG et al., 2009).  
Health datasets that would provide insight to answering questions like these are often collected 
by diverse groups (researchers, analysts) in the public and private sector.  It takes skilled 
researches months or years to obtain and link these datasets to extract meaningful information 
(Bradley CJ et al., 2010). However, should it be possible to link these datasets, it provides a 
unique source to perform epidemiological studies, which would otherwise not be possible with 
single source data (Tromp M et al., 2010).  Weaknesses in the recording, reporting and accurate 
measurement of HIV and TB control programmes have limited the use of observational data for 
research purposes due to the separate treatment and data collection systems.  
This data can be greatly enriched by linking this reporting system with other sources of 
population data, making it suitable for interrogation to address important questions facing 
decision-makers in terms of treatment and prevention strategies and priorities and resource 
allocation, (Johnson WD et al., 2008; Heunis C et al., 2009). 
Electronic data linkage has been in use in a myriad of fields over the last 40 years.  The need for 
complete and longitudinal datasets on patients to make better informed decisions to improve 
quality of care has been a critical factor in healthcare (Rogot M et al., 1983; Zingmond DS et al., 
2004; Parker DP et al., 2008).   Furthermore, by using previously collected data it saves time, 
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money, and the burden of collecting data once more, therefore driving the need for linkage 
strategies   (Bradley CJ et al., 2010). 
Two methods are available for data linkage, deterministic and probabilistic linkage.  Initially 
deterministic linkage was more common, however with increased computing power probabilistic 
matching gained popularity.   In deterministic record linkage a predefined subset of linking 
variables have to agree to consider a pair as a link.  With probabilistic record linkage weights for 
agreement (rewards) or disagreement (penalty) are estimated for each variable based on the 
difference in probability that a variable agrees among matches and non-matches (Tromp M et al., 
2010). 
A link is established when two or more records in a set of databases represent the same 
individual and could be combined to form one record in a new database.  False-positive links are 
records incorrectly linked, false-negatives are difficult to determine; these refer to records that 
should have been matched but they were not matched.  A true match is a correctly matched 
record.  The aim is to maximise true matches and minimise false matches.  There is always a 
trade-off to consider, to obtain more matches it is likely that there will be more mismatches 
(Hser YI et al., 2008). 
While trials have since provided compelling evidence supporting early ART for co-infected 
patients (Naido K et al., 2013), they represent small patient populations recruited from research-
augmented programmes, and so findings may not be generalisable to large public sector 
populations where ART and TB treatment are provided at scale.  However, observational cohort 
data can be used to support or refute RCT findings in these populations, provided that 
appropriate statistical methods are used to minimise potential biases associated with 
observational data (Franke MF et al. 2011; Lawn SD et al. 2011). This is particularly true of 
programmes followed for several years during which policy and clinician enthusiasm for treating 
co-infected patients with ART changed, permitting comparisons to be made between patients 
who received treatment earlier or later, or not at all. 
In the Free State Province of South Africa systems were in place to support and manage large 
scale routine TB and HIV programme data.  However, these datasets were not linked and could 
consequently not being used to evaluate the scale of the problem of co-infection in the Free State 
province, to describe the heterogeneity of the epidemic, to identify populations at greatest risk of 
co-infection, establish the factors driving the co-epidemic, and the impact of effective treatment 
39 
on the prognosis of these patients.  This study has created a unique linkage that provides the 
opportunity to interrogate the dataset to evaluate the effectiveness of ART over a long term in a 
public health service setting, in preventing TB in HIV positive patients, reducing the risk of 
mortality in these co-infected patients, and the impact thereof on TB treatment outcomes.  It is 
estimated that ART’s effectiveness is overestimated in smaller controlled settings, therefore this 
study aims to evaluate the effect of ART, compared to patients not receiving ART, in a 
heterogeneous setting with a large sample size, appropriately adjusted for confounding to reduce 
the effect of bias and to provide an epidemiological evidence base for the formulation of 
evidence-informed target and prevention strategies. 
First I will describe the process of linking the HIV and TB programme datasets to establish a 
data platform from which sample populations were identified to evaluate the effect of ART on 
incidence of TB in this HIV positive population, how ART affected the risk of mortality in this 
HIV-TB co-infected  population and their outcomes.  
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2. METHODS 
The purpose of this study was to evaluate the effectiveness of ART on TB incidence and 
outcomes in co-infected adults in the Free State Province’s public sector.  The ART and TB 
treatment programmes were managed separately, therefore it was important to link the Free State 
public sector HIV programme database with the provincial TB register to obtain an all-inclusive 
dataset to support aims listed below. 
2.1. Aims 
1. Estimate the effect of ART on incidence of TB disease (time to first TB episode1, and 
rate of recurrent TB episodes) in HIV positive patients. 
2. Estimate the effect of ART and cotrimoxazole on mortality (time to death) in co-infected 
HIV-TB patients. 
3. Estimate the effect of ART on TB treatment outcomes in co-infected HIV-TB patients. 
2.2. Study population 
The study population was all HIV positive people, 16 years and older, enrolled in the Free State 
Comprehensive Care, Management and Treatment of HIV/AIDS Programme from the start of 
the programme in May 2004 until July 2010, when final extracts of the relevant datasets were 
drawn and closed for analyses.  This HIV cohort was linked to additional data sources to enrich 
the dataset and reduce the amount of missing baseline and outcome data.  Patients between the 
ages of 16 and 18 were included since they received standard adult treatments.  Patient 
populations are defined separately for each analysis. 
2.3. Setting and data collection 
2.3.1. HIV Treatment Programme 
The Free State Department of Health opened their first ART facilities in May 2004 after the 
South African government made ART available in the public sector. At the start of the 
programme, ART was provided at 25 facilities, five facilities per district, and scaled up during 
                                                          
1 A TB episode was defined as the day when TB treatment was started until the date it was completed, stopped 
(transferred), or the patient became lost to follow-up (defaulter).  Due to a lack of TB diagnosis date it was 
assumed that TB treatment started soon after TB diagnosis or on the same date. 
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consecutive years such that by the close of the study healthcare was provided at 21 assessment 
clinics, 12 treatment sites and 13 combined assessment/treatment sites throughout the five 
districts in the Province.  Assessment sites (clinics) were staffed by nurses while doctors were 
mostly based at treatment sites (hospitals); this required the patient to travel between sites since 
different services were provided at each site.  Some facilities operated as a combined site when 
nurses and doctors (permanent or visiting) were based at the same premises (Fairall LR et al. 
2008, Ingle SM et al. 2010).  See Figure 9 for a map of the Free State Province with districts and 
ART facilities. 
 
Figure 9: Map of Free State Province displaying clinic (assessment sites), hospitals (treatment sites) and 
combined treatment-assessment sites at the close of the study, July 2010. 
Patients testing positive for HIV at any primary care facility were sent to an ART facility, 
typically a clinic (assessment site) and triaged according to their CD4 cell count. Patients with a 
CD4 cell count above 500 were monitored annually.  When the HIV programme was initiated in 
2004, patients with a CD4 cell count between 200 and 500 were monitored six monthly and 
others with a CD4 cell count below 200 or clinical AIDS were referred to a doctor at a hospital 
(treatment site), or later to a doctor visiting rural assessment sites on a sessional basis.  Eligible 
patients would then undergo a treatment readiness program for three weeks before the first line 
ART regimen comprising stavudine (d4T), lamivudine (3TC), and efavirenz or nevirapine was 
initiated.  Patients receiving ART were monitored on a monthly basis at assessment sites (nurse 
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visit) and six monthly doctor visits at treatment sites.  Monthly monitoring included weight 
measurement, family planning, screening for TB and side effects, and monitoring ART 
adherence.  Blood samples were taken every six months to measure a patient’s CD4 cell count 
and viral load (HIV viral RNA copies/ml) (South African National Department of Health 
(NDOH) National Antiretroviral Treatment Guidelines; 2004). Second line treatment was 
reserved for patients who failed first line treatment and comprised zidovudine (AZT), didanosine 
(ddI) and lopinovir. 
Clinical policy regarding the CD4 cell count eligibility criteria for ART and timing of initiation 
in co-infected HIV-TB patients evolved as the programme expanded, WHO (World Health 
Organisation) revised guidelines in 2009 and more data became available, suggesting a risk 
benefit ratio in favour of starting ART earlier (Table 4).  At the outset of the programme patients 
were started on ART when their CD4 cell count was 200 cells/μl or less whereas currently 
patients are started when their CD4 cell count is below 350 cells/µl.  Table 4 displays ART 
eligibility criteria policies implemented by the Free State during the study period (May 2004 to 
July 2010). 
Table 4: Eligibility criteria for starting ART and in patients diagnosed with TB. Source: PALSA PLUS a 
guidelines implemented in the Free State Province based on policy guidelines published by the Free State – 
and National Department of Health. 
Year Eligibility for ART (adult criteria only) Timing of ART when patient has TB (adult criteria) 
2004 Adults and pregnant women: CD4 b ≤ 200 
and/or WHO c Stage 4 
Complete standard TB treatment (6 months) before 
starting ART. 
2006 Pregnant women: CD4 ≤ 350 and/or WHO 
Stage 4 
Men and non-pregnant women: CD4 ≤ 200 
and/or WHO Stage 4 
Dependent on CD4 cell count measured during TB 
episode: 
CD4 < 50:  Start ART as soon as possible. 
CD4 50-200: Defer ART until the end of the intensive 
phase of TB treatment (2 months). 
CD4 > 200: Repeat CD4 test and re-evaluate eligibility 
for ART at the end of TB treatment.   
2009 Unchanged Start ART within 2 to 8 weeks of starting TB treatment, 
and as early as possible in those with CD4 ≤ 50. 
2010 TB and pregnant women: CD4 ≤ 350 and/or 
Stage 4 
Men and non-pregnant women: CD4 ≤ 200 
and/or Stage 4 
Unchanged 
2011 CD4 ≤ 350 and/or Stage 4 (regardless of 
whether pregnant or TB) 
Unchanged 
a PALSA PLUS: Practical Approach to Lung Health and HIV/AIDS in South Africa 
b CD4: CD4 cell count in cells/µl 
c WHO Staging 
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At the start of the programme in 2004, guidelines recommended that ART be deferred in co-
infected TB patients until TB treatment was completed.  By 2006, co-infected patients with a 
CD4≤50 cells/µl were referred for urgent ART work-up.  More recently doctors have tended to 
start ART patients with very low CD4 counts or who are clinically ill, as soon as they have been 
stabilised on TB treatment.  On World AIDS Day 2009, the South African Department of Health 
expanded eligibility criteria to include pregnant women or those with TB and a CD4 cell count 
between 201 and 350 cells/μl (South African National Department of Health Government speech 
2009).  In 2011, this was again expanded to include all HIV positive patients with a CD4 cell 
count of 350 cells per μl or less (South African National Department of Health,  2011). 
2.3.2. HIV Programme data collection 
Nine structured paper clinical records were designed for clinicians and nurses to record 
consultations before and after ART was started (see Appendix B for HIV Programme clinical 
visit forms).  Figure 10 presents a schematic diagram of HIV programme visits.  There was a 
form for each type of visit for example voluntary counselling and testing (VCT) visit, drug 
readiness training visit etc. For patients on ART only two forms were used: a nurse follow-up 
and a doctor follow-up form.  Data clerks were appointed to capture completed clinical records 
into the Province’s computerised patient information system.  At some facilities, additional 
computers were installed for health care personnel to capture visit information directly on the 
system during a consultation.  Captured forms (visit data) were uploaded to a central database 
server in Bloemfontein once a week. 
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Figure 10: HIV programme visits in the Free State Province. 
 
Visit information was saved in a database (data warehouse) combining information from the 
different facilities, which was designed to facilitate reporting, run quality routines for data 
cleaning, support monitoring and evaluation of the HIV programme, and longitudinal data 
analysis of the HIV programme before and after ART initiation (Fairall LF et al, 2008; 
Louwagie G et al. 2007; Kotze JE et al, 2010).  The HIV database and data loading processes 
were developed by a team (of which the candidate was part) at the Medical Research Council 
during 2004-2005 and handed over to the Free State Department of Health (DOH) in December 
2005. A Microsoft SQL (Structured Query Language) Server 2000™ was used to deploy the 
HIV database on in the Free State.  The Free State DOH information technology manager 
incorporated the HIV database in a data warehouse at the Department, which included human 
resource data, hospitalisation data, laboratory data, and death population registry data.  The Free 
State Department of Health has linked hospital and laboratory data monthly with the HIV 
programme data since June 2009 and incorporated death registry information from the 
Department of Home Affairs. 
Voluntary  
Counseling & 
Testing ( VCT ) 
Baseline 
Assessment 
Follow Up (FU)  
Visit 
Refer to 
hospital 
Refer to clinic 
ARV Treatment 
commenced 
Treatment  
initiation 
Drug  
Readiness 
Training 
Refer for TB  
Treatment 
8 months  
FU Visit 
1 year 
FU Visit 
Nurse visits Doctor visits 
Admit to  
hospital 
HIV + 
CD4 >  
500 
CD4 between  
200 & 500 
CD4  <= 200 
&/or AIDS 
Delay  
Treatment 
Approved for ART  
Refer for  DRT 
X 3 
Ready to  
start ART 
Counseling  – Practise safe sex 
HIV  - 
Refer to 
hospital 
Refer to 
hospital 
Refer to 
clinic 
Refer to 
clinic 
Stop  
ART 
Change  
regimen 
Event at Clinic (Assessment Site) 
Event at Hospital (Treatment Site) 
Ad hoc event 
Normal flow 
Ad hoc flow 
X times 
45 
The death linkage was done monthly by the Department of Home Affairs based on a list of 
South African identification numbers (SA ID) exported from the HIV programme database.  A 
date of death was provided by the Department of Home Affairs based on the SA ID match and 
imported back into the data warehouse.  The cause of death was not available.  It is estimated 
that the national death population register captures over 90% of adult deaths in South Africa 
(Statstics SA, 2003; Joubert G et al., 2007).  ID numbers were considered to be valid if the DOB 
corresponded with the first six digits of the ID number and if the ID number appeared on the 
Department of Home Affairs’ database.  A check was implemented at the point of data entry at 
facilities in the Free State to alert data clerks or healthcare workers if the ID number appeared to 
be incorrect based on the algorithm used by Department of Home Affairs to create ID numbers 
or if a patient with the same ID number existed on the system.   A concerted effort was made by 
the Free State Department of Health and clinics to obtain ID numbers for patients to improve 
linkage with the population register and support monitoring of the programme (Kotze JE et al, 
2007). 
The Free State HIV database was unique since it contained visit data, both before and after ART 
was started for all ART facilities in the Province.  However, TB information collected by the 
HIV programme was limited, and included TB status at the time of each visit (Figure 11). This 
recorded whether the patient was receiving TB treatment, had symptoms suggestive of TB, or 
was neither on treatment nor symptomatic. Categories were mutually exclusive.  TB information 
not recorded by the HIV programme included TB treatment start date, TB classification 
(pulmonary or extra-pulmonary), culture results, sputum conversion information or TB treatment 
outcomes. 
 
Figure 11: Example of TB information collected during HIV programme visits. 
2.3.3. TB Programme 
Patients were referred to TB facilities from primary care clinics or ART facilities.  There were 
328 facilities providing TB care at the close of the study, 91 of the facilities were mobile 
facilities and 237 fixed band facilities located within the primary care clinic.  The WHO and 
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South African National TB programme defined clinical algorithms for the diagnosis of TB (SA 
National Dept of Health, 2007,2008; WHO 2008).  Diagnosis of pulmonary TB is confirmed by 
a positive sputum smear for acid fast bacilli while smear negative patients are diagnosed by a 
medical doctor considering all available diagnostic information.  Treatment is divided in two 
phases, a two to three month intensive phase followed by a four month continuation phase.  A 
new TB treatment episode is treated with a fixed combination of  -rifampicin, isoniazid, 
pyrazinamide, and ethambutol (RHZE) during the intensive phase, and rifampicin and isoniazid 
during the continuation phase.  Depending on the sputum smear outcome after two months of 
treatment, intensive phase treatment is continued for an additional month (smear positive) or the 
patient can start with continuation phase drugs, (rifampicin and isoniazid),  for four to seven 
months  (National TB Strategic Plan, 2007-2011). 
TB treatment outcomes are recorded based on WHO definitions.  A patient is cured when 
sputum converted from an initial positive result to smear negative in the last month of treatment 
and at least one previous occasion; Failed is when a patient was initially smear positive and 
remained smear positive five months later; Completed is when patient a completed treatment but 
did not meet the criteria for cure or failure; Defaulted is when a patient’s treatment was 
interrupted for two consecutive months or more; Success is a combination of cure and completed.  
Other outcomes include death, moved, transferred out, or not evaluated.  TB episodes are also 
classified as a new or retreatment case.  An episode was classified as new if the patient never had 
treatment for TB before or received TB treatment for less than one month.  A Retreatment case 
was when a patient received at least one month or more TB treatment in the past or when a 
patient was returning after default or retreated after treatment failure (WHO treatment guidelines 
2008, 2009, 2011). 
2.3.4. TB Programme data collection 
TB treatment information was recorded on a paper-based TB register at each TB clinic.  
Information was collected on four copies.  The first copy was submitted to the sub-district office 
when the TB initiation section was completed for each record on the page or at the end of a 
quarter.  A data capturer (or health care worker) captured the data into a standalone (not 
connected to a central server database) electronic TB register (ETR) at sub-district level.  The 
ETR software created an encrypted dispatch file with newly added and/or updated data, which 
was sent to a district manager who collated and integrated all the sub-district data in a district 
database.  The same process was repeated to collate data from district to provincial level and 
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then from provincial to national level.  Baseline characteristics recorded at diagnosis included 
age, sex, smear results (positive, negative or no smear), new or retreatment case, and anatomical 
site of disease (pulmonary, extra-pulmonary or both).  From January 2007, SA ID numbers and 
date of birth (DOB) were entered on the ETR, however the data are still limited (Table 5 and 
Table 6).  From a total of 111 930 records in the ETR 2007-2010, only 3.5% (3 954 / 111 930) 
records contained a SA ID number with 13 characters, which could be used for linkage.  Only 
1.1 % (1 194 / 111 930) of TB records with a valid SA ID number were linked to HIV database 
patients. 
Table 5: ID numbers recorded in ETR between 2007 and 2010. 
Year TB 
registered 
 
Number of 
Records 
N 
Valid ID number 
(13 characters) 
n (%) 
Linked to HIV 
database  
n (%) 
2007 28 715 1 (0%) 0% 
2008 32 299 921 (2.9%) 214 (0.7%) 
2009 32 985 2 036 (6.2%) 670 (2.03%) 
2010 17 931 996 (5.6%) 310 (1.7%) 
 
111 930 3 954 (3.5%) 1 194 (1.1%) 
Overall, DOBs were entered for 35.1% (70 220 / 199 998) of records in the ETR.  Initially only 
4.2% of records had a DOB in 2007 but it increased to 98.7% by June 2010 when the data 
extract were exported (Table 6). 
Table 6: DOBs entered in ETR between 2007 and 2010. 
Year TB registered 
 
Number of Records  
N 
DOB entered  
n (%) 
2007 28 715 1 198 (4.2%) 
2008 32 299 19 160 (59.3%) 
2009 32 985 32 161 (97.5%) 
2010 17 931 17 701 (98.7%) 
 
111 930 70 220 (62.7%) 
Since 2003 the HIV status of a TB patient was recorded in the ETR (Table 7).  However, the 
completeness of this variable ranged between 25% in 2003 to 46% in 2009 and the percentage of 
records with a HIV positive status ranged between 2.4% in 2003 and 3.8% in 2009, suggesting 
substantial under-reporting. 
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Table 7: HIV status entered in ETR between 2003 and 2010. 
Year TB 
registered 
Number of Records 
N 
HIV status recorded 
n (%) 
HIV positive 
n (%) 
2003 16 395 4 111 (25.1%) 394 (2.4%) 
2004 21 246 6 982 (32.8%) 661 (3.1%) 
2005 23 288 7 042 (30.2%) 727 (3.1%) 
2006 27 139 4 903 (18.1%) 504 (1.9%) 
2007 28 715 5 713 (19.9%) 831 (2.9%) 
2008 32 299 15 159 (46.9%) 1 239 (3.8%) 
2009 32 985 15 058 (45.7%) 1 256 (3.8%) 
2010 17 931 5 466 (30.5%) 666 (3.7%) 
 
199 998 64 434 (32.2%) 6 278 (3.1%) 
The ETR software was expanded in 2003 to capture more HIV related information.  Table 8 
shows the HIV related variables, the total number of records registered per year and how many 
records contained data entered for the specific variables.  Given that public sector ART was 
implemented in May 2004, either HIV related information was entered more regularly since 
2008 or the clinical profile of TB patients started to change, explaining the difference in the 
completeness of the variables for example 26% of records had a CD4 cell count entered in 2008 
compared to <1% before 2008 and 46% of records had an indication of a patient receiving 
cotrimoxazole therapy in 2008 whereas less than 10% of records recorded cotrimoxazole therapy 
it in the preceding years. 
Table 8: HIV related information entered in ETR per year of TB registration. 
Year 
TB reg. 
Number 
of records 
CD4 between  
1 and 2 000 
On cotrimoxazole 
treatment (Yes,No, 
Positive, Negative, 
Unknown) a 
HIV test date On ART 
(Yes,No,Not 
eligible) * 
On ART at 
start of TB 
(Yes) 
2003 16 395 0  (0%) 878  (5.4%) 3  (0.02%) 1  (0.01%) 4  (0.02%) 
2004 21 246 0  (0%) 1013  (4.8%) 15  (0.07%) 7  (0.03%) 0  (0%) 
2005 23 288 1  (0%) 1325  (5.7%) 264  (1.1%) 212  (0.9%) 7  (0.03%) 
2006 27 139 7  (0.03%) 1771  (6.5%) 837  (3.1%) 624  (2.3%) 9  (0.03%) 
2007 28 715 23  (0.08%) 2712  (9.4%) 1729  (6.02%) 724  (2.5%) 95  (0.3%) 
2008 32 299 3 172 (9.8%) 14780  (45.8%) 56  (0.2%) 6329  (19.6%) 1231  (3.8%) 
2009 32 985 8 719 (26.4%) 24016  (72.8%) 0  (0%) 11961  (36.3%) 1161  (3.5%) 
2010 17 931 5 333 (29.7%) 11509  (64.2%) 0  (0%) 7021  (39.2%) 992  (5.5%) 
  199 998 17 255 (8.6%) 58 004  (29.0%) 2 904  (1.5%) 26 879 (13.4%) 3 499 (1.8%) 
a  Answers recorded in database displayed in brackets. 
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The WHO recommended a reporting format as a key management tool to evaluate effectiveness 
of a national TB control programme.  This reporting format is based on cohort reporting, for 
example reporting will be for patients who were diagnosed with TB during the first quarter of 
the year and that particular group’s (cohort’s) outcomes, the second quarter’s patients and their 
outcomes etc.  This approach does not emphasise or report specifically on patients with multiple 
TB episodes.  Earlier versions of the ETR were also not designed to monitor patients with 
multiple TB episodes.  Reporting was structured around episode outcomes, not per patient 
outcomes due to the lack of a unique identifier.  However, multiple TB episode entries per 
patient do exist in the provincial ETR, either from multiple treatment episodes at the same 
facility or from episode information from different facilities.  The ETR database was designed 
such that each record in the TB register reflects one treatment episode, and a patient can have 
more than one record (TB episode).  The inclusion of more personal identifiers recently will 
allow for identification of multiple TB episodes per patient in future. 
2.3.5. Data security and patient confidentiality 
Data security and privacy for the HIV programme and TB programme data are managed by the 
Free State Department of Health (DOH) with secure network connections and security policies.  
Password protected TB data files were obtained by the candidate on three occasions with 
permission (Dec 2007, Jun 2008, Aug 2010).  Research copies of the HIV database were either 
collected in person at the Department of Health in the Free State or copied to a digital versatile 
disk (DVD) and sent by registered post.  The HIV database was encrypted with a public-private 
key cryptography method, which uses a pair of keys for encryption and decryption.  A public 
key, which encrypts data, and a corresponding private, or secret key for decryption.  Only the 
candidate and the Information Technology manager from the Free State DOH had access to 
these encryption keys.  The databases are hosted on a secure server at the University of Cape 
Town Lung Institute.  The candidate is the only person with administrator rights for the server 
hosting the databases and the SQL databases containing the data.  Database backups are created 
each night and stored on the server.  Backups from the server are copied to an external drive bi-
monthly and stored off-site in a secure location.  Personal identifiers were included in the data 
sources since they were required for the linkage process.  Only anonymised data (name and SA 
ID numbers removed) were shared with supervisors, and all facility information was coded as 
categorical variables.  Only the candidate had full access to personal identifiers from the HIV 
programme and TB register data. 
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2.4. Data linkage of Free State public sector ART Programme database with provincial 
TB register 
The provincial databases for the ART and TB programmes existed in parallel, but no substantive 
attempt had been made to link patient information between the two databases before this thesis. 
Completeness of variable rates of person identifiers, particularly in the ETR, proved challenging 
and required that the candidate explore a range of methods for data linkage, described below. 
2.4.1. Types of data linkage 
Deterministic data linkage 
With deterministic linkage a single or set of variables is used in a series of steps to link two 
datasets and it requires an exact match on the variable(s) to consider it a match.  It does not draw 
on a statistical method.  A common identifier between two datasets in order to link them for 
example social security number (USA) or national identification number (South Africa) is ideal 
and provides the best match.  However, these are not always available.  Other variables used 
include name, surname, sex, DOB, addresses, area codes and any other discriminating variables 
pertaining to the datasets (Qayad MG et al., 2009).  Rules are developed to specify which 
variables and in which combination the variables need to match exactly before a linkage is made. 
For example, if six variables are available (name, surname, DOB, gender, facility, and street 
address) and three out of the six variables should be matched before a linkage is made, it is 
important to specify which three variables (combination) must match.  An exact match on 
surname, name, and DOB could be considered a better match than gender, DOB and facility.  
Experimenting with rule-variable combinations is necessary to identify the best rules for a 
particular dataset. 
Deterministic linkage is particularly useful when the scrutinised outcome is very critical and 
incorrectly linked outcomes could cause problems, for example legal issues, fatalities, treatment 
outcomes, and blood results.  It provides a high level of specificity, but at the cost of sensitivity 
(Hser YI et al., 2008; Tromp M et al., 2010).  Data errors or missing data will hamper 
deterministic linkage and the magnitude of under-linkage depends heavily on the accuracy of the 
linking variables (Winkler WE, 2006; Qayad MG et al., 2009). 
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In addition to linking different datasets, computerised record linking is very useful for 
identifying duplicates within a dataset.  Often the majority of work (estimated at 90%) in data 
warehouses is associated with eliminating (cleaning) duplicates (Fayad U et al., 2000) which is 
costly (Thornton SN, 2005).  Identifying duplicates in such a way is often referred to as one-file 
matching where the same file is linked to itself to identify the duplicates (Kotze E et al., 2010).  
Duplicate records may also put the safety and wellbeing of patients at risk due to information 
captured under a different record (patient name mistyped for instance), which is not available at 
the time of decision making (Stiell A et al., 2003). 
Probabilistic data linkage 
Newcombe and Kennedy (1962) introduced probabilistic record linkage concept and in 1969 
Fellegi and Sunter formalised a mathematical method which is the basis for probabilistic 
matching.  A mathematical criterion or probability is used to separate matches from non-matches 
(Felligi IF et al., 1969). 
Statistical methods have been developed to improve the accuracy and efficiency of the original 
work specifically to compensate for data quality problems by adjusting weights or scores used 
for deciding whether a pair of records is a match (Jaro MA, 1989 & 1995; Winkler WE, 1993).  
In order to decide on probabilities a priori knowledge of the variables is helpful, i.e. distribution 
characteristics and information gathered from working with these variables.  In the absence of 
knowledge about the dataset and variables, arbitrary values are chosen and with trial-and-error 
better estimate for probabilities and thresholds could be developed.  This process can 
significantly increase the energy, time and cost expenditure (Hser YI et al., 2008). 
Matching relies heavily on computerised routines; however human judgment should never be 
completely omitted for either method of linkage.  Matching records is not always an 
unambiguous choice between a match and a non-match.  It is often the combination of available 
data at hand and human judgement which helps to make the decision during review processes 
(Hser YI et al., 2008; Bradley CJ et al., 2010). 
In South Africa, some attempts at linkage have been made to strengthen reporting systems in the 
government-run public health service.  For example, the Free State Department of Health 
implemented a computerised data collection system in all public sector ART facilities and set up 
a system that links provincial ART programme data with the national death population register 
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using national ID numbers (Fairall LR et al. 2008).  Similar linkages with a national population 
register have been set up at some sentinel and research sites (Boulle A et al. 2010, 
Manoshuthi W et al. 2006a; Van Rie A et al. 2011).  The Free State Department of Health has 
also linked their HIV programme data with admission data from government-run hospitals in the 
province and with the state laboratories to improve data availability for clinical decision making 
and reporting purposes (Kotze JE et al, 2007). 
For research purposes of this thesis the candidate linked the provincial HIV database and ETR 
using Microsoft SQL server 2005™ for data cleaning and linkage of the two datasets.  A 
database copy of the Free State HIV database was provided to the candidate after integration of 
laboratory, hospitalisation and death registry data and the provincial TB manager extracted data 
from the TB register in excel format for the purpose of this project. 
2.4.2. Overview of basic steps for deterministic data linkage 
Before any linkage could start a comprehensive data cleaning effort was needed to create 
variables that would be useful for the data linkage process and to increase specificity.  These 
tasks included removal of non-alphabetical characters, standardising the format of names, and 
consolidating age data using multiple sources (for example DOB, age at registration) to improve 
comparability.  SQL server’s text and string manipulation functions were studied to understand 
the programmability potential of SQL server to define rigid and more flexible rules for linkage.  
A rule matrix (cross tab) was designed to identify rules which could be programmed using a 
combination of linking variables.  Reviewing of linked output results was crucial to develop a 
sense of the accuracy of a linking rule and its feasibility, as well as reviewing multiple linkages 
for the same person.  Overlapping TB episodes, generated by combining TB treatment 
information from both the ART and TB programmes, then had to be reviewed creating a 
coherent history of TB episodes when multiple episodes were identified.  The steps are now 
described in detail in sections 2.4.3 to 2.4.7. 
2.4.3. Data preparation prior to linkage 
The provincial TB manager of the Free State Province provided data in EXCEL spreadsheet 
format, extracted from the TB register, for each year from 2003 to 2010.  Older versions of 
EXCEL have a maximum row set of 65 569 resulting in some loss of data during data exports, 
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hence each year was extracted separately and merged into one table (TB register source file) 
with SQL server. 
The final HIV dataset was updated with mortality data on 3 Aug 2010 and the latest TB 
treatment date registered on the ETR was 13 June 2010.  The death population registry database 
was current at the time of linkage with the most recent death date reported in the extract being 
2 Aug 2010 on an extract provided by the Department of Home Affairs on the following day.  
Table 9 summarises the key variables used for the linkage, and the availability of these in each 
dataset. 
Table 9: Completeness of variables in HIV programme database and ETR database. 
Variable  HIV database 
N (%) 
ETR 
N (%) 
Total no of records in database 97 476 199 998  
Full name 78 338 (80.0%) 198 681 (99.3%) 
Surname 97 445 (99.9%) 199 977 (99.9%) 
DOB 97 430 (99.9%) 70 220 (35.1%) 
Sex 97 476 (100.0%) 199 998 (100.0%) 
Age at enrolment 97 476 (100.0%) 199 998 (100.0%) 
SA ID number 76 226 (78.0%) 3 954 (0.02%) 
Facility 97 455 (99.9%) 199 998 (100.0%) 
District 97 455 (99.9%) 199 998 (100.0%) 
Is the patient on TB treatment? 12 336 (12.6%) 199 997 (100.0%) 
Address (more than 4 digits long) 93 766 (96.0%) 176586 (88.3%) 
HIV status 97 476 (100.0%) 64 434 (32.2%) 
ART status: 
Recorded (Yes/No) 
On ART treatment (Yes) 
ART start date available 
 
97 467 (100.0%) 
52 119 (54.0%)  
52 119 (100.0%) 
 
26 879 (13.4%) 
4621 (17.0%) 
277 (0.06%) 
Personal identifiers like name, surname, sex, facility, age and address were fairly complete and 
could be used for linkage.  However, DOB, South African ID number and HIV information were 
less complete on the TB register.  Linkage then proceeded as follows: 
a) Preparation of source datasets.. 
• Copies of the datasets were made before any changes/updates were performed.  A 
copy of the variables, which were used during the linking process, was made in 
each dataset (name, surname, district, DOB, ID number, facility, and district). 
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• A unique row number was created for each record in the TB register database.  A 
unique patient identifier (ZU number) existed in the HIV database for each record. 
• Before linkage was performed it was necessary to make sure that the data types of 
the variables to be compared were of the same type for example ID number was a 
float in one set and a text variable in the other.  The float variable was converted 
to a text variable in this instance. 
• Additional columns were added to the HIV and TB dataset to use as markers 
(cross referencing) to indicate which records have been matched. 
b) Identification and merging of duplicate patients. 
Duplicate patients (same person but with two unique identifiers) in the HIV database were 
identified and merged to obtain one unique identifier.  The duplicates were identified by sorting 
the HIV dataset on surname and DOB and counting patients with the same surname and DOB.  
In cases where more than one record were found, entries were manually reviewed to determine if 
it was the same patient based on additional information (name, address, facility, gender, ID 
number). Occasionally data capturers in the HIV programme registered a patient twice, creating 
two unique patient identifiers for the same patient.  Either the ID number was mistyped or an ID 
number was not entered for one of the patient registrations.  The HIV programme data collection 
software used ID numbers to warn the data capturer if they were about to register a duplicate 
patient.  For data linkage (and reporting) purposes, it was necessary to identify these duplicate 
patient identifiers and to eliminate them.  One unique identifier (study number) was selected and 
used to overwrite the second (or sometimes a third duplicate) study number such that all visit 
information and blood result records could be linked to the chosen primary identifier in the 
database. 
c) Cleaning of name variables. 
Names and surnames needed extensive cleaning for the linkage rules to perform best since 
deterministic linkage is based on exact matching.  Variables had to be spelled exactly the same 
before a computer regarded it as an exact match.  Database matches are very specific; a double 
space between two words (“Joan   Smith”) would not be matched with the same name with a 
single space between the words (“Joan Smith”). 
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Name variables were cleaned as follows: 
1. Copies of FIRSTNAME and SURNAME columns were created before any changes 
were made to the data variables themselves. 
2. Spaces or atypical characters at the beginning of each name or surname were removed. 
3. Zeros “0” were replaced with “o” (alphabet letter o) 
4. Numbers or atypical characters within names or surnames were removed. 
5. Names with a length of three or less characters: full stops were removed and consecutive 
initials were created. 
6. Full stops in names with a length of six or less and with two or more full stops in it were 
cleaned. 
7. Commas were replaced with a space. 
8. Surnames repeating within the NAME field were removed, for example,        
SURNAME: ‘Smith’ NAME: ‘Joe Smith’ > NAME: ‘Joe’. 
9. Spaces at the beginning of a name (first character) were removed. 
10. Variables where surnames were removed and the comma replaced by a space (step 7 and 
8), the extra space had to be removed, for example; 
‘Smith, Joe’ > ‘Smith  Joe’ (step 7) 
                                > ‘  Joe’ after step 8 (surname removed) 
                                            > ‘Joe’ after repeating step 9 twice 
11. Extra spaces between names were removed for example ‘Monku  A  T’ > ‘Monku AT’ 
12. A list of distinct names and surnames were prepared for manual review, to ensure all 
atypical characters and spaces were removed and to determine if any rules had to be 
repeated. 
13. Spaces and full stops were removed from initials columns. 
14. A surname count variable was added to each dataset to display the frequency of the 
surname in the dataset. 
d) Cleaning of facility information 
Records on the ETR had different ways of referring to the same facility for example “FS 
BATHO CLINIC” and “BATHO CLINIC”.  All facility names were standardised by removing 
FS prefixes and duplicate names were merged to one name if there were small spelling 
differences.  The HIV database’s facility and district names were standardised during the data 
loading process therefore no cleaning was necessary for it and each facility had a unique site-ID.  
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Two extra columns were added to the TB table, DISTRICT and SITE_ID.  Districts were 
assigned to all the facilities in the TB dataset and where it was possible to map a TB facility to 
one with an ART service (TB and ART facility on the same premises or TB and ART facilities 
servicing the same town), the same site-ID from an ART facility was assigned to the TB facility. 
e) Calculating patient age 
As of 2007, the TB programme collected DOB on their electronic system.  Before this, only the 
age of the patient at the start of TB treatment had been recorded.  For each of these records the 
patient’s age at the time of creating the dataset was added by subtracting two dates, the year in 
which the TB dataset was extracted (2010) less the year when TB treatment was started, and 
added to the age at registration.  Figure 12 displays two examples of how this variable was 
calculated. 
TBRegID 
(unique row 
identifier) 
AGE 
(at registration) 
TB treatment date CURRENT_AGE 
(new calculated field) 
131 30 2004/03/12 36 
132 28 2007/02/10 31 
Figure 12: Example of variables and how CURRENT_AGE was calculated. 
This calculated variable was compared with an age calculated from documented DOB in the 
HIV programme database.  A difference of one to two years between the two variables were 
allowed (Age ± 1 or Age ± 2) during the matching process. 
2.4.4. Software used to execute linkage 
Microsoft SQL server™ has standard build-in functions which can be used with database 
programming.  Text string manipulation functions were used with the programming of the 
linkage rules.  An easy match is when first names match exactly like “Marie” = “Marie”.  In 
some cases two first names were recorded on a dataset, “Marie Liouse” and “Liouse”.  Some 
linking rules were programmed to search for the word “Liouse” in “Marie Liouse”.  The same 
principle was applied to search for a piece of an address (first 6 letters) within the address field 
of the other dataset.  A small typing error would result in a mismatch for example “Liouse” is 
not the same as “Louise” therefore a SQL soundex function was used that would identify 
“Liouse” and “Louise” as a match. 
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Initials were inconsistently recorded, for example “LR” or “RL”.  A SQL function was used to 
swap the initials from one of the variables and to test it for an exact match with the other 
variable.  The month and day of a DOB were often swapped between datasets.  The month and 
day of each DOB variable were extracted separately and compared with the other date parts of 
the DOB variable, for example 1956-03-09 and 1956-09-03. 
A frequency count of each surname in the TB and HIV dataset was calculated and stored in a 
surname count variable in the separate datasets.  The surname count variable was used during the 
manual review process.  If there was any doubt regarding a linkage, and the surname was a very 
popular surname with a high surname count, for example “Mokoena” with 3 081 repeats of the 
surname on the HIV database, and 2008 repeats on the TB dataset, the linkage would be 
discarded.  However, if it was a scarce surname like “Matsi” with only three appearances on the 
HIV database and five appearances on the TB dataset, it would be used in favour of the linkage 
after considering the other matching variables. 
2.4.5. Linkage and rule matrix 
A cross-tab/rule matrix (Table 10) was developed during pilot linkage projects of the datasets to 
identify “linking rules” based on combinations of variables from the two separate datasets, 
which could be used to match patients.  The table was also used to keep a record of rules which 
have been programmed.  Table 10 displays variables used for linkage and a unique rule number 
assigned to each combination of variables used for the linkage and rules.  The unique rule 
number in a cell represents the combination of variables intersecting in that particular cell and if 
any additional restrictions besides the variable combinations were used.  Colour coding and 
indentation indicate if the matching criteria applies to variables on a level below.  All cells 
below the dark orange “DOB the same” also matched on DOB unless otherwise indicated in the 
cell.  All of the records have an exact match on sex or surname (basic condition).  For example, 
Rule 1-1a matched on the same surname, sex, DOB, facility and first name.  An additional rule 
was used in some cases called “HIV TB”, which means a patient was identified with TB on the 
HIV database.  This criteria was used during the linkage process when name variables did not 
match perfectly, but there was an indication in the HIV programme that the patient was 
undergoing TB treatment, making the linkage more likely. 
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Table 10: Rule matrix used during linkage process. 
Basic Condition: 
Exact match on 
Surname and Sex  
Same first 
name 
Name sounds 
alike 
Matching initials (either one or 
both of the first names are 
missing) 
 
Rule 
Number   
One initial Two or more initials 
DOB the same 
     Same Facility 1 1a 1g 
  
Same District 1 
1h- HIV TB 
1n- Day and 
month swap in 
DOB 
1m-HIV TB 
1k - HIV TB 
& TB pat must 
have ID 
number 
 
Not same  
District 
1 
1h- HIV TB 
1n- Day and 
month swap in 
DOB 
1m- HIV TB 
  
Age +- 1      
Same Facility 1 1b 1q 1i 
1c  
1e-TB patient 
must have ID 
number 
Same District 1 
 
1p- Soundex 
(Surname) and  
Part of address 
match 
 
1d 
1j- IDs match 
Not same District 1 
    
Age +- 2      
Same Facility 2 1b 1q 1i 
1c 
1e-TB pat must 
have ID number 
Same District 2 
 
1p- Soundex 
(Surname) and 
Part of address 
match 
 
1d 
1j- IDs match 
Not same District 2 
    
These rules were programmed with SQL.  It was recorded on both the HIV and TB dataset if a 
patient or TB record was linked; the unique identifier from each source was copied to the other 
source (cross referencing).  After a record from the ETR was matched and linked to a patient on 
the HIV database, it was excluded from further matching.  Therefore, it was important to execute 
rules with the best possibility of identifying a match between a patient on the HIV database with 
a patient on the TB database first, for example linking on exactly the same first name, surname, 
DOB, ID number and facility was a definite match.  If a very certain match was found, there was 
no need to try and link the record with less strict criteria, therefore, it was removed from the set 
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to match.  Once a match was found for an HIV database patient, the patient was not excluded 
from further matching since the patient could be matched with a different rule to a second/third 
TB record. 
A database table (TB-Linkages) was created to keep record of HIV database patients and TB 
records being matched as well as all the variables from both sources used for the linkage and the 
particular linkage rule.  Each rule had a unique number such that a particular linkage could be 
traced back to the rule in case it was found later that a specific rule did not link patients 
accurately enough.  All the records linked (linkages) with such a rule could then be 
reversed/cancelled.  Table 11 displays a few variables and fictitious data to illustrate the TB-
linkages table. 
Table 11: Example of some variables in TB-Linkages table after execution of linkage rules. 
TB
R
eg
ID
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IV
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U
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H
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A
G
E
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C
U
R
R
EN
T_
A
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E
 
235 ZU00023 2-1a Y Venessa Vanessa Smith Smit 29 30 
1025 ZU00204 1-1d Y Ben Benjamin Coetzee Coetzee 35 35 
120158 ZU00999 1-1h N John Johanna Mokoena Mokoena 29 36 
21025 ZU00023 2-1b Y Venessa Venessa Smith Smit 30 30 
 
2.4.6. Review of linkage output 
Record (patient) linkages were reviewed manually after each rule was executed to ensure that the 
linkages were accurate.  A binary variable (USE) was added to the TB-Linkages table and used 
to identify/indicate a mismatch and to “undo” the link by removing the cross referencing 
variables on the TB Register and HIV table. 
If it was noted that a rule returned ambiguous matches, the rule was discarded, linkages from the 
particular rule were deleted from the TB-Linkages table and the cross referencing on the separate 
data sources were removed. 
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Patients known to have TB according to the HIV programme, but who were not yet linked to a 
record on the TB register, were manually searched for on the ETR after the programmed rules 
were executed.  This process helped to identify more rules which could be programmed and 
identified matches that had too many variances for a deterministic computer linkage method.  
Typing errors in name, surname, ID number and sex (for the same person) would not result in a 
computer linkage but using human judgement the patient could be linked. 
The rules recognised that a patient may have multiple TB records or episodes.  Each time a 
patient enrolled for a TB treatment episode lasting between six and nine months, a record was 
entered in the ETR.  Therefore more than one TB record can be linked to an HIV patient due to 
the multiple TB episodes, see HIV_SUBJECT = ZU00023 in Table 11.  Additional information 
from the TB register such as the TB treatment start date and treatment end date as well as TB 
outcomes (died, failed, defaulted etc.) were often used to clarify/confirm multiple linkages to the 
same subject and to determine if the multiple episodes made logical sense.  There should not be 
an overlap between TB episode start dates. A patient can only start a second episode after he/she 
completed the first episode.  Also, the first record/episode may not have “Died” as an outcome 
and a second TB episode recorded a year later with a different outcome (cured).  If there was any 
uncertainty regarding a linkage, the linkage was discarded.  
Table 12 displays a summary of the programmed rules, how many TB records were linked by 
the rule and how many TB linkages were removed after the manual review process.  Only Rule 
group 1 is displayed in Table 12.  Rule group 2 used the same combinations of matching 
variables except for age ± 2 years. In total 52 rules were programmed. 
Table 12: Linkage results 
Rule group Rule No. No. linked No. Discarded 
1 1a 2205 10 
1 1b 4027 130 
1 1c 227 2 
1 1d 541 
 1 1da 68 
 1 1db 357 1 
1 1e 43 
 1 1Ga 723 
 1 1Gb 634 1 
1 1Gc 52 
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Rule group Rule No. No. linked No. Discarded 
1 1Gd 209 2 
1 1Ge 94 
 1 1Gf 1340 3 
1 1Gg 802 7 
1 1Gh 630 6 
1 1Gi 833 27 
1 1Gj 1713 47 
1 1H 130 
 1 1I 63 
 1 1j 23 
 1 1k 31 1 
1 1L 17 
 1 1M 49 
 1 1Ma 67 
 1 1N 4 
 1 1P 291 
 
After the linkage process was completed, 14.2% (24 279 / 199 998) records of the TB register 
records were linked to an HIV database patient.  The reviewing process discarded 281 linkages, 
resulting in 20.4% (18 438 / 90 367) of HIV database patients linked to a record in the TB 
register, containing TB treatment episode data between 2003 and 2010.  Seventy three percent 
(73%, 8 730 / 11 896) of HIV patients known to have TB, as recorded by the HIV programme, 
were linked to the TB register, while the other 27% (3166 / 11 896) of HIV patients could not be 
linked to any record on the ETR after programmed rules and manual searches.  This likely 
indicates under-reporting of TB cases in the ETR, as reported by other studies (Van Hest NAH. 
et al., 2006; Melosini L et al., 2012 ) but may reflect a sensitivity of 73% for the record linkage 
process  An additional 9 708 HIV patients were identified as co-infected with TB, after the 
linkage to the ETR, which was not recorded at any HIV programme visit.  In total, 24% (18 438 
+ 3 166) / 90 367) of HIV patients were known to have TB, either recorded by ETR (45%, 
9 708 / 21 604), HIV database (14.6%, 3 166 / 21 604), or both (40.4%, 8 730 / 21 604).  See 
Figure 13 for a diagram representing the linkage results. 
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Figure 13: TB linkage results. 
TB episodes were then arranged logically, especially for the 8 730 patients with TB information 
from both the HIV programme (HIV-TB) and electronic TB register (ETR-TB).  This was done 
to make sure that the recorded HIV-TB episode occurred during the same time period the ETR 
has a recorded TB episode for the patient.  If not, the HIV-TB episode could be a different TB 
episode not matched or recorded on the TB register.  An “estimated TB episode” had to be used 
for patients with HIV programme TB information since no TB treatment start or end date was 
available.  Section 2.4.7 describes how these HIV-TB episodes dates were created. 
2.4.7. Refinement of TB episode data 
TB data collected in the HIV programme was limited (Figure 11).  This information was not 
accurate enough to calculate an exact TB start date, therefore an estimated TB start date was 
calculated from the HIV programme visit data.  HIV programme visit records, indicating that the 
patient was on TB treatment, were retrieved and sorted by patient and visit date (consultation 
date) as indicated on the form.  The first date in the sequence was selected, 12 months were 
added to it and recorded as a TB episode.  The first record with TB information after this 12 
month period was taken as the start date for a new TB episode etc.  See Figure 14 for a 
schematic representation of the process described.  Each blue cross on the timeline represents an 
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HIV visit form where “On TB treatment” was selected by the healthcare worker.  Although a 
standard TB episode is usually between 6-9 months, a 12-month period was used for an HIV 
programme TB episode1. 
 
Figure 14: A schematic representation to indicate how HIV programme TB episodes were calculated. 
 
Linked TB register data were also cleaned to identify episodes to be used for analyses. On 
occasion it was found that two episodes were registered for a patient within three months of each 
other.  The first episode’s outcome would be moved/not evaluated and the second episode would 
be cured/completed/died.  The first episode would be discarded and the second one would be 
used.  If the TB start date of second episode was within three months of the first episode, the 
earliest start date would be used to replace the start date of the episode selected. 
The ETR episodes (ETR-TB) and HIV programme TB episodes (HIV-TB) were combined after 
being cleaned separately.  Records were sorted on TB episode start date and numbered 
consecutively from ‘1’ to ‘N’ per patient.  If any HIV-TB treatment start date was within a six 
month period of an ETR-TB treatment start date, the HIV-TB episode was discarded, since the 
TB treatment episode dates in the ETR were more accurately recorded (Figure 15).  After the 
HIV-TB episodes were removed, the data were sorted and numbered again.  TB episodes within 
six months of the first episode would get the same episode number and were reviewed manually 
to decide if it was referring to the same episode or if it was a new episode.  If it was evident from 
                                                          
1 Only 100 patients were recorded as having multi-drug resistance TB (MDR TB) on ETR.  The maximum treatment 
duration recorded for these patients in the ETR was 9 months and a failed treatment outcome was recorded for all 
of them. 
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the data that the patient was treated for a second time, the episode number was changed to ‘2’, 
for example; 
TB Start: 15 Feb 2009, TB Stop:  8 Aug 2009, TB outcome: Completed   >  Episode 1. 
TB Start: 10 Aug 2009, TB Stop: 10 Feb 2010, TB outcome Died   >  Episode 2 
  
Figure 15: Diagram indicating how TB episodes were selected after ETR and MT TB merge. 
Patients with more than 4 episodes were reviewed manually to confirm that the linkages were 
correct and any incorrect linkages were removed. After the data cleaning and TB episode 
selections were completed, the final record set was created which was used as the starting dataset 
for study populations in section 2.5 (Aim 1), 2.6 (Aim 2), and 2.7 (Aim 3). 
2.5. Effect of ART on incidence of TB disease in HIV-positive patients (Aim 1) 
This analyses was designed to include all of the HIV database patients (≥16 years) who were 
HIV-positive and enrolled between 2004 and 2010.  This provided the opportunity to evaluate 
the effect of ART on incidence of TB disease (time to first episode of TB) for two groups of 
patients in this high risk cohort, those who did not receive ART by the end of follow-up and 
those who had.  It was also possible to evaluate the effect of ART on multiple episodes of TB 
and the effect of the linkage with the ETR. 
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2.5.1. Specific aims 
1. To estimate TB treatment episode incidence rates for the overall group, and crude 
incidence rate ratios comparing follow-up periods during which patients received ART 
with follow-up periods during which patients did not receive ART. 
2. To estimate the effect of  initiating ART compared with not initiating ART on time until 
the first episode of TB treatment, taking into account the competing risk of death. 
3. To perform a sensitivity analysis estimating the effect of initiating ART compared with 
not initiating ART on time until the first episode of TB, but limited to TB information 
collected by the HIV programme, thereby assessing the effect of the linkage with the 
ETR on results.   
4. To estimate the effect of receiving ART on incidence rates of multiple TB episodes, i.e. 
ART initiated at different time points (before, during or after TB treatment episodes) 
2.5.2. Study population 
This study was conducted among all HIV positive adults enrolled in the Free State Province HIV 
programme at public sector facilities between May 2004 and June 2010.  This dataset included 
patients who have and have not received ART as well as patients with and without TB.  TB case 
information was determined either from the ETR using standard treatment definitions (section 
2.3.3) or from TB information routinely collected during HIV programme visits (section 2.3.2). 
Inclusion criteria: 
• Patients enrolled in HIV programme between May 2004 and June 2010. 
• Patients 16 years or older at enrolment in the HIV programme. 
Exclusion criteria: 
• HIV negative patients 
• Patients starting ART before public sector HIV programme rollout. 
• Patients without a valid SA ID number and one visit to the HIV programme in 
whom it was thus not possible to link to the population register to evaluate time at 
risk of TB. 
• Patients with no visit information recorded on the HIV programme. 
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• Patients with discrepancies in the sequencing of key dates 
• Patients who died on the date of enrolling in the HIV programme, and thus had 
not follow-up time to contribute to the analysis. 
2.5.3. Design 
This was a retrospective cohort study to estimate the effect of ART on incident TB in Free State 
public sector HIV programme patients.  
2.5.4. Data variables 
Individual patient level data from the HIV programme data were analysed.  TB patients were 
identified from either HIV programme (HIV-TB) or from ETR-TB (section 2.4.7).  Patients with 
incident TB were those with a TB treatment start date after their enrolment in the HIV 
programme.  History of TB was defined as TB episodes before enrolling in the HIV programme 
or being on TB treatment at the time of enrolment (prevalent TB). 
Follow-up time, also referred to as person-time or time at risk, was divided in two records, 
follow-up time during the period of no ART treatment (no-ART) or also known as pre-ART, and 
follow-up time when the patient received ART (ART).  The no-ART period was from enrolment 
in the HIV programme until one day before ART was initiated and the ART period was from the 
date of ART initiation to the censor date.  Patients on ART contributed person-time to both no-
ART and ART records.  Follow-up time (time at risk for TB) was defined as time from HIV 
programme enrolment to the first TB diagnosis or censoring event (date) and this follow-up time 
was divided in a no-ART and ART record.   
Follow-up time was censored as follows: 
a) Death date for patients who died. 
b) Patients with a valid South African ID number (including lost to follow up patients) and 
not known to be dead when the last linkage with the death population register was done 
(2010/08/03), were assumed to be alive on this date, and so have the date of linkage 
(2010/08/03) as their censor date1 
                                                          
1 The death population register was considered to be comprehensive and up to date.  The extract included 
deceased patients with death dates as recent as the week before the date when the death extract was prepared 
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c) For patients without a valid South African ID number and not known to be dead, the date 
of their most recent visit to any health facility for example hospital visit, laboratory test 
date, HIV programme visit or TB treatment completion date was used. 
Patients who were lost to follow up to the ART programme might have moved, had their care 
transferred or had a visit at other healthcare facilities after their last ART programme visit.  
Linkage of the different health system data sources provided more follow-up information (time) 
than using only the ART programme database.  In the absence of a valid South African ID 
number, using their last health system contact date gave them  maximum follow-up time.   
Outcome variable 
The outcome was a diagnosis of TB either recorded during an HIV programme visit (HIV-TB) 
or from linkage to the electronic TB register (ETR-TB).  A binary variable (TB) was used to 
indicate if a patient had TB during the no-ART or ART record. 
Explanatory variables 
The primary explanatory variable for incidence of TB was whether or not the patient received 
ART by the end of follow-up.  Other explanatory variables included in the regression models 
were history of TB at enrolment, sex, age, and district. A binary variable (PREPOSTART) was 
created to classify no-ART and ART follow-up time records.  For no-ART records, 
PREPOSTART was set to ‘0’ and for ART records PREPOSTART was set to ‘1’.  Age was 
modelled as cubic splines with knots at the 25th, 50th, and 75th percentiles to optimise adjustment 
for confounding without assuming a linear relationship (Fairall LR et al., 2008).  The respective 
cut-points  were 29, 36 and 43 years.   
A binary variable (DIED) was coded for use in the competing risks analysis.  In this analysis the 
assumption was that TB and death compete with each other for the outcome.  This is simply 
because patients who die cannot be diagnosed with TB.  DIED was set to ‘1’ if a patient died 
during the no-ART or ART record and had no TB prior to death.   
CD4 cell count, weight and cotrimoxazole prescription were also included in the regression 
models. 
                                                                                                                                                                                           
by the Department of Home Affairs (2010/08/03).  The extracts were done on a monthly basis for the Free State 
Department of Health. 
68 
A CD4 cell count and weight documented closest to enrolment in the HIV programme were used 
for no-ART records, and a CD4 cell count and weight documented closest to the date when ART 
was started were used for ART records.   The no-ART CD4 cell count and weight values were 
from the period six months before the patient enrolled in the HIV programme and six months 
after the enrolment date but closest to the enrolment date.  A six month window before and after 
enrolment in the HIV programme was used since a CD4 cell count was a key factor for referring 
the patient to the HIV programme and for monitoring the patient’s status before ART could be 
initiated.  For ART records, values between six months before ART was started and fourteen 
days thereafter were searched to identify a value closest to the date when ART was started. 
Categorical variables for CD4 cell count and weight were created for no-ART and ART records.  
CD4 cell count categories were CD4 0-49, CD4 50-99, CD4 100-199, CD4 200-349, and 
CD4 350-2000 cells/µl.  The 25%, 50%, and 75% percentiles were used to define the weight 
categories.  Weight categories were thus 0-49 kg, 50-56 kg, 57-65 kg, and 66-160 kg for this 
population. 
Cotrimoxazole prescription was coded as a binary variable (COTRI).  It was assumed that once 
cotrimoxazole was prescribed, the patient remained on it and the COTRI variable was set to ‘1’.  
If no record of cotrimoxazole prescription was found, it was assumed that the patient did not 
receive cotrimoxazole and the variable was set to ‘0’.  In the case of patients with two records, if 
a patient was on cotrimoxazole during no-ART follow-up time, COTRI was set to ‘1’ for both 
the no-ART and ART record.  However, if cotrimoxazole was only prescribed during ART 
follow-up time, COTRI was set to 0 for the no-ART record and ‘1’ for the ART record. 
2.5.5. Statistical analysis 
Baseline demographics were characterised using standard descriptive statistics.  Categorical 
variables were described as number (%) and continuous variables as mean (standard deviation) 
or median (inter quartile range).  Binary outcome variables were compared with Pearson chi-
squared test and continuous outcomes with hierarchical linear regression.  A complex survey 
design was used since the data had a multi-level structure.  Outcomes tend to be concentrated 
within clinics within districts.    It was  assumed that patients who started ART remained on 
therapy through to the end of follow-up. 
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TB incidence rate was defined as the number of TB cases occurring per 100 person-years 
observation at risk for either the no-ART group, on ART group or overall. 
When multiple TB episodes are taken into account, person-time accrued during TB episodes 
(either prevalent TB at enrolment or during TB treatment after enrolment) was excluded from 
the denominator (person time at risk) when TB incidence rates were calculated.  Figure 16 gives 
a schematic representation of how follow-up time was counted; the red lines on the time line was 
added for no-ART follow-up time, and the green lines represent follow-up time counted during 
ART.  Unadjusted TB incidence rates and incidence rate ratios were calculated under a Poisson 
distribution and expressed as number of events per 100 person-years. 
 
Figure 16: Schematic representation of how follow-up time was counted and divided between no-ART (pre-
ART) and ART follow-up for analysis of multiple TB episodes. 
Censoring was described under section 2.5.4.  For analyses of time to first TB episode, each 
person could contribute a maximum of one case. 
The primary analysis, a competing risks proportional hazards regression model was used to 
estimate adjusted associations of patient characteristics with rates of incident TB (Fine JP et al. 
1999). Time from enrolment to TB diagnosis was analysed, with death as a competing risk.  Sub 
distribution hazards (SHR) were estimated for these competing events and can be interpreted 
similarly to hazard ratios estimated in standard Cox models, but account for the hazard of the 
competing event (Ingle SM et al. 2010b).  Andersen and colleagues (2012) summarise the key 
feature of competing risks regression as being “that the one-to-one correspondence between 
cause-specific hazard and cumulative incidence, between rate and risk, is lost. This fact has two 
important implications. First, the naıve Kaplan–Meier that takes the competing events as 
censored observations, is biased. Secondly, the way in which covariates are associated with the 
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cause-specific hazards may not coincide with the way these covariates are associated with the 
cumulative incidence.” (Andersen PK et al., 2012).  A Marginal Structural Model (MSM) could 
not adequately account for the competing risk of death, that is, they could not distinguish 
between censorship due to death, censorship due to incident TB and censorship due to end of 
follow-up for other reasons. 
The ART facility variable was excluded from competing risks model due to the large dataset and 
the impact of the facility variable on computing time and performance of the statistical software.  
Also cotrimoxazole prescription was excluded from the model since we know that cotrimoxazole 
does not prevent TB, although it prevents death and is highly correlated with ART prescription 
(Fairall LR et al., 2008; Grimwade K et al., 2005).  Multiple imputation was used to impute 
missing CD4 cell counts and weights (Royston P, 2005). 
Stata offers procedures for creating and analysing multiple imputed datasets for incomplete 
multivariate data. Multiple imputation provides a useful strategy for dealing with datasets with 
missing values.  Instead of filling in a single value for each missing value, Rubin’s (1987) 
multiple imputation procedure replaces each missing value with a set of plausible values that 
represent the uncertainty about the right value to impute.  These multiple imputed datasets are 
then analysed by using standard procedures for complete data and combining the results from 
these analysis.  No matter which complete-data analysis is used, the process of combining results 
from different imputed datasets is essentially the same. This results in statistically valid 
inferences that properly reflect the uncertainty due to missing values. 
Initiation of ART is based on a CD4 count (threshold) and CD4 counts improve while being on 
ART. An interaction term was included in models to test if the effectiveness of ART was 
different at different CD4 levels.  Wald tests were used to determine if the interaction was 
significant. Sub-hazard ratios for the interaction term factors were estimated by exponentiation 
of coefficients from the linear combinations of coefficients (Stata help file: lincom).  Also, the 
effect of ART versus no-ART prescription on TB incidence was evaluated within each of the 
CD4 strata (primary and secondary models). 
 Kaplan Meier curves were used to characterize the failure function to first TB episode. A 
secondary analysis for time to first TB was prepared with a Cox proportional hazards regression 
model, which estimates hazard ratios and 95% confidence intervals for risk factors for incident 
TB. 
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 A Poisson regression model, which is used to model count data and contingency tables, was 
used to evaluate the effect of ART on multiple TB episodes (counts). 
For all models included in this analyses, a crude model was prepared as well as the adjusted 
model with and without the interaction term. 
2.5.6. Sensitivity analysis 
A sensitivity analysis using Cox proportional hazards model, restricted to TB information 
obtained solely from the HIV programme, was used to investigate the effect of ETR linkage on 
findings. 
A summary of the planned statistical analyses is presented in Table 13 
Table 13. Summary of statistical analyses for evaluating the effect of ART on TB incidence. 
Investigate Model used Effect estimate 
Baseline demographics: 
a) Descriptive statistics 
(Number (%), 
mean(SD), median) 
b) Testing for trend over 
time 
a) Chi-squared test; Hierarchical 
linear regression 
b) Extension of Wilcoxon rank sum 
test 
p-value 
Baseline demographics 
a) Descriptive statistics 
b) TB incidence rate 
c) TB incidence rate ratio 
Number (%), mean(SD), 
median; IR, IRR 
Primary analysis for effect of 
ART on time to first TB episode 
taking into account competing 
risk of death.  (TB from HIV 
programme and ETR.) 
a) Crude competing risks model.  
No imputation. 
b) Adjusted competing risks model. 
Imputed data [10 sets]. 
SHR 
Secondary analysis for effect of 
ART on time to first TB 
episode. (TB from HIV 
programme and ETR.) 
a) Crude Cox proportional hazards 
model. No imputation.  
b) Adjusted Cox proportional 
hazards model.  Imputed data [10 
sets].  
c) Adjusted Cox proportional 
hazards model.  No imputation. 
HR 
Sensitivity analysis for effect of 
ART on time to first TB episode 
but limited to TB information 
from HIV programme only 
a) Adjusted Cox proportional 
hazards model.  No imputation. HR 
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Investigate Model used Effect estimate 
Secondary analysis to model 
count data and the effect of ART 
on multiple TB episodes.  (TB 
from HIV programme and ETR) 
a) Crude Poisson regression model. 
No imputation. 
b) Primary analysis for effect of 
ART on incidence rate of multiple 
TB episodes: Adjusted Poisson 
regression model. Imputed data 
[25 sets]. 
IRR 
SHR: Sub-hazard ratio;  HR: Hazard ratio;  IR: Incidence rate; IRR: Incidence rate ratio 
2.6. The effect of ART on mortality (time to death) in co-infected HIV-TB patients 
(Aim 2) 
TB remains a major cause of death in patients infected with HIV and accounted for almost 25% 
of AIDS-related mortality globally (WHO report, 2011).  The effectiveness of ART on mortality 
was described previously for the Free State HIV programme for all patients enrolled between 
2004 and 2005 (Fairall LR et al., 2008).  The current analysis aimed at understanding the effect 
of ART in the co-infected HIV-TB Free State population six years after ART was first 
implemented in the public sector. 
2.6.1. Specific aims 
1. To evaluate the effect of  receiving ART or initiating ART during or after TB treatment 
compared with not receiving ART, on survival in co-infected HIV-TB patients. 
2. To identify risk factors associated with time to death in HIV patients diagnosed with TB. 
3. To evaluate the effect of linkage with ETR on survival outcomes. 
2.6.2. Study population 
All HIV positive adults enrolled in the HIV programme between May 2004 and June 2010 who 
were treated for TB treatment after enrolment.  Co-infected HIV-TB patients were identified 
from TB treatment status information collected in the HIV programme and linkage to the ETR.  
ART initiation could have been before, during or after TB treatment, or not at all. 
Inclusion criteria: 
• Patients 16 years or older of age at the start of TB treatment. 
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Exclusion criteria: 
• HIV negative patients. 
• Patients with TB prior to their enrolment in the HIV programme, in whom the 
date of HIV diagnosis is not known. 
• Patients without a valid SA ID and one visit to the HIV programme in whom it 
was not possible to evaluate survival time (Pettit AC et al., 2011). 
• Patients who died on the date they enrolled for the HIV programme and so could 
not contribute follow-up time to the analysis. 
2.6.3. Study design 
This was a retrospective cohort study comparing survival in co-infected HIV-TB patients on 
ART and not on ART using observational public sector HIV and TB data.  Survival time was 
from the date when TB treatment was started until death or censoring (see Section 2.6.4). 
Two models were used to evaluate survival, a marginal structural model (MSM) and Cox 
proportional hazards model.  In contrast to standard methods, marginal structural regression 
models appropriately account for selection bias and adjust for time-varying covariates which are 
simultaneously confounders and intermediate variables (Robins JM et al., 2000; Hernan MA et 
al., 2000; Cole SR et al., 2003).  Selection bias occurs when subjects are selected into the 
exposure group (ART in this case) according to factors that are part of the outcome (death in this 
case). CD4 count, weight and AIDS progression were part of the outcomes of treatment leading 
to death as well as being key variables used to select patients for treatment. Selection bias in 
estimation of treatment effects is also known as confounding by indication.  
When CD4 counts (time-varying confounders) are themselves predicted by ART (previous 
exposure) they become intermediate variables on the pathway between ART exposure and death.   
See the directional acyclic graph (DAG) in Figure 17 displaying the confounding problem.  
MSM helps to solve the problem of should one adjust for the confounder or not (Steenland K, 
2013). 
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Figure 17: Directional acyclic graph to demonstrate confounding scenario. 
 “Marginal structural models apply inverse-probability weights based on an ‘exposure’ model 
which assesses the probability for each subject that they have received their own exposure and 
confounder history up to each time t, with the follow-up period divided into T (t=1 to T) 
categories.  These weights are then used in standard regression models (eg, pooled logistic 
regression models across the categories of follow-up time) assessing treatment/exposure effects 
on disease, and their use amounts to analysing a pseudo-population where the time-varying 
confounding is eliminated. Such weights also enable the investigator to account for censoring 
which may be due to past exposure or confounder history (‘informative’ censoring)” (Steenland 
K, 2013). 
For the Cox model and marginal structural model, patient follow-up time (survival time) was 
taken from start of TB treatment to censoring and divided in no-ART follow-up time and ART 
follow-up time.  Three groups of patients were identified: 
1. Patients who were treated for TB before ART was started: 
No-ART follow-up time was from the TB treatment start date to one day before ART 
was started, ART follow-up time was from the date ART was started to the censor date 
(see Section 2.6.4).  This resulted in two records per patient. 
2. Patients who were treated for TB after ART was started: 
Follow-up time was from the date when TB treatment started to the censor date (ART 
follow-up time only).  This resulted in one record per patient. 
3. Patients who were only treated for TB, and have not received ART by the end of follow-
up: 
Follow-up time was from the date when TB treatment was started to the censor date (no-
ART follow-up time only).  This resulted in one record per patient. 
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Figure 18 gives a graphical depiction of the three groups of patients and how follow-up time was 
divided. 
 
Figure 18: Time lines indicating how no-ART and ART follow-up time was divided. 
For marginal structural models the dataset was transformed into a longitudinal format to create 
one record per month (person-month) per patient.  For each patient a person-month record was 
created between the date when follow-up was started and the censor date.  Each monthly record 
reported on available weight, CD4 cell count, ART and cotrimoxazole prescription for the 
patient.  It was assumed that once a patient received ART or cotrimoxazole therapy, they 
remained on it.  If there were more than one CD4 cell count or weight measurement per month, 
the first measurement during that month was used.  Baseline or latest weights and CD4 values 
were carried forward to person-months for which they were missing. Thereafter weights and 
CD4 values that were still missing (because there were no previous measurements) were 
imputed using multiple imputation by chained equations (Royston P. 2004; Cole SR et al., 2003; 
Fairall LR et al., 2008). 
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2.6.4. Data variables 
The data collection process for the HIV programme and TB programme was described in section 
2.3.2 and section 2.3.4. respectively.  TB patients were identified using both sources of TB 
information, the HIV programme and ETR.  The data variables used for analyses were mostly 
from the HIV database after linkage to the laboratory, hospital and death population registry data. 
Censor date 
For patients with two records (no-ART and ART record), the no-ART record was censored one 
day before ART was started.  The ART record was censored at one of the following 
endpoints/dates: 
a) Death date for patients who died. 
b) Patients with a valid SA ID number and not known to be dead when the last linkage with 
the death  population register was done (2010/08/03), were assumed to be alive on this 
date, and so had the date of linkage (2010/08/03) as their censor date. 
c) For patients without a valid South African ID number and not known to be dead, the date 
of their most recent visit to any health facility was used, for example hospital visit, 
laboratory test date, HIV programme visit or TB treatment completion date. 
In patients who did not start ART by the end of follow-up, and so had only no-ART follow-up 
time (i.e. one record) the record was censored at one of the following dates: 
a) Death date for patients who died 
b) Patients with a valid SA ID number and not known to be dead when the last linkage with 
the death  population register was done (2010/08/03), were assumed to be alive on this 
date, and so had the date of linkage (2010/08/03) as their censor date. 
c) For patients without a valid South African ID number and not known to be dead, the date 
of their most recent visit to any health facility was used, for example hospital visit, 
laboratory test date, HIV programme visit or TB treatment completion date. 
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Patients who were lost to follow up to the ART programme might have had a visit at other health 
facilities after their last ART programme visit.  Using their last health system contact date in the 
absence of a valid South African ID number gave them maximum follow-up time. 
Survival time 
Survival time was defined as the time in days (or months) between the date TB treatment was 
started and the censor date.  Months were used for the marginal structural model where one 
record for each month of follow-up was created and for presentation purposes with the Kaplan 
Meier curve. 
Outcome variable 
The outcome was whether or not the patient had died. 
A binary variable (DIED) was created to capture vital status for patients at the censor date of 
each no-ART and ART record.  If a patient was deceased at the censor date, DIED was set to ‘1’, 
otherwise DIED was set to ‘0’.  For patients who died during the ART period and contributed 
follow-up time to no-ART and ART records, DIED was set to ‘0’ for the no-ART record, while 
DIED was set to ‘1’ for the ART record.  Figure 19 gives a graphical representation of how 
follow-up time was divided between no-ART and ART and how the outcome variable was coded 
for each particular record.  
Explanatory variables 
The primary explanatory variable for mortality was whether or not the patient received ART.  
Other explanatory variables included in the model were follow-up time in days (survival time), 
sex, age, history of TB and district. 
A binary variable (PREPOSTART) was created to identify no-ART and ART follow-up records.  
For no-ART records, PREPOSTART was set to ‘0’, and for ART records PREPOSTART was 
set to ‘1’.  Age categories were created instead of using age as a continuous variable.  Age was 
modelled as cubic splines with knots at the 25th, 50th, and 75th percentiles to optimise adjustment 
for confounding without assuming a linear relationship (Fairall LR et al., 2008).  Age categories 
thus included 16-29 years, 30-35 years, 36-42 years, and 43 to 100 years. 
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Figure 19: Graphical representation of no-ART and ART follow-up time records for time to death analysis. 
CD4 cell count, weight and cotrimoxazole prescription were also included in the models.  For 
no-ART records, a CD4 cell count and weight documented closest to the start of TB treatment 
were searched for, and for ART records a CD4 cell count and weight closest to the date when 
ART was started.  The no-ART CD4 cell count and weight values included values from the 
period twelve months before TB treatment was started until three months after TB treatment was 
started. Where multiple values were available, the value closest to the TB treatment start date 
was used.  For ART records, a narrower window period for CD4 cell counts and weights was 
used since CD4 cell count and weight increase rapidly after a patient has started ART.  Values 
from the period six months before ART was started until fourteen days after ART was started 
were searched, and the value closest to the date when ART was started was used in the model.  
A six month window period was used for the ART record compared to the twelve month 
window period for the no-ART record.  A CD4 cell count was a qualifying criteria mostly for 
patients to start ART therefore it was more likely to find a CD4 cell count within a six month 
window period close to the ART start date, whereas with TB treatment the patient could have a 
CD4 cell count above 200 and only be seen bi-annually for follow-up monitoring in the HIV 
programme at the time.  Therefore a wider window period was chosen for a CD4 cell count 
closest to the TB start date.  
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Categorical variables for CD4 cell count and weight were created after the appropriate results 
were found.  CD4 cell count categories were CD4 0-49, CD4 50-99, CD4 100-199, 
CD4 200-349, and CD4 350-2000 cells/µl.  Weight categories were 0-45 kg, 46-52 kg, 53-59 kg, 
and 60-150 kg. As with age, the 25%, 50%, and 75% percentiles were used to define the weight 
categories. 
Cotrimoxazole prescription was coded as a binary variable (COTRI).  It was assumed that once 
cotrimoxazole was prescribed, the patient remained on it and the COTRI variable was set to ‘1’.  
If no record of cotrimoxazole prescription was found, it was assumed that the patient did not 
receive cotrimoxazole and the variable was set to ‘0’.  In the case of patients with two records, if 
a patient was on cotrimoxazole during no-ART follow-up time, COTRI was set to ‘1’ for both 
the no-ART and ART record.  However, if cotrimoxazole was only prescribed during the ART 
follow-up time COTRI was set to ‘0’ for the no-ART record and ‘1’ for the ART record. 
Explanatory variables (parameters) used to estimate the MSM weights: 
A. MSMs of ART effectiveness 
 
Treatment weight denominator:  
Cotrimoxazole prescription at baseline and during follow-up, CD4 at baseline and 
during follow-up, weight at baseline and during follow-up, TB classification, history 
of TB, age, sex, district, TB treatment episode number, month of follow-up.  
 
Treatment weight numerator: 
Cotrimoxazole prescription at baseline, CD4 at baseline, weight at baseline, TB 
classification, history of TB, age, sex, district, TB treatment episode number, month 
of follow-up. 
 
Censorship weight  denominator: 
Cotrimoxazole prescription at baseline and during follow-up, CD4 at baseline and 
during follow-up, weight at baseline and during follow-up, TB classification, history 
of TB, age, sex, district, TB treatment episode number, month of follow-up. 
 
Censorship weight  numerator: 
Cotrimoxazole prescription at baseline, CD4 at baseline, weight at baseline, TB 
classification, history of TB, age, sex, district, TB treatment episode number, month 
of follow-up. 
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B. MSMs of Cotrimoxazole effectiveness 
Treatment weight denominator:  
ART prescription at baseline and during follow-up, CD4 at baseline and during 
follow-up, weight at baseline and during follow-up, TB classification, history of TB, 
age, sex, district, TB treatment episode number, month of follow-up.  
 
Treatment weight numerator:  
ART prescription at baseline, CD4 at baseline, weight at baseline, TB classification, 
history of TB, age, sex, district, TB treatment episode number, month of follow-up.  
 
Censorship weight  denominator: 
ART prescription at baseline and during follow-up, CD4 at baseline and during 
follow-up, weight at baseline and during follow-up, TB classification, history of TB, 
age, sex, district, TB treatment episode number, month of follow-up.  
Censorship weight  numerator: 
ART prescription at baseline, CD4 at baseline, weight at baseline, TB classification, 
history of TB, age, sex, district, TB treatment episode number, month of follow-up.  
 
2.6.5. Statistical analysis 
Patient characteristics at the start of episodes were tabulated and described as follows. 
Categorical variables were described as number (%) and continuous variables as mean (standard 
deviation) or median (inter quartile range).  Binary outcome variables were compared with 
Pearson chi-squared test and continuous outcomes with hierarchical linear regression after the 
data were adjusted.  A complex survey design was used since the data had a multi-level structure.  
Outcomes tend to be concentrated within clinics within districts.  It was  assumed that patients 
who started ART remained on therapy through to the end of follow-up. 
Survival of co-infected HIV-TB patients was determined by the method of Kaplan-Meier, 
considering survival time in months (Kaplan EL et al. 1958).  A crude Kaplan-Meier test was 
applied to estimate the probability of death and median time to death after a diagnosis of TB and 
the log-rank test was used to compare the median time to death between patients with and 
without ART. 
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The primary analysis was a marginal structural regression model (MSM) which used 
longitudinal data to account for selection bias, time-varying covariates and intermediate 
variables.  Analysis was performed at person-month level, using a longitudinal data extract with 
multiple records per patient (see section 2.6.3).  Probability weights were used to adjust for 
confounding by time-varying covariates which were also treatment outcomes.  Two logistic 
regression models were used to estimate stabilised inverse probability of censoring treatment 
weights.  Both models used censorship as outcome and included baseline covariates and months 
of follow-up.  However, the second model had extra time-varying covariates.  Stabilised inverse 
probability of treatment and censoring weights were produced by combining the weights.  The 
probability weights were used in the final pooled logistic regression model with death as 
outcome.  A Cox proportional hazards regression model was used since subjects were removed 
from the population at risk after the outcome had occurred (Fairall LF et al, 2008).  A sensitivity 
analysis with inverse probability of treatment weights truncated at 1st/99th percentiles or 5th/95th 
percentiles were done to evaluate the robustness of the MSMs and the treatment weights. 
Secondary analyses used Cox proportional hazard models (with and without imputation) to 
evaluate the independent effect of ART upon patient survival and to identify risk factors 
associated with survival in co-infected HIV-TB patients. To account for the non-independence 
of outcomes in patients who received ART and who therefore each have two records, Cox 
regression analyses included Huber-White robust estimation of errors, using Stata’s “cluster” 
option.  The only variables to be considered for inclusion in the final multivariable models were 
those that were available and considered clinically relevant.  The results from the final model 
were expressed in terms of Hazard Ratio (HR) and 95% confidence intervals. 
The statistical significance of differences in effects between subgroups were tested by adding 
interaction terms to the models.  An interaction between CD4 cell count and ART prescription 
was modelled by including an interaction term in the primary and secondary models.  Post-
model statistics were used to determine if the interaction was significant and hazard ratios for the 
interaction term factors were estimated by exponentiation of coefficients from the linear 
combinations of coefficients (Stata help file: lincom).  Also, the effect of ART versus no-ART 
prescription on survival was evaluated within each of the CD4 strata (primary and secondary 
models). 
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2.6.6. Sensitivity analysis 
A sensitivity analysis using a Cox proportional hazards model without imputation, and restricted 
to TB information obtained solely from the HIV programme, was used to investigate the effect 
of ETR linkage on findings. 
A summary of planned statistical analyses is displayed in Table 14. 
Table 14. Summary of statistical analyses to evaluate the effect of ART on time to death. 
Investigate Model used Effect estimate 
Baseline demographics: 
a) Descriptive statistics 
(Number (%), mean(SD), 
median) 
       b)  Testing for trend over time 
 
a) Chi-squared test; Hierarchical 
linear regression 
b) Extension of Wilcoxon rank sum 
test 
p-value 
Baseline demographics a) Descriptive statistics  Number (%), mean(SD), median 
Estimating probability of survival 
after TB diagnosis (start of TB 
treatment episode) for ART and 
pre-ART patients 
a) Kaplan-Meier 
 
Primary analysis for effect of ART 
on time to death taking into account 
selection bias, time-varying 
covariates and intermediate 
variables.  (TB from HIV 
programme and ETR.) 
a) Adjusted MSM. Imputed data [25 
sets]. HR 
Primary analysis for effect of 
cotrimoxazole on time to death 
taking into account selection bias, 
time-varying covariates and 
intermediate variables.  (TB from 
HIV programme and ETR.) 
a) Adjusted MSM. Imputed data [25 
sets]. HR 
Secondary analysis for effect of 
ART on time to death (TB from 
HIV programme and ETR.) 
a) Crude Cox proportional hazards 
model. No imputation.  
b) Adjusted Cox proportional hazards 
model.  Imputed data [25 sets].  
c) Adjusted Cox proportional hazards 
model.  No imputation. 
HR 
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Investigate Model used Effect estimate 
Sensitivity analysis for effect of 
ART on time to death but limited to 
TB information from HIV 
programme only 
a) Adjusted Cox proportional hazards 
model.  No imputation. HR 
MSM: Marginal structural model;   HR: Hazard ratio;   
 
2.7. The effect of ART on TB treatment outcomes in ART-naïve co-infected HIV-TB 
patients (Aim 3) 
The Free State Province’s ETR records treatment outcomes for patients, using standardised 
guidelines consistent with WHO guidelines.  Linkage of the ETR with the HIV programme 
database made it possible to add additional information, like death status, clinical and laboratory 
information, to perform sophisticated analyses with explanatory and confounding variables, 
which are mostly absent from the ETR.  TB treatment outcomes and the effect of ART on those 
outcomes were evaluated for the period 2004 to 2008, using descriptive statistics and logistic 
regression models. 
2.7.1. Specific aims 
1. Describe and compare baseline characteristics of patients, grouped by: 
a) Year TB treatment was started. 
b) Those who did or did not receive ART during TB treatment. 
c) Those who died during the first year of TB treatment and those who survived the 
first year since TB treatment commenced. 
2. Evaluate effect of ART, initiated during TB treatment compared with not receiving ART, 
on TB treatment outcomes, as defined by WHO, between 2004 and 2008. 
2.7.2. Study population 
The study population included all HIV positive patients with their first episode of TB registered 
at a public sector TB facility between January 2004 and December 2008.  Patients were 
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considered to have TB through information obtained exclusively from the ETR since TB 
outcomes are studied in this analysis.  The TB register extract, which was used for linkage, was 
received in June 2010, allowing up to 18 months follow-up time for ascertainment of TB 
treatment outcomes for patients who started TB treatment in December 2008. 
Inclusion criteria: 
• Patients 16 years or older when they started TB treatment. 
• First TB treatment episode recorded on the ETR for the patient between January 
2004 and December 2008. 
Exclusion criteria:  
• Patients starting ART before their first TB episode. 
• Patients with missing TB treatment outcomes. 
• Patients known to have TB from either database (ETR or HIV database) but who 
could not be linked. 
2.7.3. Study design 
This was a retrospective cohort study which analysed data for individual patients from the 
provincial ETR linked to the HIV programme.  TB treatment outcomes were compared in 
patients who did not receive ART and patients who received ART during their TB episode.  
Patients were assumed to have stayed on ART once they have started treatment.   
2.7.4. Data variables 
The data collection process for the HIV programme was described in section 2.3.2, TB 
programme data collection in section 2.3.4 and WHO definitions of TB treatment outcomes were 
provided in section 2.3.3. 
Outcome variables 
TB treatment outcomes routinely recorded in the ETR at the end of each TB episode were the 
primary outcomes.  TB outcome is a seven category variable (cured, completed, died, failed, 
transferred out, defaulted, not evaluated) and mutually exclusive, however each possible 
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outcome was re-coded as a binary variable for logistic regression purposes.  Success was an 
additional binary category for patients classified as either cured or completed.  Two additional 
death variables were added for this study.  The first death variable was for all deaths that 
occurred during the TB episode, whether recorded by the ETR or HIV database.  Non-fatal 
outcomes on the ETR were overwritten if linkage to HIV database identified that a patient died 
during the episode.  The second binary death variable was for deaths that occurred during the 
year following commencement of TB treatment (either during TB treatment or thereafter), and 
was derived using information from both databases. 
Explanatory variables 
The primary explanatory variable was whether or not a co-infected patient started ART during 
TB treatment.  A binary ART variable was created and set to 1 if the patient received ART at 
any point after TB treatment started.  An additional ART categorical variable was created to 
capture the timing of ART.  The first category included all patients who never started ART by 
the end of follow-up, or started ART after completion of TB treatment.  The second category 
included patients who started ART in the first 61 days of TB treatment (early ART), and the last 
category included patients who started ART after 61 days of TB treatment but before TB 
treatment was completed (late ART). 
Covariates 
Other explanatory variables included in the model were sex, age, ART facility and district, 
anatomical classification of TB (pulmonary, extra-pulmonary or both sites), whether new or 
retreatment case, and TB smear results, and CD4 cell count measured closest to start of TB 
treatment. 
A window period was used to determine baseline values; for CD4 cell counts the period twelve 
months before TB treatment was started and three months after TB treatment was started was 
searched for values, and the value closest to the TB treatment start date was used. 
Multiple imputation was used to impute missing CD4 cell counts due to a high proportion of 
missing data even after linkage with the laboratory results (Royston P, 2005).  CD4 cell count 
categories were generated after imputation to optimise adjustment for confounding without 
assuming linear relationships between these variables and the respective outcome.  CD4 cell 
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count categories were CD4 0-24, CD4 25-49, CD4 50-99, CD4 100-199, CD4 200-349, and 
CD4 350-2000 cells/µl.   
2.7.5. Statistical analysis 
Baseline characteristics for patients were compared by the year patients started TB treatment, by 
those who received ART and those who did not, and by those who died and did not die during 
the first year of treatment, adjusting standard errors of variable estimates for clustering of 
estimates within clinics within districts using Stata version 11.  The significance of a trend over 
time for baseline characteristics was evaluated using an extension of the Wilcoxon rank sum test.  
Categorical variables were compared with Pearson’s chi-squared test and continuous variables 
with one-way ANOVA (analysis of variance). 
Logistic regression analyses aimed to estimate the effect of ART on TB treatment outcomes, 
adjusting for differences in patient characteristics in the ART and no-ART groups to account for 
selection bias.  Separate analyses were carried out for each treatment outcome. All analyses were 
done at the individual patient level, accounting for stratification by health district and intra-clinic 
correlation of outcomes using Huber-White adjustment.  Results are presented with odds ratios, 
95% confidence intervals and p-values. 
Significant survivor bias was expected as only survivors were able to receive ART.  To address 
this, a sub-analysis was included to evaluate the effect of ART compared with no-ART on non-
fatal TB outcomes.  To ignore the effect of ART timing (early or late ART), an additional set of 
sub-analyses was done for patients who died during the first year since TB treatment 
commenced, and for all the other non-fatal TB treatment outcomes.  These analyses evaluated 
the effect of ART initiated during TB treatment (coded as a binary variable, ignoring when it 
was initiated) on the outcomes.  A summary of the planned statistical analyses is presented in 
Table 15. 
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Table 15.  Summary of statistical analyses to evaluate the effect of ART on TB treatment outcomes. 
Investigate Model used Effect estimate 
Baseline demographics: 
    a)  Descriptive statistics (Number       
(%), mean(SD), median)  
    b)  Testing for trend over time 
 
a) Chi-squared test; One-way 
ANOVA 
b) Extension of Wilcoxon rank 
sum test 
p-value 
Effect of ART (early, late or no 
ART) on TB treatment outcomes.  
Each outcome coded as a binary 
variable. 
Logistic regression OR 
Survivor bias expected therefore a 
sub-analysis to evaluate of effect of 
ART on TB treatment outcomes but 
limited to a sample of patients with 
non-fatal outcomes 
Logistic regression OR 
Sub-analysis ignoring timing of 
ART to evaluate effect of ART on 
TB treatment outcomes with ART 
coded as a binary variable 
Logistic regression OR 
 OR: Odds ratio;   
 
2.8. Ethics 
Approval to complete longitudinal analyses of patients recorded in the Free State’s HIV 
programme warehouse has previously been provided by the Research Ethics Committee of the 
University of Cape Town (REC/REF 082/2006), initially as an independent project and later as 
part of the NIH-funded International Epidemiological Databases to Evaluate AIDS (IeDEA) 
programme.  Specific approval to complete the analyses described in this proposal was sought 
through and granted an addendum application to the main cohort proposal (REC/REF 082/2006). 
It was not feasible to obtain consent for the use of medical records from the tens of thousands of  
patients included in these analyses.  However, ethical principles for the use of medical records 
without a patient’s consent (Haines A et al., 2000) were followed.  The research is of significant 
benefit to large scale ART programmes, and the inclusion of patients’ medical record data in the 
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analyses in no way influenced individuals’ care.   The data (except for TB linked data) have been 
used by the candidate, her supervisors and their collaborators for programme evaluation 
(monitoring and evaluation reports), a randomised clinical trial (Fairall LR et al., 2012) and 
observational evaluation of ART effectiveness in the programme cohort (Fairall LR et al., 2008) 
on behalf of the provincial health department. 
Patient confidentiality was protected by removing all personal identifiers (name, surname, DOB, 
address, South African ID number) when data were shared with supervisors.  Data extracts were 
provided in an anonymised, unlinked format and site information was coded as categorical 
variables.  Only the candidate kept a dataset with personal identifiers which was used for the 
linkage process and stored the password protected back-up copies of the dataset in a secure 
location at UCT Lung Institute.  The databases used to prepare the dataset for this project were 
removed from the SQL database server after completion of the analyses. 
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3. AN EVALUATION OF THE EFFECTIVENESS OF 
ANTIRETROVIRAL TREATMENT (ART) ON 
INCIDENCE OF TUBERCULOSIS IN HIV POSITIVE 
ADULTS 
The Free State HIV programme database includes tens of thousands of patients followed for 
several years, and includes follow-up time among patients receiving and not yet receiving ART.  
This allows for an evaluation of the effectiveness of ART on the incidence of TB (time to first 
episode of TB during follow-up, number of TB episodes per 100 person years) in this high risk 
population, results of which are presented in this chapter. 
3.1. Selection and characteristics of patients included in this analysis 
A total of 97 476 patients were documented as being enrolled in the HIV programme between 
May 2004 and June 2010, of which 23 401 patients were excluded because: 
a) they were younger than 16 years when they enrolled in the HIV programme (n=7 063), or  
b) they were documented as being HIV negative (n=1 839) 1, or  
c) they had no means of being followed because there was no valid South African ID 
number with which to link to the death population register and they only had information 
for one visit recorded (n=4 616), or 
d) there was no visit information recorded for them on the programme (n=8 026) 2, or  
e) discrepancies in the sequencing of key dates could not be resolved (n=1 021), or 
f) they died on the date of enrolling in the programme and so could not contribute follow-
up time to this analysis (n=836) (Figure 20). 
                                                          
1 The structured clinical records implemented as part of the Free State’s HIV programme made provision for the 
process of HIV testing to be documented.  This was used, at least during the early stages of the programme, to 
document all testing completed during enrolment in the programme, regardless of outcome.  As the programme 
expanded and clinicians battled to cope with large patient numbers, the practise of completing documentation for 
patients testing negative, was dropped.   
2 Patients were registered (capturing personal contact details) on the HIV programme database but no visit data were 
recorded for the patient, either because the patient never returned to the HIV service, or the visit data was never 
captured, or the patient was registered a second time without noticing the first registration.  Often one of the 
registrations did not have enough personal information (identifiers) available to identify it as a duplicate registration, 
and therefore the first registration with missing visit information remained on the system.   
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Of the remaining 74 075 patients who were included in the final analyses, 26 480 (36%) had not 
started ART by the date on which their follow-up time was censored, and 47 595 (64%) patients 
had started ART. 
Selection of patients for inclusion in these analyses is displayed in Figure 20, which also shows 
the categorisation of the follow-up records.  Follow-up time for patients was measured from 
enrolment in the HIV programme to the first diagnosis of TB and divided into no-ART and ART 
follow-up time (Methods 2.7.4).  No-ART follow-up was defined from the day patients enrolled 
in the HIV programme until one day before ART treatment was started or the censor date. Both 
patients who had not started ART by the end of follow-up (n=26 480) and patients who had 
started ART during follow-up (n=39 326), contributed time to no-ART follow-up.  ART follow-
up time was from the date when ART treatment was started until the censor date.  Ten percent of 
ART follow-up records (4 572 / 43 898) was contributed by patients who started ART on the day 
they were documented as being enrolled in the HIV programme, therefore they only contributed 
ART follow-up time  (Figure 20).  Patients who had started TB treatment before ART was 
started, only contributed no-ART follow-up time to this analysis (n=3 697) since follow-up was 
censored at the first diagnosis of TB. 
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Figure 20: Selection of patients for analyses 
Baseline characteristics for these patients are displayed in Table 16.  The majority of patients 
included in this analysis were young women in their thirties (67.4% women, mean 37 years).  
The patients’ CD4 counts at enrolment suggested they had advanced disease with a median CD4 
cell count below 200 cells/µl (IQR: 66-234).  Only 24.8% of patients with an available CD4 
result, had a CD4 cell count above 200 cells per µl.  A SA ID number was available for most of 
the patients (88.7%), permitting follow-up through linkage with the national death population 
43 898 
records 
 
39 326 
records 
 
Patients documented as enrolling 
in Free State HIV programme 
between May 2004 and June 2010  
N = 97 476 
 
Patients who did not 
start ART: 
26 480 (36%) 
 
Excluded: 23 401 patients (24%) 
 Age<16:  7 063 (30.2%) 
 HIV negative:  1 839 (7.8%) 
 Invalid ID and 1 visit: 4 616 (19.7%) 
 Registered but 0 visits: 8 026 (34.3%) 
 Date inconsistencies: 1 021 (4.4%) 
 Died on the day of enrolment: 836 (3.6%) 
No-ART follow-up records 
N = 65 806 (60%) 
 
26 480 (40%) records from 
patients who did not start 
ART, and  
39 326 (60%)  no-ART 
records from  ART patients. 
 
   TB episodes: 5 669 
ART follow-up records 
N = 43 898 (40%) 
 
4 572 (10%) records from 
patients contributing ART 
follow-up time only 
(Enrolment date = ART 
start date) 
 
   TB episodes: 3 858 
Patients who had started 
ART by June 2010: 
47 595 (64%) 
 
N=74 075 Patients  
Characteristics at the 
time of enrolment are 
displayed in Table 13 
N=109 704 records 
 
Characteristics at the 
start of TB for no-ART 
records and at the start 
of ART for ART records 
are displayed in 
Table 14 
3 697 Patients who 
received ART treatment, 
had TB before ART was 
started therefore 
contributed only a no-ART 
follow-up record. 
Censoring at first TB episode 
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register.  Almost a fifth (19.4%) of the patients had a history of TB treatment or were receiving 
TB treatment when they were registered on the HIV database.  Twenty five percent 
(18 357 / 74 075) of the patients died, 66% (12 123 / 18 357) of them before they could be 
started on ART. 
Table 16: Characteristics of patients included in this analysis.  Data presented for the overall group, and 
disaggregated into those who did not receive ART by the end of follow-up, and patients who received ART 
during follow-up. The latter two categories are mutually exclusive. 
Factors Overall Did not receive 
ART by the end 
of follow-up 
Received ART 
by the end of 
follow-up 
p value a 
 
n (%) n (%) n (%) 
Number of patients  74 075 26 480  47 595  
 
Women 49 938 (67.4) 17 121 (64.7) 32 817 (68.9) <0.001 
Age in years: Mean (SD) 37 (10) 36 (10) 37 (9) <0.001 
Mean weight at enrolment, kg. 
Mean (SD) b 
58 (13) 
n=59 089 (79.8) 
57 (14) 
n=18 556 (70.1) 
59 (13) 
n=40 542 (85.2) 
<0.001 
Mean CD4 cell count at enrolment, 
cells/µl., Mean (SD) b 
181 (171) 
n=60 731  
(82.1) 
254 (231) 
n=21 453  
(81.0) 
142 (108) 
n=39 278 
(82.5) 
<0.001 
 
Median CD4 cell count at 
enrolment, cells/µl. Median 
( IQR) b 
140 (66-234) 
n=60 731 (82.1) 
192 (73-371) 
n=21 453 (81.0) 
127 (64-188) 
n=39 278 (82.5) 
 
 
Number of patients per CD4 cell 
count category at enrolment    
<0.001 
CD4 missing 13 344(18.0) 5 363 (18.0) 7 981 (18.0) 
 
CD4 0-49 11 563(15.6) 4 583(15.4) 6 980 (15.7) 
 
CD4 50-99 10 420 (14.1) 3 401 (11.4) 7 019 (15.8) 
 
CD4 100-199 20 445 (27.6) 5 208 (17.5) 15 237 (34.4) 
 
CD4 200-349 10 854 (14.6) 5 029 (16.9) 5 825(13.1) 
 
CD4 >= 350 7 448 (10.1) 6 141(20.7) 1 307 (2.9) 
 
Valid SA ID number 65 728 (88.7) 23 314 (88.0) 42 414 (89.1) 0.003 
History of TB at enrolment in HIV 
programme 14 382 (19.4) 3 142 (11.9) 11 240 (23.6) <0.001 
ART: Antiretroviral therapy;  SD: Standard deviation;  IQR: Inter quartile range. 
a Comparing patients who did not receive ART by end of follow-up with patients who received ART for 
complex survey data, adjusted for district strata and clustering within subjects, using hierarchical linear 
regression for continuous outcomes and logistic regression for binary outcomes. 
b Value from period six months before enrolment in HIV programme and six months after enrolment date but 
closest to the enrolment date. 
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Table 17 displays patient characteristics used in the analyses to adjust for confounding.  For no-
ART follow-up records, characteristics at the time of enrolling in the HIV programme are shown.  
For ART records, characteristics at the time of starting ART are shown.  Categories are not 
mutually exclusive as ART patients may have contributed follow-up time to both.  Whereas 
Table 16 reports on a total of 74 075 patients, Table 17 reports on all 109 704 no-ART and ART 
records contributed by these 74 075 patients. 
Out of a total of 109 704 records, no-ART follow-up records contributed 60% (65 806 / 109 704) 
of the records.  Overall, the same trend in data was observed as in Table 16, that is women 
contributed most of the records and the mean age was 36 (SD 10) at enrolment and 37 (SD 10) at 
the start of ART.  A history of TB at enrolment was reported for almost a fifth of the records; 
19.6% of no-ART follow-up records, and 24.6% of ART follow-up records reported TB before 
HIV programme enrolment.  The majority of TB episodes recorded after enrolment occurred 
during no-ART follow-up period (60%, 5 669 / 9 527). 
No-ART follow-up records had a total of 63 342 person years (py) and ART follow-up records a 
total of 79 321 person years.  The overall TB incidence rate for this Free State HIV positive 
cohort was 6.68 per 100 py ((5 669+3 858 TB cases) / (63 342 py+79 321 py) × 100).  The 
incidence rate of TB in patients not receiving ART by the end of follow-up was 8.95 per 100 
person years (5 669 TB cases / 63 342 py × 100), while for patients receiving ART the incidence 
rate of TB was 4.86 per 100 person years (3 858 TB cases / 79 321 py × 100).  Thus the crude 
TB incidence rate ratio (IRR) was 0.54 (CI: 0.52-0.56) for patients on ART compared to patients 
not receiving ART at the end of follow-up (Table 17). 
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Table 17: Characteristics of patients included in the analysis at the time of first enrolling in the HIV 
programme (no-ART follow-up record) and at the time of starting ART (ART follow-up record). 
Factors No-ART follow-up period 
n (%) 
ART follow-up 
period 
n (%) 
p value a 
 
Number of patients 65 806 43 898 
 
Women 44 310 (67.3) 30 599 (69.7) <0.001 
Age in years: Mean (SD) 36 (10) 37 (10) <0.001 
Mean weight at start of record, kg. Mean 
(SD) b 
58 (14) 
n=53 400 (81.1) 
59 (13) 
n=33 079 (75.3) <0.001 
Mean CD4 cell count at start of record, 
cells/µl.  Mean (SD) b 184 (174) 129 (90) <0.001 
Median CD4 cell count at start of record, 
cells/µl. Median (IQR) b 
142 (66-239) 
n=56 145 (85.3) 
122 (61-176) 
n=35 876 (81.7) <0.001 
Number of patients per CD4 cell count 
category at start of record b   
<0.001 
    CD4 missing 9 662 (14.7) 8 022 (22.4) 
 
    CD4 0-49 10 647 (16.2) 7 260 (20.2) 
 
    CD4 50-99 9 576 (14.6) 7 257 (20.2) 
 
    CD4 100-199 18 678 (28.4) 16 432 (45.8) 
 
    CD4 200-349 10 022 (15.2) 4 353 (12.1) 
 
    CD4 >= 350 7 221 (11.0) 574 (1.6) 
 
Valid SA ID number 58 488 (88.9) 39 471 (89.9) <0.001 
History of TB at enrolment 12 904 (19.6) 10 790 (24.6) <0.001 
TB episode during follow-up period 5 669 (8.6) 3 858 (8.8) 0.314 
Person years (time to first TB) 63 342 79 321 <0.001 
ART: Antiretroviral therapy;  SD: Standard deviation;  IQR: Inter quartile range. 
a Comparing patients who did not receive ART by end of follow-up with patients who received ART for 
complex survey data, adjusted for district strata and clustering within subjects, using hierarchical 
linear regression for continuous outcomes and logistic regression for binary outcomes. 
b No-ART: Weight or CD4 cell count from period six months before enrolment in HIV programme and 
six months after enrolment date but closest to the enrolment date.   
 ART: Weight or CD4 cell count between six months before ART was started and fourteen days after 
ART was started but closest to the date when ART was started. 
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3.2. Effect of ART on time to TB 
3.2.1. Primary analysis 
The primary analysis, a competing risks proportional hazards regression model, estimated 
associations of patient and facility characteristics with rates of TB incidence, ART and death.  
The model controlled for sex, age, weight, CD4 cell count, district, and history of TB.  CD4 cell 
counts were missing for 18% of patients, and weight for 20% of patients and were assumed to be 
missing at random (Table 16).  Ten imputed datasets, using chained equations, were used to 
replace each missing value with a set of plausible values that represent the uncertainty about the 
right value to impute (Rubin D, 1987; Royston P, 2005).  For all other analyses in this thesis 25 
sets of data were imputed, but due to the large size of the TB incidence dataset and computing 
power limitations, only 10 sets were used.  The interaction between ART and CD4 cell count at 
enrolment and at the start of ART was also modelled by adding an interaction term. 
The crude competing risks regression model (data not shown) indicated that the hazard of TB 
was reduced by 32% (SHR 0.68 CI: 0.65-0.71) for patients receiving ART at the time of TB 
diagnosis compared to patients who had not yet started ART when they were diagnosed with TB, 
allowing for the competing risk of death.  Figure 21 displays the crude cumulative incidence of 
TB over time with death as competing risk for patients receiving ART or not by the end of 
follow-up.  For on-ART patient records, 559/43 898 (1.27%) started TB treatment within 30 
days of starting ART and 1 137 (2.6%) died.  Within 60 days of starting ART 1 008/43 898 
(2.30%) started TB treatment and 1 827 (4.2%) died. 
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Figure 21: Cumulative incidence of TB with death as competing risk.  Crude competing risks model; imputed 
data [10 sets]. 
The effect estimate obtained from an adjusted competing risks model using imputed data was 
very similar to the crude competing risks model (Table 18).  ART reduced the hazard of TB by 
36% while adjusting for the competing risk of death (SHR 0.64 CI: 0.61-0.67). 
The competing risks model shown in the first column of Table 18 did not include a variable to 
model the interaction between receiving ART and the CD4 cell count at the start of ART, 
whereas the model shown in the second column included an interaction term to model the 
interaction between ART usage and CD4 cell count at enrolment and at the start of ART.  The 
interaction was significant (p=0.021). 
Table 18 shows that the hazard of TB in HIV infected patients was reduced by 36% (SHR 0.64 
CI: 0.61-0.67) when patients received ART compared to patients not receiving ART for the 
competing risk model without the interaction term, while the competing risks model with the 
interaction term included, the hazard of TB was reduced by 38% (SHR 0.62 CI: 0.56-0.69).  The 
model without the interaction term was selected as the primary model since the primary aim was 
to estimate the effectiveness of ART in all patients.  For patients with CD4 cell counts between 
200 and 350 cells/µl (SHR 0.82 CI: 0.76-0.89) or above 350 cells/µl (SHR 0.55 CI: 0.50-0.61), 
the hazard of TB was lower than for patients with a CD4<50 cells/µl.  Men had an increased 
hazard of developing TB (SHR 1.33 CI: 1.27-1.39) as well as patients between the ages of 30 
and 39 (SHR 1.22  CI: 1.01-1.50) compared to patients younger than 20 years.  Increases in 
weight reduced the hazard of TB.  Surprisingly, a history of TB at HIV programme enrolment 
                       No-ART                                On ART 
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reduced the hazard of TB (SHR 0.86 CI: 0.82-0.91) compared to patients with no history of TB 
reported at episode enrolment. 
Table 18: Factors associated with the effect of ART on incidence of TB in HIV positive patients using a 
competing risks model; imputed data [10 sets]. 
Factors Competing risks regression 
model a 
(TB from HIV programme and 
ETR) 
Computing risks regression 
model with interaction term a 
(TB from HIV programme and 
ETR) 
 
 
SHR 95% CI  p value SHR 95% CI p value 
ART treatment status 
      
 
No ART 1 
  
1 
  
 
ART 0.64 0.61 - 0.67 <0.001 0.62 0.56 - 0.69 <0.001 
CD4 cell count  at start of 
follow-up record (cells/µl) d 
      
 
CD4 0-49 1 
  
1 
  
 
CD4 50-99 1.17 1.10 - 1.25 <0.001 1.21 1.10 - 1.33 <0.001 
 
CD4 100-199 1.01 0.95 - 1.07 0.73 0.99 0.91 - 1.08 0.80 
 
CD4 200-349 0.82 0.76 - 0.89 <0.001 0.79 0.72 - 0.87 <0.001 
 
CD4 >350 0.55 0.50 - 0.61 <0.001 0.53 0.48 - 0.60 <0.001 
Interaction between CD4 
and ART b,c 
      
 
No ART and CD4 <50 
   
1 
  
 
ART and CD4 50-99 
   
0.93 0.81 – 1.07 0.30 
 
ART and CD4 100-199 
   
1.05 0.92 – 1.19 0.47 
 
ART and CD4 200-349 
   
1.13 0.95 – 1.34 0.18 
 
ART and CD4 >350 
   
1.44 1.02 – 2.03 0.34 
Sex 
      
 
Women 1 
  
1 
  
 
Men 1.33 1.27 - 1.39 <0.001 1.33 1.27 - 1.39 <0.001 
Age category at HIV 
programme enrolment 
(years) 
      
 
<20 1 
  
1 
  
 
20-29 1.21 0.99 - 1.49 0.07 1.21 0.98 - 1.48 0.07 
 
30-39 1.22 1.01 -1.50 0.05 1.22 1.00 - 1.50 0.06 
 
40-49 1.14 0.93 - 1.40 0.22 1.13 0.92- 1.40 0.23 
 
>50  0.97 0.78 - 1.20 0.76 0.96 0.78-  1.19 0.74 
Weight at start of follow-up 
record (kg) d 
      
 
30-45 1 
  
1 
  
 
46-52 0.88 0.82 - 0.95 0.001 0.88 0.82 - 0.96 0.002 
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Factors Competing risks regression 
model a 
(TB from HIV programme and 
ETR) 
Computing risks regression 
model with interaction term a 
(TB from HIV programme and 
ETR) 
 
 
SHR 95% CI  p value SHR 95% CI p value 
 
53-59 0.79 0.73 - 0.86 <0.001 0.79 0.73 - 0.86 <0.001 
 
60-160 0.60 0.56 - 0.65 <0.001 0.60 0.56 - 0.65 <0.001 
History of TB at HIV 
programme enrolment 
      
 
No previous TB 1 
  
1 
  
 
Previous TB 0.86 0.82-0.91 <0.001 0.87 0.82-0.91 <0.001 
District 
      
 
Fezile Dabi 1 
  
1 
  
 
Lejweleputswa 0.86 0.80 - 0.93 <0.001 0.86 0.80-0.93 <0.001 
 
Motheo 1.11 1.04 - 1.19 0.001 1.11 1.04 - 1.19 0.002 
 
Thabo Mofutsanyane 0.80 0.74 - 0.85 <0.001 0.79 0.74 - 0.85 <0.001 
 
Xhariep 2.06 1.90 - 2.23 <0.001 2.06 1.90 - 2.23 <0.001 
SHR: Sub-hazard ratio;  CI: Confidence interval 
a Competing risks regression model also adjusting for clustering within districts and intra-patient 
correlation of outcomes. 
b Test for equality of coefficients for interaction term, p=0.021 
c Point estimates and confidence intervals were computed for linear combinations of coefficients after 
the estimation command. Recalculated values displayed in Table 19. 
d No-ART: Weight and CD4 cell count from period six months before enrolment in HIV programme 
and six months after enrolment date but closest to the enrolment date. 
 ART: Weight and CD4 cell count between six months before ART was started and fourteen days after 
ART was started but closest to the date when ART was started. 
Addition of ART-CD4 interaction terms significantly improved the model’s fit with the data 
(p=0.021). That is, that the estimated effectiveness of ART was significantly different at 
different CD4 levels, as shown in Table 16.   This shows that ART was similarly effective at 
preventing TB across all CD4 categories, but not when the CD4 cell count was more than 350 
cells/µl (SHR 0.90 CI: 0.66-1.23). 
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Table 19: Effect of ART on time to TB within each CD4 stratum; Competing risks model with imputed data 
[10 sets]. 
Factor: 
Adjusted competing risks model a, b, c 
(TB from HIV programme and ETR) 
Interaction between CD4 
category (cells/µl) and ART SHR 95% CI p value 
CD4 0-49 and on ART 0.62 0.56 - 0.69 <0.001 
CD4 50-99 and on ART 0.58 0.53 - 0.64 <0.001 
CD4 100-199 and on ART 0.65 0.61 - 0.70 <0.001 
CD4 200-349 and on ART 0.70 0.62 - 0.80 <0.001 
CD4 >=350 and on ART 0.90 0.66 - 1.23 0.50 
SHR: Sub-hazard ratio;  CI: Confidence interval 
a Adjusting for sex, age, CD4, weight, history of TB,  and for clustering 
within districts and intra-patient correlation of outcomes. 
b Point estimates and confidence intervals were computed for linear 
combinations of coefficients after the estimation command. 
c Test for equality of coefficients for interaction term, p=0.021 
3.2.2. Secondary analysis: Cox Regression Models 
An adjusted Kaplan Meier curve was used to estimate the probability (incidence) of active TB 
for patients receiving ART and patients not receiving ART by the end of follow-up (Figure 22).  
The log-rank test for equality of survivor functions confirmed a significant difference in the 
incidence of TB for patients who had not started ART by the end of follow-up compared to 
patients who had started ART (p<0.001).  This was investigated further with Cox models. 
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Figure 22: Adjusted Kaplan-Meier survival estimates by treatment status.  For patients who received ART, 
time is since commencement of ART.  For patients who did not receive ART by the end of follow-up, time is since 
enrolment in the HIV programme.  Adjusted for sex, age, weight, CD4, cotrimoxazole prescription, and for 
clustering within clinics within districts and intra-patient correlation of outcomes. 
Cox proportional hazards models were also used to assess the effectiveness of ART on the 
incidence of TB.  The crude Cox proportional hazards model (data not shown), which only 
adjusted for intra-patient correlation of outcomes, showed that the hazard of TB was reduced by 
39% (HR 0.61 CI: 0.59-0.64) for patients who received ART compared to patients not receiving 
ART by end of follow-up.  Explanatory variables added to the model included sex, age, weight, 
CD4 cell count, history of TB at enrolment, and an interaction term modelling CD4 cell count 
and ART prescription. 
Table 20 shows the results for two adjusted Cox models using imputed data (10 sets used for 
imputation), one model without the interaction between CD4 and ART and one model with the 
interaction modelled.  The hazard of TB was reduced by 49% (HR 0.51, CI: 0.49-0.53) in the 
model without the interaction term, which is a larger effect than that obtained from the 
competing risks model (SHR 0.64, CI: 0.61-0.67, Table 18).  The Cox model with the interaction 
term included had an even larger TB hazard reduction, 58% (HR 0.42, CI: 0.38-0.47, Table 20).  
For both Cox models, men were more at risk of developing TB, patients between 20 and 49 
years had an increased hazard of TB compared to patients younger than 20 years, and patients 
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with higher body weights at enrolment were associated with a lower hazard of being diagnosed 
with TB. 
Table 20: Factors associated with the effect of ART on incidence of TB patients using a Cox proportional 
hazards model; imputed data [10 sets]. 
Factors Adjusted Cox proportional 
hazards model a 
(TB from HIV prog. and ETR) 
Adjusted Cox proportional 
hazards model with 
interaction term a 
(TB from HIV prog. and ETR) 
 
 
HR 95% CI p value HR 95% CI p value 
ART Treatment status   
  
 
 No ART 1 
   
 ART 0.51 0.49-0.53 <0.001 0.42 0.38-0.47 <0.001 
Baseline CD4 at HIV programme 
enrolment  (cells/µl) d 
 
    CD4 0-49 1   1 
   CD4 50-99 1.06 0.97-1.13 0.21 1.04 0.95-1.13 0.16 
 CD4 100-199 0.83 0.77-0.89 <0.001 0.74 0.68-0.81 <0.001 
 CD4 200-349 0.49 0.45-0.54 <0.001 0.51 0.46-0.57 <0.001 
 CD4 >350 0.27 0.24-0.30 <0.001 0.31 0.28-0.35 <0.001 
Interaction between ART and CD4 b, c  
   
 No ART and CD4 0-49    1 
   ART and CD4 50-99    1.03 0.88-1.19 0.73 
 ART and CD4 100-199    1.28 1.13-1.46 <0.001 
 ART and CD4 200-349    1.62 1.36-1.94 <0.001 
 ART and CD4 >350    2.22 1.57-3.13 <0.001 
Sex 
 
 
   
 Women 1   1 
  
 Men 1.39 1.33 - 1.45 <0.001 1.39 1.33 - 1.45 <0.001 
Age at HIV programme enrolment 
(years) 
 
    <20 1   1 
   20-29  1.27 1.03-1.57 0.02 1.27 1.03-1.56 0.03 
 30-39 1.31 1.07-1.62 0.009 1.31 1.07-1.62 0.01 
 40-49 1.23 1.00-1.52 0.05 1.23 1.00-1.52 0.05 
 >50 1.08 0.87-0.34 0.48 1.08 0.87-1.34 0.49 
Weight at HIV programme enrolment 
(kg)d 
 
    30-45 1   1 
   46-52 0.81 0.75-0.87 <0.001 0.81 0.75-0.87 <0.001 
 53-59 0.70 0.63-0.74 <0.001 0.69 0.63-0.74 <0.001 
102 
Factors Adjusted Cox proportional 
hazards model a 
(TB from HIV prog. and ETR) 
Adjusted Cox proportional 
hazards model with 
interaction term a 
(TB from HIV prog. and ETR) 
 
 
HR 95% CI p value HR 95% CI p value 
 60-160 0.50 0.47-0.54 <0.001 0.50 0.47-0.54 <0.001 
 
 
History of TB  
   
 No previous TB 1   1 
  
 Previous TB 0.82 0.78-0.87 <0.001 0.83 0.78-0.87 <0.001 
District  
    Fezile Dabi 1    1 
   Lejweleputswa 0.94 0.82-0.95 0.001 0.88 0.82-0.95 0.001 
 Motheo 1.01 1.05-1.20 0.001 1.11 1.04-1.19 0.002 
 Thabo Mofutsanyane 0.87 0.78-0.90 <0.001 0.84 0.78-0.90 <0.001 
 Xhariep 2.41 1.94-2.23 <0.001 2.09 1.94-2.27 <0.001 
HR: Hazard ratio;  CI: Confidence interval 
a Cox proportional hazards model also adjusting for clustering within districts and intra-patient 
correlation of outcomes. 
b Test for equality of coefficients for interaction term, p<0.001 
c Point estimates and confidence intervals were computed for linear combinations of 
coefficients after the estimation command. Recalculated values displayed in Table 21. 
d No-ART: Weight and CD4 cell count from period six months before enrolment in HIV 
programme and six months after enrolment date but closest to the enrolment date.   
 ART: Weight and CD4 cell count between six months before ART was started and fourteen 
days after ART was started but closest to the date when ART was started. 
Table 21 shows the post-estimation analysis to recalculate the hazard ratios within the CD4 
strata for the interaction term in the Cox model.  This shows that although ART is effective in 
reducing the hazard of TB in all strata, as CD4 cell count increases the effectiveness of ART is 
less prominent, especially for CD4 above 350 cells/µl (HR 0.93 CI: 0.68-1.28). 
Table 21: Effect of ART on time within each CD4 stratum; Cox model with imputed data [10 sets]. 
Factor: 
Adjusted Cox proportional hazards 
model a, b, c 
(TB from HIV programme and ETR) 
Interaction between CD4 category (cells/µl) and 
ART HR 95% CI p value 
CD4 0-49 and on ART 0.42 0.38-0.47 <0.001 
CD4 50-99 and on ART 0.43 0.39-0.48 <0.001 
CD4 100-199 and on ART 0.54 0.50-0.58 0.002 
CD4 200-349 and on ART 0.68 0.60-0.77 0.003 
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Factor: 
Adjusted Cox proportional hazards 
model a, b, c 
(TB from HIV programme and ETR) 
Interaction between CD4 category (cells/µl) and 
ART HR 95% CI p value 
CD4 >350 and on ART 0.93 0.68-1.28 0.67 
HR: Hazard ratio;  CI: Confidence Interval 
a Adjusting for sex, age, CD4, weight, history of TB, and for clustering within districts and intra-
patient correlation of outcomes. 
b Point estimates and confidence intervals were computed for linear combinations of coefficients 
after the estimation command. 
c Test for equality of coefficients for interaction term, p<0.001 
The complete case analysis of the adjusted Cox model is shown in Table 22.  ART reduced the 
hazard of TB by 39% (HR 0.61 CI: 0.58-0.65) in the model without the interaction term, which 
was less effective in reducing the hazard of developing TB compared to the adjusted Cox model 
using imputed data (10 sets), with a 49% hazard reduction (HR 0.51 CI: 0.49-0.53, Table 20). 
Unlike in previous models, the inclusion of an interaction term for CD4 and ART prescription 
made a substantial difference to the Cox complete case analysis model (Table 22).  The effect 
estimate from the adjusted Cox model with the interaction term, limited to complete cases, 
showed that ART was more effective in preventing TB than the model without the interaction 
term; the hazard of TB was reduced by 53% (HR 0.47, CI: 0.41-0.52) compared to the 39% 
reduction in hazard from the model without the interaction term (HR 0.61 CI: 0.58-0.65).  A 
post-analysis estimation test indicated that the interaction term included in the model was 
significant (p<0.001). 
Table 22 also shows that patients from Xhariep district (HR 2.44 CI: 2.23-2.68), and men were 
more at risk of TB (HR 1.40 CI: 1.33-1.47), while patients with higher CD4 cell counts and body 
weights had a decreased hazard of developing TB.  As with the other models, patients with a 
history of TB when they enrolled in the HIV programme experienced a protective effect in the 
incidence of subsequent TB (HR 0.81 CI: 0.76-0.86) compared to patients with no history of TB 
at enrolment. 
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Table 22: Factors associated with the effect of ART on incidence of TB patients using a Cox proportional 
hazards model; no imputation. 
Factors Adjusted Cox proportional 
hazards model a 
(TB from HIV prog. and ETR) 
Adjusted Cox proportional 
hazards model with interaction 
term a 
(TB from HIV prog. and ETR) 
 
 
HR 95% CI p value HR 95% CI p value 
ART Treatment status   
    No ART 1 
   
 ART 0.61 0.58-0.65 <0.001 0.47 0.41-0.52 <0.001 
Baseline CD4  at HIV programme 
enrolment  (cells/µl) d 
 
    CD4 0-49 1   1 
   CD4 50-99 1.06 0.97-1.13 0.21 1.02 0.92 - 1.13 0.71 
 CD4 100-199 0.83 0.77-0.89 <0.001 0.70 0.64 - 0.77 <0.001 
 CD4 200-349 0.49 0.45-0.54 <0.001 0.40 0.36 - 0.45 <0.001 
 CD4 >350 0.27 0.24-0.30 <0.001 0.23 0.21 - 0.25 <0.001 
Interaction between ART and CD4 b, c  
   
 No ART and CD4 0-49    1 
   ART and CD4 50-99    1.09 0.93 - 1.27 0.23 
 ART and CD4 100-199    1.45 1.25 - 1.66 <0.001 
 ART and CD4 200-349    1.99 1.67 - 2.40 <0.001 
 ART and CD4 >350    3.59 2.49 – 5.11 <0.001 
Sex 
 
 
   
 Women 1   1 
  
 Men 1.40 1.33-1.47 <0.001 1.41 1.33 - 1.48 <0.001 
Age at HIV programme enrolment 
(years) 
 
    18-29 1   1 
   30-35  1.13 1.06-1.21 <0.001 1.14 1.06 - 1.22 <0.001 
 36-42 1.06 0.98-1.14 0.13 1.06 0.99 - 1.14 0.09 
 43-99 0.98 0.91-1.06 0.69 0.99 0.92 - 1.07 0.77 
Weight  at HIV programme enrolment 
(kg)d 
 
    30-45 1   1 
   46-52 0.78 0.73-0.82 <0.001 0.78 0.73 - 0.83 <0.001 
 53-59 0.66 0.61-0.70 <0.001 0.65 0.61 - 0.70 <0.001 
 60-160 0.50 0.46-0.53 <0.001 0.49 0.46 - 0.53 <0.001 
History of TB  
   
 No previous TB 1   1 
  
 Previous TB 0.81 0.76-0.86 <0.001 0.82 0.77 - 0.87 <0.001 
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Factors Adjusted Cox proportional 
hazards model a 
(TB from HIV prog. and ETR) 
Adjusted Cox proportional 
hazards model with interaction 
term a 
(TB from HIV prog. and ETR) 
 
 
HR 95% CI p value HR 95% CI p value 
Cotrimoxazole prescribed at any point 
during follow-up 
 
   
 No cotrimoxazole 1   1 
  
 Cotrimoxazole prescribed 0.49 0.46-0.52 <0.001 0.49 0.46 - 0.52 <0.001 
District  
    Fezile Dabi 1    1 
   Lejweleputswa 0.94 0.86-1.03 0.20 0.94 0.86 - 1.03 0.16 
 Motheo 1.03 0.95-1.12 0.47 1.01 0.94 - 1.10 0.63 
 Thabo Mofutsanyane 0.88 0.82-0.96 0.003 0.87 0.80 - 0.95 0.002 
 Xhariep 2.44 2.23-2.68 <0.001 2.42 2.21 - 2.66 <0.001 
HR: Hazard ratio;  CI: Confidence Interval 
a Cox proportional hazards model also adjusting for clustering within districts and intra-patient correlation of 
outcomes. 
b Test for equality of coefficients for interaction term, p<0.001 
c Point estimates and confidence intervals were computed for linear combinations of coefficients after the 
estimation command. Recalculated values displayed in Table 23. 
d No-ART: Weight and CD4 cell count from period six months before enrolment in HIV programme and six 
months after enrolment date but closest to the enrolment date. 
 ART: Weight and CD4 cell count between six months before ART was started and fourteen days after ART 
was started but closest to the date when ART was started. 
A post-estimation analysis was done on the Cox model to recalculate the hazard ratios for the 
interaction term within the different CD4 strata (Table 23).  This showed that ART had an 
almost similar effect at the different CD4 levels, ranging between 48% (CD4 50-99, HR 0.52 CI: 
0.46-0.56) and 63% (CD4 200-350, HR 0.37 CI: 0.32-0.43) effectiveness in reducing the 
incidence of TB. 
Table 23: Effect of ART on time to TB within each CD4 stratum; Cox model with no imputation. 
Factor: 
Adjusted Cox proportional hazards 
model a, b, c 
(TB from HIV programme and ETR) 
Interaction between CD4 
category (cells/µl) and ART HR 95% CI p value 
CD4 0-49 and on ART 0.47 0.41-0.52 <0.001 
CD4 50-99 and on ART 0.52 0.46-0.56 <0.001 
CD4 100-199 and on ART 0.47 0.43-0.52 <0.001 
CD4 200-349 and on ART 0.37 0.32-0.43 <0.001 
CD4 >350 and on ART 0.38 0.27-0.54 <0.001 
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Factor: 
Adjusted Cox proportional hazards 
model a, b, c 
(TB from HIV programme and ETR) 
Interaction between CD4 
category (cells/µl) and ART HR 95% CI p value 
HR: Hazard ratio;  CI: Confidence Interval 
a Adjusting for sex, age, CD4, weight, history of TB, and for clustering 
within districts and intra-patient correlation of outcomes. 
b Point estimates and confidence intervals were computed for linear 
combinations of coefficients after the estimation command. 
c Test for equality of coefficients for interaction term, p<0.001 
A sensitivity analysis was performed, using an adjusted Cox proportional hazards model with 
complete case data, to evaluate the effect of ART on TB incidence (Table 24).  This dataset 
included TB reported by the HIV programme only.  A total of 10 472 subjects were identified as 
receiving TB treatment, 5 583 had a TB episode during the no-ART period and 4 889 patients’ 
first episode of TB was reported while receiving ART.  These categories are mutually exclusive 
since censoring was done at the first TB episode. 
The Cox model results displayed in Table 24 shows that ART reduced the hazard of TB by 52% 
(HR 0.48, CI 0.45-0.51) in this sensitivity analysis - a larger effect size when compared with the 
equivalent model using a combination of ETR information and the HIV programme TB 
information , HR 0.61 CI: 0.58-0.65 (Table 22). 
  
107 
Table 24: Sensitivity analysis: Factors associated with the effect of ART on incidence of TB patients using a 
Cox proportional hazards model with TB identified from HIV programme only; no imputation. 
 
Factors 
Adjusted Cox proportional hazards 
model a 
(TB from ART programme only) 
 
 
HR 95% CI p value 
ART Treatment status  
 No ART 1 
 ART 0.48 0.45-0.51 <0.001 
Baseline CD4  at HIV programme enrolment  
(cells/µl) b 
 
 CD4 0-49 1   
 CD4 50-99 0.90 0.84-0.98 0.01 
 CD4 100-199 0.71 0.66-0.75 <0.001 
 CD4 200-349 0.62 0.56-0.67 <0.001 
 CD4 >350 0.50 0.45-0.56 <0.001 
Sex 
 
 
 Women 1   
 Men 1.43 1.36-1.51 <0.001 
Age at HIV programme enrolment (years)  
 18-29 1   
 30-35  1.03 0.96-1.10 0.41 
 36-42 0.96 0.89-1.03 0.24 
 43-99 0.86 0.79-0.92 <0.001 
Weight  at HIV programme enrolment (kg) b  
 30-45 1   
 46-52 0.81 0.76-0.86 <0.001 
 53-59 0.71 0.66-0.76 <0.001 
 60-160 0.55 0.51-0.60 <0.001 
History of TB  
 No previous TB 1   
 Previous TB 5.26 4.98-5.57 <0.001 
Cotrimoxazole prescribed at any point 
during follow-up 
 
 No cotrimoxazole 1   
 Cotrimoxazole prescribed 1.65 1.55-1.75 <0.001 
District 
 
 
 Fezile Dabi 1   
 Lejweleputswa 0.67 0.62-0.74 <0.001 
 Motheo 1.28 1.18-1.39 <0.001 
 Thabo Mofutsanyane 0.75 0.69-0.82 <0.001 
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Factors 
Adjusted Cox proportional hazards 
model a 
(TB from ART programme only) 
 
 
HR 95% CI p value 
 Xhariep 2.16 1.97-2.36 <0.001 
HR: Hazard ratio;  CI: Confidence interval 
a Cox proportional hazards model also adjusting for clustering within clinics within 
districts and intra-patient correlation of outcomes. 
b No-ART: Weight and CD4 cell count from period six months before enrolment in 
HIV programme and six months after enrolment date but closest to the enrolment 
date. 
 ART: Weight and CD4 cell count between six months before ART was started and 
fourteen days after ART was started but closest to the date when ART was started. 
 
3.3. Effect of ART on incidence rate of multiple TB episodes 
All of the above analyses modelled a single episode of TB, and considered follow-up time until 
TB was diagnosed.  However, some patients experienced multiple TB episodes after enrolment, 
either during the no-ART follow-up time, or during ART follow-up time, or during both periods.  
A Poisson regression model was used to determine the association between TB incidence rate 
and ART treatment, accounting for multiple TB episodes that occurred after enrolment in the 
HIV programme. 
Table 25 summarises data for patients who contributed time to no-ART follow-up and ART 
follow-up for the Poisson model as well as the total number of TB episodes that occurred during 
these follow-up periods.  The overall incidence rate (IR) of TB was 9.08/100 py [(6 471+7 346) 
TB cases / (65 738 py+86 404 py) × 100], which was much higher than the 6.68 / 100 py 
reported for first (single) episode TB (Table 17).  The TB incidence rate in patients not receiving 
ART by the end of no-ART follow-up was 9.8 / 100 py (6 471 TB cases / 65 738 py × 100), 
while the incidence rate of TB during ART follow-up was 8.5/100 person years (7 346 TB 
cases / 86 404 py × 100).  The crude incidence rate ratio (IRR) for TB was 0.85 (CI: 0.82-0.87) 
for patients who received ART during follow-up compared to patients who had not received 
ART during follow-up. 
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Table 25: Characteristics of patients included in the Poisson model evaluating the effect of ART on number 
of TB episodes at the time of first enrolling in the HIV programme (no-ART follow-up record) and at the 
time of starting ART (ART follow-up record).  Categories are not mutually exclusive. 
 
No-ART 
follow-up period 
ART 
follow-up period p value a 
 
n (%) n (%) 
Number of patients contributing a 
record 65 806 47 595   
Person years (TB risk free follow-up) 65 738 86 404 <0.001 
History of TB 13 186 (19.6) 10 569 (22.2) <0.001 
Median CD4 cell count at start of follow-
up period, cells/µl.  Median (IQR) b 
140 (66-226) 
 n=58 318 (86.5) 
126 (64-182) 
n=40 147 (84.4)  
Weight at start of follow-up period, kg, 
Mean (SD) b 
58 (13) 
 n=56 801 (84.2) 
59 (13) 
n=37 703 (79.2) <0.001 
Total number of TB episodes during 
follow-up period 6 471 7 346 <0.001 
Patients with more than one TB episode 
during follow-up period 1 046 1 368 <0.001 
ART: Antiretroviral therapy;  SD: Standard deviation; IQR: Inter quartile range. 
a Comparing patients who did not receive ART by end of follow-up with patients who received ART, 
adjusted for district strata and clustering within subjects, using hierarchical linear regression for 
continuous outcomes and logistic regression for binary outcomes. 
b No-ART: Value from period six months before enrolment in HIV programme and six months after 
enrolment date but closest to the enrolment date.   
 ART: Value between six months before ART was started and fourteen days after ART was started. 
Table 26 shows an adjusted Poisson regression evaluating the effect of ART on TB incidence 
among these patients accounting for multiple episodes of TB, using 25 sets of imputed data in 
two models.  One model included an interaction term for ART and CD4 cell count at the start of 
each follow-up record and one model did not include the interaction term. The incidence rate 
ratio (IRR) in the model without an interaction term showed that ART reduced the incidence rate 
of TB by 34% (IRR 0.66, CI: 0.64-0.69).  The model with the interaction term included showed 
that ART was more effective, reducing the incidence of TB by 68% (IRR 0.32 CI: 0.30-0.35). 
As before, men were at greater risk of TB (1.37 CI: 1.30-1.43), patients between the age of 30 
and 43 had an increased hazard of developing TB compared to patients in their twenties, and 
district variability in the incidence of TB was evident. 
In Table 26, the model without the interaction term showed that, compared to patients with 
CD4<50 cells/µl, patients with a CD4 cell count between 50 and 99 and between 200 and 350 
cells/µl were at higher risk  (CD4 50-99: IRR 1.10 CI: 1.02-1.18), while patients with a CD4 
above 350 cells/µl had a lower rate of developing TB (IRR 0.75 CI: 0.69-0.83).  The model 
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estimated the effect of a history of TB at enrolment into the HIV programme on subsequent 
episodes of TB, adjusting for all other factors, including whether or not they had started ART.  
Patients who had TB before or during enrolling in the HIV programme had a 47% higher risk of 
TB compared to patients who had no history of TB at enrolment (IRR 1.47 CI: 1.39-1.55).  
Between 2005 and 2009 a sequential increase in the hazard of developing TB was noted, ranging 
from IRR 1.13 (CI: 1.03-1.23) in 2005 to IRR 3.39 (CI: 3.09-3.71) in 2009, probably due to 
more intensive screening and case-finding. 
Table 26: Factors associated with the effect of ART on TB using a Poisson regression model; imputed data 
[25 sets]. 
Factors 
Adjusted Poisson regression 
model a 
(TB from HIV prog. and ETR) 
Adjusted Poisson regression 
model with interaction term a 
(TB from HIV prog. and ETR) 
 
 
IRR 95% CI p value IRR 95% CI p value 
ART Treatment status  
      
 No ART 1 
  
1 
  
 ART 0.66 0.64-0.69 <0.001 0.32 0.30-0.35 <0.001 
Baseline CD4  at HIV 
programme enrolment 
(cells/µl) c 
       CD4 0-49 1 
  
1 
   CD4 50-99 1.10 1.02 - 1.18 0.02 1.01 0.91 - 1.10 0.942 
 CD4 100-199 0.97 0.91 – 1.04 0.39 0.77 0.71 - 0.84 <0.001 
 CD4 200-349 1.10 1.02 – 1.19 0.02 0.51 0.47 - 0.57 <0.001 
 CD4 >350 0.75 0.69 - 0.83 <0.001 0.28 0.25 - 0.31 <0.001 
Interaction between ART 
and CD4 b       
 No ART and CD4 0-49 
   
1 
   ART and CD4 50-99 
   
1.18 1.06 - 1.33 0.003 
 ART and CD4 100-199 
   
1.48 1.35 - 1.64 <0.001 
 ART and CD4 200-349 
   
4.28 3.82 - 4.80 <0.001 
 ART and CD4 >350 
   
13.37 11.68 - 15.31 <0.001 
Sex 
      
 Women 1 
  
1 
  
 Men 1.37 1.30-1.43 <0.001 1.37 1.30-1.43 <0.001 
Age at HIV programme 
enrolment (years) 
       18-29 1 
  
1 
   30-35  1.17 1.10 - 1.24 <0.001 1.16 1.09 - 1.23 <0.001 
 36-42 1.12 1.05 - 1.19 <0.001 1.11 1.04 - 1.18 <0.001 
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Factors 
Adjusted Poisson regression 
model a 
(TB from HIV prog. and ETR) 
Adjusted Poisson regression 
model with interaction term a 
(TB from HIV prog. and ETR) 
 
 
IRR 95% CI p value IRR 95% CI p value 
 43-99 1.02 0.96 - 1.09 0.52 1.01 0.95 - 1.07 0.745 
Weight  at HIV programme 
enrolment (kg) c 
       30-45 1 
  
1 
   46-52 0.87 0.82 - 0.92 <0.001 0.88 0.83 - 0.93 <0.001 
 53-59 0.74 0.69 - 0.78 <0.001 0.74 0.70 - 0.79 <0.001 
 60-160 0.55 0.52 - 0.59 <0.001 0.55 0.52 - 0.59 <0.001 
History of TB 
      
 No previous TB 1 
  
1 
  
 Previous TB 1.47 1.39 - 1.55 <0.001 1.43 1.36 - 1.52 <0.001 
Year of enrolment in HIV 
programme 
       2004 1 
  
1 
   2005 1.13 1.03-1.23 0.008 1.14 1.04-1.24 0.004 
 2006 1.38 1.27-1.51 <0.001 1.37 1.26-1.49 <0.001 
 2007 1.93 1.77-2.10 <0.001 1.86 1.72-2.02 <0.001 
 2008 2.25 2.07-2.46 <0.001 2.11 1.94-2.29 <0.001 
 2009 3.39 3.09-3.71 <0.001 3.21 2.94-3.51 <0.001 
 2010 5.87 5.21-6.61 <0.001 5.33 4.74-5.99 <0.001 
District 
       Fezile Dabi 1 
  
1 
   Lejweleputswa 0.91 0.84 - 0.98 0.02 0.89 0.82 - 0.96 0.003 
 Motheo 1.18 1.10 - 1.27 <0.001 1.12 1.04 - 1.20 0.001 
 Thabo Mofutsanyane 0.89 0.82 - 0.96 <0.001 0.87 0.81 - 0.93 <0.001 
 Xhariep 2.13 1.96 - 2.30 <0.001 2.12 1.96 - 2.29 <0.001 
IRR: Incidence rate ratio;  CI: Confidence interval 
a Cox proportional hazards models also adjusting for district, and intra-patient correlation of outcomes. 
b Test for equality of coefficients for interaction term, p<0.001 
c No-ART: Value from period six months before enrolment in HIV programme and six months after 
enrolment date but closest to the enrolment date. 
 ART: Value between six months before ART was started and fourteen days after ART was started. 
A post-estimation analysis to recalculate the hazard ratios for the interaction term was performed 
on the Poisson regression with the interaction term to evaluate the effect of ART on multiple 
episodes of TB within each of the CD4 strata separately (Table 27).  This analysis showed that 
ART was effective in reducing the hazard of TB in CD4 strata less than 200 cells/µl but is 
associated with an increased TB incidence rate if CD4 > 350 cells/µl (IRR 4.34, CI: 3.92-4.81). 
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Table 27: Effect of ART on incidence rate of multiple TB within each CD4 stratum; Poisson regression 
model with imputed data [25 sets]. 
Factor: 
Adjusted Poisson regression model 
a,b,c 
(TB from HIV programme and ETR) 
Interaction between CD4 
category (cells/µl) and ART IRR 95% CI p value 
CD4 0-49 and on ART 0.32 0.30 0.35 <0.001 
CD4 50-99 and on ART 0.39 0.36 0.41 <0.001 
CD4 100-199 and on ART 0.48 0.46 0.51 <0.001 
CD4 200-349 and on ART 1.39 1.29 1.50 <0.001 
CD4 >350 and on ART 4.34 3.92 4.81 <0.001 
a Adjusting for sex, age, CD4, weight, history of TB, and for clustering 
within districts and intra-patient correlation of outcomes. 
b Point estimates and confidence intervals were computed for linear 
combinations of coefficients after the estimation command. 
c Test for equality of coefficients for interaction term, p<0.001 
3.4. Summary 
The adjusted competing risks regression model showed that ART reduced the hazard of 
developing TB by 36% (SHR 0.64 CI: 0.61-0.67). The Cox models that ignored the competing 
risk of death over-estimated the effectiveness of ART on time to TB, producing point estimates 
corresponding to a reduction in hazard of TB of between 39% (Cox model using complete case 
data, HR 0.61 CI: 0.58-0.65) and 49% (Cox model with imputed data, HR 0.51 CI: 0.49-0.53). 
Similarly, ignoring TB information obtained through linkage with the ETR over-estimated the 
effect of ART on time to TB (HR 0.48 CI: 0.45-0.51).   
Since initiation of ART is strongly associated with a CD4 cell count, heterogeneity across the 
CD4 strata in the ART prescription was expected and tested for with the inclusion of an 
interaction term between CD4 category and ART.  The interaction term was significant for all 
the models.  The competing risks model without the interaction term had a similar effect 
estimate as the model with it (SHR 0.64 vs. SHR 0.62 respectively), while the Cox and Poisson 
models with an interaction terms showed that ART was more effective than in the models 
without the interaction term (HR 0.42 for Cox and interaction term vs. HR 0.51 (no interaction); 
IRR 0.32 for Poisson and interaction term vs. IRR 0.66 (no interaction)).   
The competing risks models with ART-CD4 interaction included showed that the effect of ART 
decreased with increasing CD4 levels, and ART had no significant effect for CD4>350 
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(Table 19 and Table 21). The Cox model did not show ART effectiveness to depend on CD4 
(Table 23), but this model was probably biased because it did not account for the competing risk 
of death. 
The Poisson models which evaluated the effectiveness of ART on number of TB episodes also 
showed a substantial effect with ART reducing the incidence rate of TB by 34% (IRR 0.66 
CI: 0.64-0.69). 
The analyses were limited by the proportion of patients with missing weight or CD4 values or 
both. This is evident in the difference between estimates obtained in Cox models using complete 
case data (HR 0.61 CI: 0.58-0.65) and imputed data (HR 0.51 CI: 0.49-0.53).   Post estimation 
analyses by CD4 strata showed that ART was most effective at preventing TB in patients with 
lower CD4 counts and had minimal impact in patients with CD4 counts in excess of 350. 
The models also highlighted other associations between risk factors and the development of TB 
for example men were at risk.  Patients with a higher body weight and age at enrolment had a 
lower hazard of TB, and as CD4 cell count increased the hazard of TB decreased.  A history of 
TB treatment at enrolment in the HIV programme was protective in all the models, except the 
sensitivity analysis model which used TB information reported by the HIV programme only 
(HR 5.26 CI: 4.98-5.57) and the Poisson regression model accounting for multiple episodes of 
TB (IRR 1.47 CI: 1.39-1.55).  Unfortunately the TB register did not record the number of TB 
treatment episodes the patient had. Thus if a patient had a TB episode during the study period it 
could have been their second or third episode since the pre-TB information was unavailable.  
This limited the possibility to evaluate if a first episode of TB was associated with further 
episodes compared to people without prior TB. 
District heterogeneity was seen in all the models, Motheo and Xhariep districts were mostly at 
risk while in the other districts ART reduced the hazard of TB incidence compared to Fezile 
Dabi district. 
Overall, ART is associated with a reduced hazard of developing TB. 
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Table 28: Summary of primary outcome for models to evaluate the effect of ART on TB incidence.  Models 
displayed in this table do not include the interaction term. 
Model used 
Effect of ART on incidence of TB 
(TB from HIV programme and ETR) 
 
Effect 
estimate 95% CI p value 
Primary analysis for effect of ART on 
time to first TB episode: Adjusted 
competing risks model. Imputed data 
[10 sets]. 
SHR 0.64 0.61-0.67 <0.001 
Crude competing risks model.  No 
imputation. SHR 0.68 0.65-0.71 <0.001 
Adjusted Cox proportional hazards 
model.  Imputed data [10 sets]. HR 0.51 0.49-0.53 <0.001 
Crude Cox proportional hazards 
model. No imputation. HR 0.61 0.59-0.64 <0.001 
Adjusted Cox proportional hazards 
model.  No imputation. HR 0.61 0.58-0.65 <0.001 
Primary analysis for effect of ART on 
incidence rate of multiple TB 
episodes: Adjusted Poisson regression 
model. Imputed data [25 sets]. 
IRR 0.66 0.64-0.69 <0.001 
Crude Poisson regression model. No 
imputation. IRR 0.85 0.82-0.87 <0.001 
SHR: Sub-hazard ratio;  HR: Hazard ratio;  IRR: Incidence rate ratio 
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4. AN EVALUATION OF THE EFFECTIVENESS OF 
THE PRESCRIPTION OF ART AND 
COTRIMOXAZOLE ON MORTALITY (TIME TO 
DEATH) IN CO-INFECTED HIV-TB PATIENTS 
The Free State HIV programme database includes mostly HIV positive patients.  Linkage with 
the provincial ETR was crucial to identify the sub-population of HIV patients co-infected with 
TB, due to suspected under-reporting of TB in the HIV programme.  The HIV programme 
database also documented follow-up time before and after ART was started and could therefore 
support (survival) analyses to evaluate the effectiveness of ART on mortality in co-infected 
people.  This chapter reports on the effect of ART on survival in co-infected HIV-TB patients by 
applying different types of regression models. 
4.1. Selection and characteristics of patients included in this analysis. 
Between 2004 and 2010 a total of 97 476 patients were documented as being enrolled in the HIV 
programme, of whom 12 258 were identified as co-infected HIV-TB patients.  The source of TB 
information was either from the HIV programme database or from the ETR.  A total of 1 760 co-
infected HIV-TB patients were excluded because: 
a) they were younger than 16 when they enrolled in the HIV programme (n=760), or  
b) they were documented as being HIV negative (n=66)1, or  
c) they had no means of being followed because there was no valid South African ID 
number with which to link to the population register and they only had information 
for one visit recorded (n=772), or  
d) they died on the date of enrolling in the programme and so could not contribute 
follow-up time to this analysis (n=162). 
                                                          
1 The structured clinical records implemented as part of the Free State’s HIV programme made provision for the 
process of HIV testing to be documented.  This was used, at least during the early stages of the programme, to 
document all testing completed during enrolment in the programme, regardless of outcome.  As the programme 
expanded and clinicians battled to cope with large patient numbers, the practise of completing documentation for 
patients testing negative, was dropped 
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Of the remaining 10 498 patients who were included in the analysis, 2 679 (25.5%) patients had 
not started ART by the date on which their follow-up time was censored and 7 819 (74.5%) 
patients had. 
 
Figure 23: Enrolment of patients in analysis. 
7 766  
records 
3 767  
records 
Patients documented enrolling in 
Free State HIV programme between 
May 2004 and June 2010 and 
diagnosed with TB (from HIV 
database and/or ETR). 
N = 12 258 
 
Patients who did not 
start ART (no-ART): 
2 679 (25.5%) 
Excluded: 1 760 (14%) 
     Age<16: 760 (43.2%) 
     HIV negative patients: 66 (3.7%) 
     1 visit and invalid ID: 772 (43.9%) 
     Follow-up time = 0 days: 162 (9.2%) 
No-ART follow-up records 
N = 6 446 (45%) 
 
2 679 (42%) records from 
    no-ART patients, and  
3 767 (58%) records from 
patients before they started 
ART (pre-ART). 
Deaths: 1 455 
ART follow-up records 
N = 7 766 (55%) 
 
 4 013 (52%) records from 
patients contributing ART 
follow-up time only (TB 
diagnosis date = ART start 
date) 
Deaths : 1 509 
Patients starting ART by 
June 2010: 
7 819 (74.5%) 
N=10 498 Patients 
Characteristics at the start of 
enrolment or at the start of 
ART displayed in Table 26. 
 
N=14 212 records 
Characteristics at the 
start of TB for no-ART 
records and at the start 
of ART for ART records 
displayed in Table 27 
53 Patients without an ART 
follow-up record: the date 
on which ART was started 
and the censor date was 
the same therefore no-ART 
follow-up time was 
calculated. 
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Table 29 displays the characteristics of co-infected HIV-TB patients at the time they first 
enrolled in the HIV programme.  They were mostly women in their thirties (60.3% women, 
mean 36 years) and from the low median CD4 cell count of 122 cells/µl (IQR: 59-203) at 
enrolment, it was apparent that these patients had advanced disease. Despite this, a quarter of the 
patients (25.5%, 2 679 / 10 498) had not received ART by the end of follow-up.   Ninety percent 
(89.6%) of patients had a SA ID numbers, allowing follow-up through linkage with the national 
death population register.  Almost a fifth (16.5%) of the patients had a history of TB treatment or 
were receiving TB treatment when they were first registered on the HIV programme database.  
Fifty four percent (1 455 / 2 679)  of the co-infected patients who had not received ART by the 
end of follow-up died, compared to 19.3% (1 509 / 7 819) of deaths reported in the patients who 
had received ART by the end of follow-up (Figure 23). 
Table 29: Characteristics of patients included in this analysis.  Data presented for the overall group, and 
disaggregated into those who did not receive ART by the end of follow-up, and patients who received ART 
during follow-up. The latter two categories are mutually exclusive. 
 
Overall 
Did not receive 
ART by end of 
follow-up 
n (%) 
Received ART 
by the end of 
follow-up 
n (%) 
p-value a 
Number of patients 10 498 2 679 7 819 
 
Women  6 331 (60.3) 1 501 (56.0) 4 830 (61.8) <0.001 
Age in years : Mean (SD) 36 (9) 36 (9) 36 (9) <0.001 
Mean weight at enrolment, kg. 
 Mean (SD) b 
55 (12) 
n=8 836 (84.2) 
54 (12) 
n=2 068 (77.2) 
55 (12) 
n=6 768 (86.6) 
<0.001 
Mean CD4 cell count at enrolment, 
cells/µl.  Mean (SD) b 
160 (151) 
n=9 026 (86.0) 
222 (212) 
n=2 253 (84.1) 
139 (116) 
n=6 773 (86.6) 
<0.001 
Median CD4 cell count at enrolment, 
cells/µl.  Median (IQR) b 
122 (59-203) 
n=9 026 (86.0) 
160 (66-316) 
n=2 253 (84.1) 
115 (58-185) 
n=6 773 (86.6)  
Number of patients per CD4 cell count 
category at enrolment b 
 
  
<0.001 
    CD4 missing 1 472 (14.0) 426 (15.9) 1 046 (13.4) 
 
    CD4 0-49 1 882 (17.9) 444 (16.6) 1 438 (18.4) 
 
    CD4 50-99 1 848 (17.6) 356 (13.3)  1 492 (19.1) 
 
    CD4 100-199 2 989 (28.5) 506 (18.9) 2 483 (31.8) 
 
    CD4 200-349 1 466 (14.0) 470 (17.5) 996 (12.7) 
 
    CD4 >= 350 841 (8.0) 477 (17.8) 364 (4.6) 
 
Valid South African ID number 9 407 (89.6) 2 349 (87.7) 7 058 (90.3) <0.001 
History of TB at enrolment in HIV 
programme 1 733 (16.5) 294 (10.9) 1 439 (18.4) <0.001 
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Overall 
Did not receive 
ART by end of 
follow-up 
n (%) 
Received ART 
by the end of 
follow-up 
n (%) 
p-value a 
ART: Antiretroviral therapy;  SD: Standard deviation;  IQR: Inter quartile range. 
a Comparing patients who did not receive ART by end of follow-up with patients who received ART for 
complex survey data, adjusted for district strata and clustering within subjects, using hierarchical linear 
regression for continuous outcomes and logistic regression for binary outcomes. 
b Value from period six months before enrolment in HIV programme and six months after enrolment date but 
closest to the enrolment date. 
As described in Methods, Section 2.6.3, patient follow-up time (survival time) was described 
from the start of TB treatment to censoring and divided into two types of follow-up records: 
records during which patients did not receive ART (no-ART) and records where patients did 
receive ART by the end of follow-up. 
No-ART follow-up was defined from the day when TB treatment was started until one day 
before ART treatment was started, or the censor date for patients who did not receive ART by 
the end of follow-up.  Patients who had not started ART by the end of follow-up (n=2 679) and 
patients who had started ART during follow-up (n=3 767), contributed time to no-ART follow-
up.  ART follow-up time was from the ART treatment start date until the censor date; 4 013 
patients’ TB diagnosis was on the same date as their ART was started and therefore they only 
contributed ART follow-up time (Figure 23). 
Table 30 displays patient characteristics at the start of these records, used in the analyses to 
adjust for confounding. For no-ART follow-up records, characteristics at the time of TB 
diagnosis are shown and for ART records, characteristics at the time of starting ART are shown.  
Categories are not mutually exclusive as ART patients may have contributed follow-up time to 
both, therefore Table 29 reports on a total of 10 498 patients whereas Table 30 reports on all 
14 212 no-ART and ART records contributed by these 10 498 patients. 
Forty percent of the records were no-ART records (6 446 / 14 212) and contributed a total of 
5 218 person-years (py), while ART records contributed a total of 13 202 py.  Women 
contributed 57.5% of the follow-up records.  Patients were older (p=0.001) when they started 
ART (41 years, ±9) than when they started TB treatment (37 years, ±9) and the majority of 
patients had a CD4 cell count below 200 (65.2% for patients not receiving ART and 78.6% for 
patients receiving ART by the end of follow-up).  The ETR identified 65% (9 304 / 14 212) of 
the TB episodes for this analysis (data not presented in Table). 
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Table 30: Characteristics of patients included in the analysis at the time of starting TB treatment (no-ART 
follow-up records) and at the time of starting ART (ART follow-up records). 
  
No-ART  
follow-up period 
n (%) 
ART  
follow-up period 
n (%) 
 p-value a 
Number of patients  6 446 (100) 7 766 (100)   
Person years (time to censor date) 5 218 13 202 
 
Women 3 706 (57.5) 4 801 (61.8) <0.001 
Age in years: Mean (SD) 37 (9) 41 (9) 0.001 
Mean weight at start of TB or ART, 
kg.  Mean ( SD) b 
53 (11) 
n=4 312 (66.9) 
55 (12) 
n=5 899 (75.9) 
0.001 
Mean CD4 cell count at start of TB or 
ART, cells/µl.  Mean ( SD) b 
153 (151) 
n=5 465 (84.8) 
115 (85) 
n=6 745 (86.9) 
0.001 
Median CD4 cell count at start of TB 
or ART, cells/µl.  Median (IQR) b 
115 (55-194)   
n=5 465 (84.8) 
105 (53-162)  
n=6 745 (86.9) 
<0.001 
Number of patients per CD4 cell 
count category at start of TB or ART   
<0.001 
    CD4 missing 981 (15.2) 1 021 (13.1) 
 
    CD4 0-49 1 235 (19.2) 1 558 (20.1) 
 
    CD4 50-99 1 190 (18.5) 1 652 (21.3) 
 
    CD4 100-199 1 773 (27.5) 2 891 (37.2) 
 
    CD4 200-349 796 (12.3) 549 (7.1) 
 
    CD4 >= 350 471 (7.3) 95 (1.2)  
Valid South African ID number 5 745 (89.1) 7 048 (90.8) 0.001 
Cotrimoxazole prescribed during 
follow-up period 4 325 (67.1) 7 407 (95.4) <0.001 
History of TB at enrolment in HIV 
programme 683 (10.6) 1 437 (18.5) <0.001 
Abbreviations:  ART- Antiretroviral therapy, SD - Standard deviation, IQR- Inter quartile range. 
a Comparing patients who did not receive ART by end of follow-up with patients who received ART for 
complex survey data, adjusted for district strata and clustering within subjects, using hierarchical linear 
regression for continuous outcomes and logistic regression for binary outcomes 
b No-ART: Value from period twelve months before TB diagnosis and three months after TB diagnosis but 
closest to  the TB diagnosis date. 
 ART: Value between six months before ART was started and fourteen days after ART was started. 
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4.2. Effect of ART on time to death 
The dramatic effect of ART on survival among co-infected patients is shown in Figure 24.  The 
probability of survival after a diagnosis of TB was estimated by the Kaplan Meier method, 
comparing patients receiving ART and patients not receiving ART by the end of follow-up.  
There was a significant difference (p<0.001) in the median time to death between patients not 
receiving ART during follow-up and patients receiving ART during follow-up. 
 
Figure 24: Crude Kaplan-Meier survival estimates by treatment status.  For patients who did not receive 
ART by end of follow-up, time is months since start of TB treatment.  For patients who received ART, time is 
since commencement of ART therapy. 
4.2.1. Primary analysis 
Marginal structural models were used to evaluate the effect of ART and cotrimoxazole therapy 
on death in these co-infected patients.  Multiple imputation was used to impute missing CD4 cell 
counts and weights due to almost 20% missing CD4 cell counts and 16% missing weights 
overall (Table 29).  It was decided to use multiple imputation since results from complete case 
analysis could be biased and not generaliseble to the population.  
Table 31 shows results of the marginal structural models (MSM).  ART reduced the hazard of 
death in co-infected patients by 47% (HR 0.53, CI: 0.47-0.61) compared with patients who had 
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not received ART by the end of follow-up.  Men were more at risk of death compared to women 
(HR 1.29, CI: 1.15-1.45).  As CD4 cell count and weight increased, the hazard of death 
decreased and for each extra month of follow-up since commencement of ART, the hazard of 
death decreased by 8% (HR 0.92 CI: 0.88-0.95)  (Table 31).  There was no interaction between 
ART and CD4 category (p=0.61) at the start of TB treatment, therefore the interaction term was 
not included in the model.  The pooled, un-weighted model showed that ART was effective at 
reducing the hazard of death by 37% (HR 0.63 CI:0.57-0.69) but less so compared to the 
weighted marginal structural model (HR 0.53, CI:0.47-0.61).  The age effect was large compared 
to the other covariates since <20 years was used as the reference group, which was a small group 
and fewer deaths occurred in this group.  The hazard ratios for the other covariates in the un-
weighted model displayed the same trends as the MSM.  The model evaluating the impact of 
cotrimoxazole therapy on death showed no effect in this analysis (HR 1.02, CI: 0.71-1.46). 
  
122 
Table 31: Factors associated with death using marginal structural regression models (MSM); imputed data [25 sets]. 
Factors  Primary MSM model for effect 
of ART on death a 
Pooled unweighted logistic 
regression model for effect of 
ART on death 
MSM model for effect of 
cotrimoxazole on death b 
 
HR 95% CI Wald p value HR 95% CI 
Wald 
p value HR 95% CI 
Wald 
p value 
ART Treatment status 
    
        
 
No ART 1 
   
1    1    
 
ART 0.53 0.47 - 0.61 <0.001 0.63 0.57 - 0.69 <0.001 0.63 0.56 - 0.71 <0.001 
Cotrimoxazole prescribed during 
follow-up     
        
 
No cotrimoxazole 1 
   
1    1    
 
Cotrimoxazole prescribed 0.92 0.83 - 1.02 0.13 1.07 0.94 - 1.23 0.32 1.02 0.71 - 1.46 0.92 
Sex 
     
        
 
Women 1 
   
1    1    
 
Men 1.29 1.15 - 1.45 <0.001 1.30 1.20 - 142 <0.001 1.50 1.27 - 1.77 <0.001 
Age at start of TB (years) 
    
        
 
<20  1 
   
1        
 
20-29 1.63 0.41 - 6.47 0.48 5.87 2.66 - 12.96 <0.001 5.87 2.40 - 14.34 <0.001 
 
30-39 1.44 0.36 - 5.71 0.60 5.86 2.66 - 12.87 <0.001 4.56 1.84 - 11.34 0.001 
 
40-49 1.47 0.38 - 5.77 0.58 5.96 2.71 - 13.10 <0.001 5.37 2.20 - 13.11 <0.001 
 
50-59 1.82 0.46 - 7.14 0.39 7.30 3.31 - 16.08 <0.001 6.50 2.65 - 15.95 <0.001 
CD4 cell count at start of TB or ART 
(cells/µl) c     
        
 
CD4 0-49 1 
   
1    1    
 
CD4 50-99 0.66 0.55 - 0.77 <0.001 0.54 0.46 - 0.65 <0.001 0.77 0.62 - 0.96 0.02 
 
CD4 100-199 0.48 0.40 - 0.57 <0.001 0.33 0.28 - 0.39 <0.001 0.66 0.51 - 0.86 0.002 
 
CD4 200-349 0.42 0.31 - 0.56 <0.001 0.19 0.16 - 0.24 <0.001 0.45 0.34 - 0.59 <0.001 
 
CD4 >350 0.26 0.19 - 0.36 <0.001 0.14 0.11 - 0.18 <0.001 0.39 0.30 - 0.52 <0.001 
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Factors  Primary MSM model for effect 
of ART on death a 
Pooled unweighted logistic 
regression model for effect of 
ART on death 
MSM model for effect of 
cotrimoxazole on death b 
 
HR 95% CI Wald p value HR 95% CI 
Wald 
p value HR 95% CI 
Wald 
p value 
 
TB episode during follow-up  
    
        
 
One TB episode 1 
   
1    1    
 
Two TB episodes 0.92 0.73- 1.17 0.51 0.96 0.77 - 1.20 0.745 0.91 0.72 - 6.46 0.44 
 
Three TB episodes 1.20 0.80 - 1.81 0.37 1.21 0.82 - 1.78 0.327 2.64 1.07 - 14.34 0.034 
Weight at start of TB or ART (kg) c 
 
                 
 
30-45 1 
   
1    1    
 
46-52 0.72 0.85 - 0.85 <0.001 0.44 0.38 - 0.51 <0.001 0.87 0.68 - 1.11 0.25 
 
53-59 0.51 0.40 - 0.64 <0.001 0.27 0.22 - 0.33 <0.001 0.75 0.57 - 0.99 0.05 
 
60-160 0.46 0.37 - 0.59 <0.001 0.17 0.13 - 0.21 <0.001 0.58 0.44 - 0.78 <0.001 
History of TB at start of TB 
    
        
 
No previous TB 1 
   
1    1    
 
Previous TB 1.08 0.88 - 1.32 0.48 1.06 0.87 - 1.29 0.52 1.18 0.96 - 1.46 0.12 
Follow-up time 
    
        
 
No follow-up time 1 
   
1    1    
 
Extra month  0.92 0.88 - 0.95 <0.001 0.92 0.89 - 0.95 <0.001 0.95 0.94 - 0.97 <0.001 
TB Classification   
    
        
 
Both 1 
   
1    1    
 
Pulmonary 0.63 0.31 - 1.30 0.21 1.02 0.77 - 1.34 0.89 1.06 0.72 - 1.53 0.77 
 
Extra-pulmonary 0.53 0.26 - 1.11 
0.24 - 1.00 
0.10 0.89 0.69 - 1.16 0.39 1.02 0.71 - 1.46 0.93 
 
No classification 0.50 0.05 0.80 0.61 - 1.03 0.09 0.68 0.44 - 1.05 0.08 
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Factors  Primary MSM model for effect 
of ART on death a 
Pooled unweighted logistic 
regression model for effect of 
ART on death 
MSM model for effect of 
cotrimoxazole on death b 
 
HR 95% CI Wald p value HR 95% CI 
Wald 
p value HR 95% CI 
Wald 
p value 
District 
 
                  
 
Fezile Dabi 1 
   
1    1    
 
Lejweleputswa 1.23 0.96 - 1.58 0.09 1.08 0.93 - 1.26 0.27 0.60 0.35 - 1.03 0.07 
 
Motheo 1.06 0.81 - 1.39 0.65 1.03 0.90 - 1.18 0.65 0.85 0.61 - 1.17 0.33 
 
Thabo Mofutsanyane 1.43 1.12 - 1.83 0.01 1.21 1.05 - 1.39 0.01 0.87 0.65 - 1.16 0.36 
 
Xhariep 1.09 0.85 - 1.41 0.49 0.93 0.80 - 1.08 0.36 0.70 0.52 - 0.96 0.03 
MSM: Marginal structural model;  HR: Hazard ratio;  CI: Confidence interval 
a weighted by inverse probability of receiving ART 
b weighted by inverse probability of receiving cotrimoxazole therapy  
c TB: CD4 cell count and weight from period twelve months before TB diagnosis and three months after TB diagnosis but closest to the TB diagnosis 
date.   
ART: CD4 cell count and weight between six months before ART was started and fourteen days after ART was started. 
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To estimate the effect of ART within each CD4 stratum, an additional MSM model was 
performed in which an interaction term was included, modelling ART prescription and CD4 
cell count at the start of TB treatment, stratified by CD4 categories.  Table 32 shows the 
recalculated hazard ratios and confidence intervals for the interaction term from this model, 
which are the point estimates and confidence intervals computed for linear combinations of 
coefficients.  This shows that the effect of ART was similar in reducing the hazard of death in 
the CD4 categories less than 350 cells/µl.  The interaction term was not significant (p=0.061). 
Table 32: Effect of ART on death within each CD4 category at the start of TB treatment 
 Factor Adjusted MSM model  a, b, c 
(TB from HIV programme and ETR) 
 
HR 95% CI p value 
CD4 0-49 and on ART 0.53 0.47 - 0.61 <0.001 
CD4 50-99 and on ART 0.49 0.38 - 0.62 <0.001 
CD4 100-199 and on ART 0.61 0.47 - 0.80 <0.001 
CD4 200-349 and on ART 0.50 0.31 - 0.79 0.004 
CD4 >= 350 and on ART 0.66 0.42 - 1.06 0.09 
MSM: Marginal structural model;  HR: Hazard ratio;  CI: Confidence interval 
a MSM adjusting for ART, CD4, CD4×ART interaction, sex, age, weight, 
history of TB, and for clustering within districts and intra-patient 
correlation of outcomes. 
b Point estimates and confidence intervals were computed for linear 
combinations of coefficients.  
c Test for equality of coefficients for interaction term, p=0.61 
Summary statistics of the distribution of stabilised weight for treatment and censorship showed 
that the MSM dataset of 60 331 484 observations had a mean (standard deviation) of 1.12 
(3.56),  median (inter quartile range) of 0.93 (0.80-1.12), and a variance of 12.70.     
MSMs might be biased by extreme inverse probability weights.  Therefore sensitivity analyses 
were done truncating inverse probability weights at the 1st and 99th percentiles, and the 5th and 
95th percentiles (Table 33).  This did not affect the estimated effect of ART, but it did affect the 
estimated effect of cotrimoxazole compared to the primary analyses shown in Table 33.  That is, 
truncation of inverse probability weights at different percentiles resulted in cotrimoxazole 
significantly reducing mortality.  
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Table 33: Sensitivity analysis with inverse probability of treatment weights truncated at 1st/99th 
percentiles or 5th/95th percentiles; imputed data [25 sets]. 
  
Adjusted MSM model a 
Truncated at 1st/99th percentile 
Adjusted MSM model a 
Truncated at 5th/95th percentile 
Reference 
category 
Explanatory 
variable HR 95% CI p-value HR 95% CI p value 
Model to evaluate effect of ART on death 
No ART ART 0.53 0.47 - 0.58 <0.001 0.53 0.48 - 0.59 <0.001 
Model to evaluate effect of cotrimoxazole on death 
Cotrimoxazole 
not prescribed 
Cotrimoxazole  
 prescribed 
0.83 0.75 - 0.92 <0.001 0.81 0.74 - 0.90 <0.001 
a Also adjusted for sex, age, baseline CD4, baseline weight, number of TB episodes, history of TB, follow-up 
time, TB classification, district and intra-patient correlation of outcomes. 
4.2.2. Secondary analysis: Cox regression. 
Cox proportional hazards models were used for secondary analyses.  A crude Cox model 
indicated that the hazard of death was reduced by 49% (HR 0.51, CI: 0.48-0.55) in co-infected 
patients (data not shown in table).  Due to a high proportion of patients with a missing CD4 cell 
count or weight or both values, multiple imputation was used to assign these values.  An 
interaction term was included to model the effect of ART and CD4 cell count at the start of TB 
treatment.  The interaction term was significant (p=0.0031). 
Table 34 shows the results for adjusted Cox models with and without an interaction term, using 
25 sets of imputed data.  The Cox model without the interaction term demonstrated that the 
hazard of death was reduced by 46% (HR 0.54, CI: 0.49-0.60) for patients receiving ART 
compared to patients not receiving ART by the end of follow-up, and by 51% (HR 0.49, 
CI:0.42-0.57) in the model with the interaction term.  These effect estimates were very similar 
to the 47% reduction in hazard of death demonstrated by the marginal structural model (HR 
0.53, CI: 0.47-0.61). 
Men (HR 1.25, CI: 1.15-1.35), patients older than 20 years (HR>7.09), and patients who had a 
history of TB at the time they started TB treatment (HR 1.11, CI: 1.01-1.24) had a higher risk 
of dying.  Patients with increasing CD4 cell counts and weights had a lower risk of dying 
compared to patients with a CD4 cell count below 50 cells/µl or a weight of 30-45kg. 
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Table 34: Cox proportional hazards model to evaluate the effect of ART on death; imputed data [25 sets]. 
 Factors Adjusted Cox model  a 
(TB from HIV programme and ETR) 
Adjusted Cox model with interaction 
term a 
(TB from HIV programme and ETR) 
 
HR 95% CI p value HR 95% CI p value 
ART Treatment status  
    
 No ART 1 1 
   
 ART 0.54 0.49 - 0.60 <0.001 0.49 0.42 - 0.57 <0.001 
CD4 cell count at start of TB 
or ART (cells/µl) d 
 
  CD4 0-49  1    1 
    CD4 50-99 0.68 0.61 - 0.76 <0.001 0.70 0.60 - 0.82 <0.001 
 CD4 100-199 0.52 0.47 - 0.58 <0.001 0.47 0.40 - 0.54 <0.001 
 CD4 200-349 0.37 0.31 - 0.43 <0.001 0.31 0.25 - 0.37 <0.001 
 CD4 >350 0.29 0.23 - 0.36 <0.001 0.26 0.21 - 0.33 <0.001 
Interaction between CD4 
category (cells/µl) and ART 
b, c 
 
    
 CD4<50 and no ART     1 
   
 CD4 50-99 and on ART     0.96 0.78 - 1.19 0.71 
 CD4 100-199 and on ART     1.21 0.99 - 1.48 0.05 
 CD4 200-349 and on ART     1.72 1.25 - 2.34 0.001 
 CD4 >350 and on ART     1.49 0.78 - 2.83 0.225 
Cotrimoxazole prescribed 
ever 
 
    
 No cotri prescribed 1    1 
   
 Cotri prescribed 0.56 0.50 - 0.63 <0.001 0.58 0.50 - 0.62 <0.001 
Sex  
    
 Women 1    1 
   
 Men 1.25 1.15 - 1.35 <0.001 1.25 1.16 - 1.35 <0.001 
Age at start of TB (years)  
     < 20      1 
   
 20-29  7.09 2.28 - 22.01 0.001 7.07 2.28 - 21.91 0.001 
 30-39  7.09 2.29 - 21.90 0.001 7.04 2.28 - 21.73 0.001 
 40-49  8.02 2.60 - 24.83 <0.001 8.01 2.59 - 24.71 <0.001 
 50-100  9.90 3.18 - 30.52 <0.001 9.83 3.18 - 30.37 <0.001 
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 Factors Adjusted Cox model  a 
(TB from HIV programme and ETR) 
Adjusted Cox model with interaction 
term a 
(TB from HIV programme and ETR) 
 
HR 95% CI p value HR 95% CI p value 
Weight category at start of 
TB or ART (kg) d 
 
     30-45 1    1    
 46-52 0.72 0.64 - 0.80 <0.001 0.72 0.64 - 0.81 <0.001 
 53-59 0.60 0.53 - 0.69 <0.001 0.60 0.53 - 0.69 <0.001 
 60-160 0.50 0.44 - 0.57 <0.001 0.50 0.43 - 0.57 <0.001 
History of TB at start of TB  
    
 No  previous TB 1    1 
   
 Previous TB 1.11 1.01 - 1.24 0.04 1.12 1.01 - 1.24 0.03 
District  
              Fezile Dabi 1    1    
          Lejweleputswa 0.73 0.36 - 1.47 0.38 0.71 0.35 - 1.45 0.03 
          Motheo 0.52 0.16 - 1.71 0.28 0.51 0.15 - 1.68 0.32 
          Thabo Mofutsanyane 0.77 0.31 - 1.92 0.58 0.76 0.30 - 1.88 0.27 
          Xhariep 0.46 0.21 - 1.03 0.06 0.45 0.20 - 1.01 0.05 
HR: Hazard ratio;  CI: Confidence interval 
a Cox proportional hazards models also adjusting for district, and intra-patient correlation of outcomes. 
b Test for equality of coefficients for interaction term, p=0.0031 
c Point estimates and confidence intervals were computed for linear combinations of coefficients after the 
estimation command.  Recalculated values displayed in Table 19. 
d TB: CD4 cell count and weight from period twelve months before TB diagnosis and three months after TB 
diagnosis but closest to the TB diagnosis date. 
 ART: CD4 cell count and weight between six months before ART was started and fourteen days after ART 
was started. 
 
Adding CD4-ART interaction  terms significantly improved the model’s fit with the data. 
(p=0.0031). That is, the estimated effectiveness of ART was different between CD4 strata  
(Table 35).  This shows that ART was most effective in preventing death if baseline CD4 was 
less than 200 cells/µl, but was less effective with a baseline CD4 of 200 cells/µl or more. 
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Table 35: Effect of ART on time to death within each CD4 stratum; Imputed data [25 sets]. 
 Factor: 
 
Adjusted Cox model a 
(TB from HIV programme and ETR) 
Interaction between CD4 category 
(cells/µl) and ART HR 95% CI p value 
CD4 0-49 and on ART 0.49 0.42 - 0.57 <0.001 
CD4 50-99 and on ART 0.47 0.40 - 0.56 <0.001 
CD4 100-199 and on ART 0.59 0.51 - 0.69 <0.001 
CD4 200-349 and on ART 0.84 0.64 - 1.11 0.211 
CD4 >= 350 and on ART 0.73 0.19 - 1.36 0.319 
HR: Hazard ratio;  CI: Confidence interval 
a Adjusting for ART, CD4, CD4×ART interactions, sex, age,  weight, history of TB, 
cotrimoxazole prescription, and for clustering within districts and intra-patient correlation of 
outcomes.  p values for all interaction terms=0.0031 
 
A second set of adjusted Cox proportional hazards models, with and without the interaction 
term, was used to evaluate the effect of ART restricted to complete case data (Table 36).  The 
results from this complete case analysis were similar to those obtained from both the marginal 
structural model (Table 31) and imputed Cox models (Table 34). The complete case analysis 
without the interaction term (Table 36) illustrated that the hazard of death in co-infected 
patients was 47% less (HR  0.53, CI: 0.47-0.60) for patients who received ART, the marginal 
structural model showed a 47% reduction in hazard of death in co-infected HIV-TB patients 
(HR  0.53, CI: 0.47-0.61, Table 31), and the imputed Cox model (without the interaction term) 
showed a 46% reduction in hazard of death (HR  0.54, CI 0.49-0.60, Table 34).   The complete 
case Cox model with the interaction term included, showed a 53% reduction in hazard of death 
(HR 0.47, CI: 0.39-0.56, Table 36). 
The Cox model showed (Table 36) that men and older patients were more at risk of dying (Men: 
HR 1.37, CI:1.24-1.51; HR 1.18 (CI: 1.03-1.36) for patients 45-99 years old compared to 16-32 
year old patients).  Better clinical prognostic factors such as a higher CD4 cell count and 
weight were associated with better survival (CD4 more than 350 cells/µl: HR 0.28, 
CI: 0.21-0.36; weight between 60-160 kg: HR 0.50 CI: 0.44-0.58).  A history of TB was 
negatively associated with hazard of death, increasing the hazard of death by 14% (HR 1.14  
CI: 1.01-1.29). 
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Table 36: Factors associated with death in co-infected HIV-TB patients using a Cox proportional hazards 
model; no imputation. 
 Factors 
  
Adjusted model  a 
(TB from HIV programme and 
ETR) 
Adjusted model with interaction 
term included a 
(TB from HIV programme and ETR) 
  
HR 95% CI p value HR 95% CI p value 
ART Treatment status     
    
 
No ART 1    1 
   
  ART 0.53 0.47 - 0.60 <0.001 0.47 0.39 - 0.56 <0.001 
Interaction between CD4 
category (cells/µl) and ART b,  c 
    
    
 
CD4<50 and no ART     1 
   
 
CD4 50-99 and on ART     0.89 0.70 - 1.14 0.35 
CD4 100-199 and on ART     1.39 1.09 - 1.76 0.006 
CD4 200-349 and on ART     2.04 1.41 - 2.95 <0.001 
CD4 >350 and on ART     1.76 0.85 - 3.65 0.13 
CD4 cell count at start of TB or 
ART (cells/µl) d 
    
    
 
CD4 0-49 1    1 
   
 
CD4 50-99 0.65 0.57 - 0.73 <0.001 0.69 0.58 - 0.83 <0.001 
 
CD4 100-199 0.51 0.45 - 0.57 <0.001 0.41 0.34 - 0.49 <0.001 
 
CD4 200-349 0.35 0.29 - 0.43 <0.001 0.26 0.21 - 0.33 <0.001 
  CD4 >350 0.28 0.21 - 0.36 <0.001 0.24 0.18 - 0.32 <0.001 
Cotrimoxazole prescribed ever     
    
 
No cotrimoxazole prescribed 1    1 
   
 
Cotrimoxazole prescribed 0.65 0.55 - 0.75 <0.001 0.64 0.55 - 0.75 <0.001 
Sex     
    
 
Women 1    1 
   
 
Men 1.37 1.24 - 1.51 <0.001 1.37 1.25 - 1.51 <0.001 
Age at start of TB or ART (years)     
    
 
16-32 1    1 
   
 
33-38  1.04 0.91 - 1.20 0.54 1.04 0.91 -1.20 0.56 
 
39-44 1.07 0.93 -1.23 0.37 1.07 0.93 -1.24 0.32 
  45-99 1.18 1.03 -1.36 0.02 1.19 1.04 -1.37 0.01 
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 Factors 
  
Adjusted model  a 
(TB from HIV programme and 
ETR) 
Adjusted model with interaction 
term included a 
(TB from HIV programme and ETR) 
  
HR 95% CI p value HR 95% CI p value 
Weight at start of TB or ART 
(kg) 
    
    
 
30-45 1       1    
 
46-52 0.68 0.60 – 0.77 <0.001 0.68 0.6 - 0.77 <0.001 
 
53-59 0.60 0.52 – 0.68 <0.001 0.60 0.53 - 0.68 <0.001 
  60-160 0.50 0.44 – 0.58 <0.001 0.50 0.44 - 0.58 <0.001 
History of TB at start of TB     
    
 
No previous TB 1    1 
   
 
Previous TB 1.14 1.01 - 1.29 0.03 1.15 1.02 - 1.30 0.03 
District     
    
 
Fezile Dabi  1       1    
 
Lejweleputswa 0.71 0.34 - 1.47 0.35 0.70 0.34 - 1.46 0.35 
 
Motheo 0.0 0.0 - 0.0 <0.001 0.0 0.0 - 0.0 <0.001 
 
Thabo Mofutsanyane 0.95 0.35 - 2.62 0.93 0.90 0.33 - 2.49 0.84 
  Xhariep 0.46 0.19 - 1.13 0.09 0.46 0.19 - 1.10 0.08 
a Cox proportional hazards models also adjusting for clinic and intra-patient correlation of outcomes. 
b Test for equality of coefficients for interaction term, p<0.001. 
c Point estimates and confidence intervals were computed for linear combinations of coefficients after the 
estimation command.  Recalculated values displayed in Table 37. 
d TB: CD4 cell count and weight from period twelve months before TB diagnosis and three months after TB 
diagnosis but closest to the TB diagnosis date. 
 ART: CD4 cell count and weight between six months before ART was started and fourteen days after ART was 
started. 
The post-estimation analysis restricted to complete case analysis to recalculate the hazard ratios 
for the interaction term per CD4 stratum (Table 37), showed that ART was effective in 
preventing death if baseline CD4 was less than 200 cells/µl or more. 
Table 37: Effect of ART on death within each CD4 stratum at the start of TB treatment; no imputation. 
  
Adjusted Cox model a, b 
(TB from HIV programme and ETR) 
Factor: 
Interaction between CD4 
category (cells/µl) and ART 
HR 95% CI p value 
CD4 0-49 and on ART 0.47 0.39 – 0.56 <0.001 
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Adjusted Cox model a, b 
(TB from HIV programme and ETR) 
Factor: 
Interaction between CD4 
category (cells/µl) and ART 
HR 95% CI p value 
CD4 50-99 and on ART 0.41 0.34 – 0.51 <0.001 
CD4 100-199 and on ART 0.65 0.54 – 0.78 <0.001 
CD4 200-349 and on ART 0.95 0.68 – 1.33 0.767 
CD4 >=350 and on ART 0.82 0.40 – 1.67 0.582 
HR: Hazard ratio;  CI: Confidence interval 
a Adjusting for ART, CD4, CD4×ART interaction, sex, age, weight, history of TB, 
cotrimoxazole prescription, and for clustering within clinic within districts and intra-
patient correlation of outcomes. 
b Point estimates and confidence intervals were computed for linear combinations of 
coefficients. 
Post estimation graphs were carried out to test the validity of the Cox model.  Since the lines 
were not crossing in the complimentary log-log plot (Figure 25), Cox proportional hazards 
model were appropriate to use. 
 
Figure 25: Complimentary log-log plot. 
A Cox model using complete case data was used in a sensitivity analysis to evaluate the impact 
of excluding TB information from the ETR, obtained through linkage (Table 38).  The 
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sensitivity analysis showed that ignoring TB information obtained from the ETR would have 
over-estimated the effectiveness of ART on time to death.  The hazard ratio from the sensitivity 
analysis was 0.39 (CI: 0.29-0.54) compared to HR 0.47 CI: 0.39-0.56 (Table 38) in the 
equivalent model which included ETR info.  The same trends were seen for age, weight, CD4 
cell count and district in the sensitivity model as with the adjusted Cox model (Table 36). 
Table 38: Sensitivity analysis: Factors associated with the effect of ART on death using a Cox proportional 
hazards model with TB information restricted to HIV programme; no imputations. 
 Factors 
  
Sensitivity analysis model a 
(TB from HIV programme database only) 
  
HR 95% CI p value 
ART Treatment status 
    
 
No ART 1 
   
  ART 0.39 0.29 - 0.54 <0.001 
CD4 cell count at start of TB or ART 
(cells/µl) 
    
 
CD4 0-49 1 
   
 
CD4 50-99 0.63 0.46 - 0.87 0.01 
 
CD4 100-199 0.47 0.34 - 0.64 <0.001 
 
CD4 200-349 0.27 0.18 - 0.4 <0.001 
 CD4 >350 0.29 0.18 - 0.46 <0.001 
Cotrimoxazole prescribed ever 
    
 
No cotrimoxazole prescribed 1 
   
 
Cotrimoxazole prescribed 0.73 0.56 - 0.96 0.02 
Interaction between CD4 category (cells/µl) 
and ART b 
    
 
CD4<50 and no ART 1 
   
 
CD4 50-99 and on ART 1.06 0.7 - 1.61 0.78 
CD4 100-199 and on ART 1.23 0.82 - 1.84 0.32 
CD4 200-349 and on ART 2.79 1.49 - 5.22 <0.001 
CD4 >350 and on ART 1.55 0.45 - 5.36 0.48 
Cotrimoxazole prescribed ever 
    
 
No cotrimoxazole prescribed 1 
   
 
Cotrimoxazole prescribed 0.73 0.56 - 0.96 0.02 
Sex 
    
 
Women 1 
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 Factors 
  
Sensitivity analysis model a 
(TB from HIV programme database only) 
  
HR 95% CI p value 
 
Men 1.38 1.16 - 1.63 <0.001 
Age at start of TB or ART (years): 
    
 
16-32 1 
   
 
33-38  1.21 0.95 - 1.55 0.12 
 
39-44 1.27 1.00 - 1.63 0.05 
 45-99 1.25 0.98 - 1.6 0.07 
CD4 cell count at start of TB or ART 
(cells/µl) 
    
 
CD4 0-49 1 
   
 
CD4 50-99 0.63 0.46 - 0.87 0.01 
 
CD4 100-199 0.47 0.34 - 0.64 <0.001 
 
CD4 200-349 0.27 0.18 - 0.4 <0.001 
 CD4 >350 0.29 0.18 - 0.46 <0.001 
Weight at start of TB or ART (kg): 
    
 
30-45 1    
 
46-52 0.66 0.53 - 0.81 <0.001 
 
53-59 0.52 0.41 - 0.65 <0.001 
 60-160 0.38 0.3 - 0.49 <0.001 
History of TB at the start of TB 
    
 
No previous TB 1 
   
 
Previous TB 0.98 0.78 - 1.23 0.86 
District: 
    
 
Fezile Dabi 1    
 
Lejweleputswa 0.56 0.21 - 1.52 0.25 
 
Motheo 0.0 0.0 - 0.0 <0.001 
 
Thabo Mofutsanyane 0.67 0.12 - 3.84 0.66 
 Xhariep 0.39 0.12 - 1.27 0.12 
HR: Hazard ratio;  CI: Confidence interval 
a Cox proportional hazards models also adjusting for clinic, and intra-patient correlation of 
outcomes. 
b Test for equality of coefficients for interaction term, p<0.001 
c No-ART: CD4 cell count and weight from period twelve months before TB diagnosis and 
three months after TB diagnosis but closest to the TB diagnosis date. 
 ART: CD4 cell count and weight between six months before ART was started and 
fourteen days after ART was started. 
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4.3. Summary of results 
Most of the co-infected HIV-TB patients received ART (75%).  This co-infected population 
had an overall median CD4 cell count of 122 cells/µl and 64% of them had a CD4 cell count 
below 200.  More than fifty percent (54.3% (1 455 / 2 679) of the patients who had not received 
ART by the end of follow-up died, while 19.3% (1 509 / 7 819) of patients who had received 
ART by the end of follow-up died. 
The marginal structural model adjusting for baseline characteristics as well as time-varying 
covariates showed that ART reduced the hazard of death by 47% (HR 0.53 CI: 0.47-0.61).  
There was no association between cotrimoxazole and death, probably because of the 
co-linearity between ART and cotrimoxazole therapy (HR 1.02 CI: 0.71-1.46).  The Cox 
models, adjusting for baseline characteristics only, showed similar effectiveness of ART, 
producing point estimates corresponding to a reduction in hazard of death of 46% (Cox model 
with imputed data, HR 0.54 CI: 0.49-0.60), and 47% (Cox model using complete case data, HR 
0.53 CI: 0.47-0.60).  The two Cox models with an interaction term found similar results overall 
compared to the models without an interaction term and showed that ART was effective in 
reducing the hazard of death between 51% and 53%.  Using TB information from the HIV 
programme database (ignoring TB information from ETR linkage) over-estimated the effect of 
ART on death, a 61% reduction in the hazard of death was found (HR 0.39 CI: 0.29-0.54).  The 
shortage of repeated (and missing) CD4 measurements over time, because most patients were 
tested every 6-12 months,  could be a reason why the results from the MSM and Cox model 
were very similar. The analyses were not limited by the proportion of patients with missing 
weight or CD4 values or both. All of the models found that ART reduced the hazard of death 
between 46% and 49% (MSM: HR 0.53 p<0.001, Cox with imputed data: HR 0.54 p<0.001, 
Cox with complete case data HR 0.53 p<0.001).   
The models also highlighted other associations between risk factors and the risk of death for 
example men and patients who had TB before enrolling in the HIV programme were at greater 
risk, and as patients’ age increased, their hazard of death increased.  The hazard of death 
decreased for patients with a higher body weight and CD4 cell count at enrolment.  Post 
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estimation analyses by CD4 strata also showed that ART was less effective at preventing death 
in patients with CD4 counts above 200 cells/µl. 
Two district homogeneity trends were seen.  In the marginal structural model all the districts 
were at risk compared to Fezile Dabi district, whereas in the other models all the districts had a 
lower hazard of mortality compared to Fezile Dabi. 
Overall, ART was effective in preventing death in co-infected patients, especially in those with 
advanced immune-suppression. 
Table 39: Estimates effectiveness of ART from different regression models. 
Model used 
Effect of ART on survival 
(TB from HIV programme and ETR) 
 
Effect 
estimate 95% CI p value 
Primary analysis: Marginal 
structural model.  
Imputed data [25 sets]. 
HR 0.53 0.47 - 0.61 <0.001 
Crude Cox proportional hazards 
model. No imputation. HR 0.51 0.48 - 0.55 <0.001 
Adjusted Cox proportional 
hazards model. 
Imputed data [25 sets]. 
HR 0.54 0.49 - 0.60 <0.001 
Adjusted Cox proportional 
hazards model.  No imputation HR 0.53 0.47 - 0.60 <0.001 
HR: Hazard ratio;  CI: Confidence interval 
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5. EFFECT OF ART ON TB TREATMENT OUTCOMES 
HIV and TB programmes are managed separately due to verticalisation in most health care 
settings, therefore large sample size surveillance data at the intersection of these programmes 
are scarce, and currently not available in South Africa.  Linkage of the Free State public sector 
provincial databases made it possible to identify these inter-programme co-infected HIV-TB 
patients, and to evaluate the effect of ART on their TB treatment outcomes.  Linkage with the 
population registry provided crucial vital status information for patients, providing an 
opportunity to monitor patients after they have completed TB treatment.  HIV database 
linkages contributed additional co-variates for inclusion in logistic regression models as 
potential confounders and risk factors associated with TB treatment outcomes. 
5.1. Cohort and TB treatment outcomes 
In total, 9 276 patients presenting with a first episode of TB between 2004 and 2008, and linked 
to the HIV programme database, were included in analyses.  HIV related information in the 
ETR was limited and greatly improved with linkage to the HIV programme database.  For 
example, HIV status was recorded for only 23.5% (2 184 / 9 276) of included patients in the 
ETR, CD4 counts for 14% (1 272 / 9 276) of patients, and death for 8.3% of patients 
(771 / 9 276) (data not shown in table).  Subsequent to linkage with the HIV programme 
database, which included linkages with the laboratory databases and death population register, 
HIV status was available for 100% of patients, CD4 counts for 49.4% and death information 
for 29% of patients (including deaths during and after TB treatment).  Patients who had died 
during TB treatment and had been registered as dead on the ETR increased from 8.3% to 9.8% 
after the linkage. 
Before linkage 11 896 patients on the HIV programme database were identified as being on TB 
treatment, 73% of them were linked to the ETR (Figure 13).  A manual search was conducted, 
searching for the remainder of unlinked TB patients on the ETR to identify patients and 
possible reasons why matches could not be identified with prior linking rules.  This helped to 
improve algorithms for linkage. 
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Table 40 shows baseline characteristics of the 9 276 co-infected HIV-TB patients enrolled in 
the TB programme between 2004 and 2008.  New enrolments of co-infected HIV-TB patients 
increased substantially from 1 133 patients during 2004 to 2 833 in 2008.  Overall, slightly 
more women (56%) enrolled and the mean age for patients was 36 years.  Enrolment age 
increased slightly during the study period, increasing from 35 to 37 years (p<0.001 testing for 
trend).  SA ID numbers were mostly collected by the HIV programme and ascertainment of ID 
numbers ranged between 84% and 89% during the study period.  A significant decrease in 
ascertainment of ID numbers over time was present (p<0.001 testing for trend).   
Overall, 75% of patients presented with pulmonary TB, and 22% with extra-pulmonary TB.  
Patients were more likely to be smear positive (51.7%) and least likely to have no evidence of a 
smear being taken (17%).  New TB cases were registered for 84% of patients and 16% 
retreatment cases overall.  Testing for trend over time shows a significant increase in new TB 
cases, no smear results, smear negative results and all three types of TB (pulmonary TB, extra-
pulmonary TB or both types), while a significant decrease is seen in retreatment cases and 
smear positive results (p<0.001 testing for trend). 
Smear positive results decreased from 59% in 2004 to 49% in 2008, new TB cases increased 
from 80% in 2004 to 86% in 2008, and the proportion of patients with a missing CD4 cell 
count declined from 80% in 2004 to 41% in 2008 (Table 40).  This co-infected population is 
overall a very immuno-compromised group with a median CD4 cell count as low as 105 
cells/µl, IQR 49-184 cells/µl.  Of the 4 581 patients with an available CD4 cell count close to 
the TB treatment start date, 78.5% (3 597) had a CD4 cell count of 200 or less and were 
therefore eligible for ART at the time of starting TB treatment according to national guidelines 
at the time (National Antiretroviral Treatment Guidelines. April 2004).  Yet, only 41% (1 484) 
patients eligible for ART on the basis of their CD4 count started ART during their TB 
treatment episode. 
In the combined group (Table 40), 21.5% ((1 534+467) / 9 276) of patients started ART during 
TB treatment.  Of the group who did not start ART during their TB treatment episode, 50% 
(3 640 / 7 275) had not started ART by June 2010 and 50% (3 635 / 7 275) started ART after 
their TB episode.  From 2006 onwards there was an increase in the number of patients starting 
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ART early during TB treatment, most likely reflecting policy changes in terms of concomitant 
treatment of TB and HIV (PALSA PLUS 2006 edition).  Testing for trend shows a significant 
increase in the number of patients starting ART during the first 61 days since TB treatment 
commenced (p=0.004), and also for patients starting ART after two months of TB treatment but 
before completion of the TB treatment episode (p<0.001). From 2006 to 2008, the percentage 
of co-infected patients starting ART during the first 14 days of TB treatment increased from 7.8% 
(4 / 51) to 17.6% (42 / 239); similarly patients starting ART between 15 and 28 days of TB 
treatment increased from 17.7% (6 / 51) to 27.2% (65 / 239) over the same period (data not 
shown).   
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Table 40: Baseline characteristics of co-infected HIV-TB patients according to the year in which TB treatment was started 
 
2004 2005 2006 2007 2008 Combined 
 
 
n (%) n (%) n (%) n (%) n (%) N (%) p valueb 
Number of patients 1 133 (12.2) 1 406 (15.2) 1 773 (19.1) 2 131 (23) 2 833 (30.5) 9 276 (100) 
 
Women 642 (56.6) 779 (55.4) 1 039 (58.6) 1 210 (56.7) 1 565 (55.2) 5 235 (56.4) 0.477 
Age in years:  Mean (SD) 35 (8.4) 36 (8.9) 36 (8.8) 37 (9.2) 37 (9.2) 36 (9) <0.001 
Valid South African ID number 1 007 (88.9) 1 249 (88.8) 1 569 (88.5) 1 806 (84.5) 2 387 (84.2) 8 018 (86.4) <0.001 
CD4 cell count at time of starting 
TB treatment, cells/µl (median, 
IQR) a 
102  
(52-195) 
121  
(55-208) 
120  
(55-213) 
97  
(46-177) 
103 
 (48-175) 
105  
(49-184)  
CD4 cell count at time of starting 
TB treatment per category, cells/µl 
(median, IQR)       
<0.001 
Missing CD4 902 (79.6) 938 (66.7) 948 (53.5) 796 (37.4) 1 211 (41.3) 4 695 (50.6) 
 
 0-24 25 (2.2) 56 (4) 105 (5.9) 168 (7.9) 225 (7.7) 579 (6.2) 
 
 25-49 29 (2.6) 49 (3.5) 78 (4.4) 195 (9.2) 229 (7.8) 580 (6.3) 
 
 50-99 59 (5.2) 92 (6.5) 157 (8.9) 327 (15.3) 386 (13.2) 1 021 (11) 
 
100-199 63 (5.6) 148 (10.5) 260 (14.7) 380 (17.8) 566 (19.3) 1 417 (15.3) 
 
200-349 33 (2.9) 76 (5.4) 145 (8.2) 155 (7.3) 218 (7.4) 627 (6.8) 
 
350-2000 22 (1.9) 47 (3.3) 80 (4.5) 110 (5.2) 98 (3.3) 357 (3.8) 
 
District of enrolment 
      
<0.001 
Fezile Dabi District 62 (5.5) 142 (10.1) 191 (10.8) 213 (10) 374 (13.2) 982 (10.6) 
 
Lejweleputswa District 249 (22) 260 (18.5) 338 (19.1) 451 (21.2) 671 (23.7) 1 969 (21.2) 
 
Motheo District 409 (36.1) 468 (33.3) 613 (34.6) 645 (30.3) 719 (25.4) 2 854 (30.8) 
 
Thabo Mofutsanyane 292 (25.8) 373 (26.5) 431 (24.3) 554 (26) 755 (26.7) 2 405 (25.9) 
 
Xhariep District 121 (10.7) 163 (11.6) 200 (11.3) 268 (12.6) 314 (11.1) 1 066 (11.5) 
 
Type of TB 
      
0.08 
Pulmonary TB 846 (74.7) 1 079 (76.7) 1 287 (72.6) 1 566 (73.5) 2201 (77.7) 6 979 (75.3) 
 
Extra-pulmonary TB 259 (22.9) 284 (20.2) 23.01 (25.5) 495 (23.2) 578 (20.4) 2 024 (21.8) 
 
Both types 28 (2.5) 43 (3.1) 78 (4.4) 70 (3.3) 53 (1.9) 272 (2.9) 
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2004 2005 2006 2007 2008 Combined 
 
 
n (%) n (%) n (%) n (%) n (%) N (%) p valueb 
New or Retreatment case 
      
<0.001 
New case 909 (80.2) 1 148 (81.7) 1 469 (82.9) 1 827 (85.7) 2 433 (85.9) 7 786 (83.9) 
 
Retreatment case 224 (19.8) 258 (18.4) 304 (17.2) 304 (14.3) 400 (14.1) 1 490 (16.1) 
 
Sputum smear results 
      
<0001 
Positive smear results 648 (57.2) 833 (59.3) 938 (52.9) 997 (46.8) 1 376 (48.6) 4 792 (51.7) 
 
Negative smear results 316 (27.9) 385 (27.4) 546 (30.8) 733 (34.4) 896 (31.6) 2 876 (31) 
 
No evidence of smear 169 (14.9) 188 (13.4) 289 (16.3) 401 (18.8) 561 (19.8) 1 608 (17.3) 
 
ART category 
      
<0.001 
Patients never started ART or 
started ART after completion of 
TB treatment episode 
1 098 (96.9) 1 295 (92.1) 1 446 (81.6) 1 405 (65.9) 2 031 (71.7) 7 275 (78.4) 
 
Starting ART during the first 61 of 
TB treatment 3 (0.3) 10 (0.7) 51 (2.9) 164 (7.7) 239 (8.4) 467 (5)  
Starting ART after 61 days of TB 
treatment but before TB treatment 
episode is completed 
32 (2.8) 101 (7.2) 276 (15.6) 562 (26.4) 563 (19.9) 1 534 (16.5) 
 
SD: Standard deviation;  CI: Confidence interval 
a CD4 test date in the period 12 months prior and three months after TB diagnosis, but closest to the TB diagnosis date if multiple CD4 test dates are 
available. 
b Testing for trend over time: binary and continuous variables were checked using an extension of the Wilcoxon rank sum test, ordered categorical 
variables were checked with Spearman’s rank correlation and nominal categorical variables were checked with multinomial logit models. 
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Table 41 shows baseline characteristics of patients who did and did not receive ART during their 
TB treatment.  Only 5% (467 / 9 276) of patients received ART during the first 61 days of TB 
treatment; a further 16.5% (1 534 / 9 276) after two months of TB treatment but before TB 
treatment was completed, and the majority (78.4%, 7 275 / 9 276) received ART either after the 
TB treatment episode (50%, 3 635 of 7 275) or had yet to start ART by the end of follow-up in 
June 2010 (50%, 3 640 of 7 275).  The average duration of a TB episode is six months, two 
months of intensive therapy (consisting of four drugs) and a continuation phase of four months 
consisting of a two drug regimen.  Follow-up time for patients registered in the ETR is limited to 
the duration of the TB treatment episode, whereas linkage with the HIV database allows for 
longer follow-up. 
A gradient in median CD4 cell count is seen across the three ART categories (Table 41).  
Patients starting ART during the first 61 days of TB treatment had the lowest median CD4 count 
of 73 cells/µl (IQR: 32-138 cells/µl), consistent with severe immuno-suppression and in part 
explaining why they received ART earlier than their counterparts.  The highest median CD4 cell 
count (119 cells/μL IQR: 55-222 cells/µl) was found in the group of patients who did not start 
ART during their TB treatment or did not start ART at all.  This also demonstrates the 
importance of adjusting for CD4 counts in the analysis of outcomes. 
For all ART categories the predominant type of TB was pulmonary, accounting for between 71% 
(331 / 466) and 76% (5 533 / 7 275) of patients.  Patients presenting with both pulmonary and 
extra-pulmonary TB accounted for between 2.8% and 3.5%.  The percentage of new TB cases 
reported for each of the ART categories was similar between the groups (84% - 85.4%).  Smear 
negative results were more common in patients starting ART during the first 61 days of TB 
treatment (205 / 467, 43.8%) compared to the other groups; 29.1% (2 117 / 7 275) of patients 
who did not receive ART during TB treatment, and 36.1% (554 / 1 534) of patients who received 
ART after 61 days of TB treatment but during TB treatment, had smear negative results. 
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Table 41: Baseline characteristics for patients on ART during TB treatment or no ART.  ART category 
divided in patients who started ART in the first 61 days of TB treatment (early ART) or thereafter (late ART). 
 Did not start 
ART by end of 
follow-up  or 
started ART after 
completion of TB 
Started ART in the 
first 61 days of TB 
treatment (early 
ART) 
Started ART after 61 
days of TB treatment 
but before TB 
treatment episode is 
completed (late ART) 
p value a 
 
n (%) n (%) n (%) 
 
No. of patients (N=9276) 7 275 (78.5) 467 (5.0) 1 534 (16.5) 
 
Women (%) (N=9276) 4 091 (56.2) 270 (57.8) 874 (57.0) 0.717 
Age in  years (mean, SD) 36 (9.0) 36 (8.6) 37 (8.7) 0.008 
Median CD4 cell count 
closest to starting TB 
treatment, cells/µl (median, 
IQR) 
119 (55-222) 73 (32-138) 92 (44-155) <0.001 
CD4 cell count closest to 
starting TB treatment per 
category, cells/µl (median, 
IQR) b 
   
<0.001 
Missing CD4 4 349 (59.8) 60 (12.8) 286 (18.6) 
 
CD4 0-24 327 (4.5) 78 (16.7) 174 (11.3 
 
CD4 25-49 329 (4.5) 66 (14.1) 185 (12.1) 
 
CD4 50-99 609 (8.4) 108 (23.1) 304 (19.8) 
 
CD4 100-199 823 (11.3) 121 (25.9) 473 (30.8) 
 
CD4 200-349 510 (7.0) 28 (6.0) 89 (5.8) 
 
CD4 350-2000 328 (4.5) 6 (1.3) 23 (1.5) 
 
Type of TB 
   
0.009 
Pulmonary TB 5 533 (76.0) 331 (71.0) 1 115 (72.7) 
 
Extra-pulmonary TB 1 542 (21.2) 117 (25.1) 365 (23.8) 
 
Both types of TB 200 (2.8) 18 (3.9) 54 (3.5) 
 
New or Retreatment case 
   
0.662 
New case 6 100 (83.9) 399 (85.4) 1 287 (83.9) 
 
Retreatment case 1 175 (16.1) 68 (14.6) 247 (16.1) 
 
Sputum smear results 
   
<0.001 
Smear positive 3 862 (53.1) 188 (40.3) 742 (48.4) 
 
Smear negative 2 117 (29.1) 205 (43.8) 554 (36.1) 
 
No evidence of smear 1 296 (17.8) 74 (15.9) 238 (15.5) 
 
Died during the year after 
TB treatment started 1 350 (18.6) 70 (15.0) 174 (11.3) <0.001 
a Comparing ART categories (no ART during TB, ART during first two months of TB treatment, ART after two 
months) with Pearson’s chi-squared test for categorical variables and one-way ANOVA for continuous variables. 
b CD4 test date in the period 12 months prior and three months after TB diagnosis but closest to the TB diagnosis 
date if multiple CD4 test dates are available. 
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Table 42 shows a summary of TB treatment outcomes recorded in the TB register between 2004 
and 2008 for co-infected HIV-TB patients. Treatment success (cured or completed treatment 
outcome) accounted for the largest proportion of outcomes and declined significantly (p<0.001 
testing for trend) from 79.7% (903 / 1 133) in 2004 to 70.9% (2 008 / 2 833) in 2008, with an 
overall success rate of 73.9% (6 855 / 9 276).  The proportion of patients cured during the study 
period also declined over time (p<0.001 testing for trend), from 40% (452 / 9 276) in 2004 to 
34.6% (979 / 9 276) in 2008, with an overall cured outcome of 36.4% (3 373 / 9 276). 
Mortality increased over time, with 4.8% (54 / 1 133) deaths recorded in 2004, which increased 
to 9.6% (273 / 2 833) in 2008, overall mortality of 8.3% (771 / 9 276; p<0.001 testing for trend).  
TB treatment completion stayed the same over the study period and accounted for 37.5% 
(3 482 / 9 276) of TB treatment outcomes overall.  Other TB treatment outcomes which changed 
minimally over time include defaulted, failed, not evaluated, and transferred out. 
Table 42: TB register outcomes grouped by the year in which TB treatment was started for co-infected 
HIV-TB patients 
 
2004 2005 2006 2007 2008 Combined   
 
n (%) n (%) n (%) n (%) n (%) N p-value a 
Number of 
patients 
starting TB 
treatment 
1 133 
(12.2) 
1 406 
(15.2) 
1 773 
(19.1) 
2 131  
(23) 
2 833  
(30.5) 
9 276  
(100)  
TB outcome recorded on ETR register 
     
Completed 451 (39.8) 527 (37.5) 656 (37) 819 (38.4) 1029 (36.3) 3 482 (37.5) 0.166 
Cured 452 (39.9) 589 (41.9) 670 (37.8) 683 (32.1) 979 (34.6) 3 373 (36.4) <0.001 
Success b 903  
(79.7) 
1 116 
(79.4) 
1 326 
(74.8) 
1 502 
(70.5) 
2 008  
(70.9) 
6 855  
(73.9) 
<0.001 
Defaulted 62 (5.5) 59 (4.2) 58 (3.3) 80 (3.8) 89 (3.1) 348 (3.8) 0.956 
Died c 54 (4.8) 104 (7.4) 138 (7.8) 202 (9.5) 273 (9.6) 771 (8.3) <0.001 
Failed 17 (1.5) 25 (1.8) 22 (1.2) 37 (1.7) 30 (1.1) 131 (1.4) 0.281 
Moved 29 (2.6) 23 (1.6) 114 (6.4) 153 (7.2) 219 (7.7) 538 (5.8) <0.001 
Not Evaluated 3 (0.3) 4 (0.3) 3 (0.2) 4 (0.2) 12 (0.4) 26 (0.3) 0.431 
Transferred out 65 (5.7) 75 (5.3) 112 (6.3) 153 (7.2) 202 (7.1) 607 (6.5) 0.077 
a Testing for trend over time: binary variables were checked using an extension of the Wilcoxon rank sum test. 
b Success is defined as cure or completion as TB outcome. 
c Deaths as recorded by the TB register only, no deaths added from HIV programme database. 
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Table 43 displays summary information for deaths recorded during the first year of TB treatment, 
grouped by the year when TB treatment commenced and the period when death occurred.  ETR 
recorded deaths during TB treatment, while the group of patients with deaths recorded during the 
first year since TB treatment commenced, includes deaths during TB as well as deaths recorded 
after TB treatment was completed, but within one year.  Linkage with the HIV programme and 
death population register provided vital status information for TB patients, specifically after 
completion of their TB episode.   This made it possible to study deaths during the first year after 
TB treatment commenced. 
Additional death information after linkage with the HIV programme database increased the 
proportion of patients who died during TB treatment by a small number (1.5% additional deaths).  
Over the study period, deaths occurring during the first year of TB treatment almost doubled, 
increasing from 10% (115 / 1 133) for patients who had started TB treatment in 2004 and are 
known to have died, to 17.2% (1 594 / 2 833) in 2008.  Importantly, the data show that overall 
nearly the same number of patients who died during their TB treatment (9.8%, 906 / 9 276), died 
in the six months immediately after their TB treatment was completed (7.4%, (1 594 –
 906) / 9 276). 
Table 43: Summary of death information: the time period when death occurred and the source of death 
information, grouped by the year in which TB treatment was started. 
 
2004 2005 2006 2007 2008 Combined 
 
 
n (%) n (%) n (%) n (%) n (%) N (%) p value a 
Number of patients starting TB 
treatment 
1 133 
(12.2) 
1 406 
(15.2) 
1 773  
(19.1) 
2 131 
 (23.0) 
2 833  
(30.5) 
9 276 
 (100)  
Number of patients with death 
registered as their outcome on 
the TB register  
54  
(4.8) 
104  
(7.4) 
138  
(7.8) 
202  
(9.5) 
273 
 (9.6) 
771 
 (8.3) 
<0.001 
Number of patients who died 
during TB treatment  (TB register 
supplemented by information from 
the HIV programme database) 
62  
(5.5) 
129  
(9.2) 
162  
(9.1) 
238  
(11.2) 
315  
(11.1) 
906  
(9.8) 
<0.001 
Number of patients known to 
have died during the first year 
after TB treatment was started b 
(information drawn from both TB 
register and HIV programme 
database) 
115  
(10.0) 
225  
(16.1) 
297  
(16.7) 
395  
(18.8) 
562  
(19.8) 
1 594  
(17.2) 
<0.001 
a Testing for trend over time: binary variables were checked using an extension of the Wilcoxon rank sum test 
b Includes patients who died during TB and after completion of TB treatment but within one year of TB start date 
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Table 44 displays baseline characteristics for co-infected patients who survived the first year 
since TB treatment commenced and those who did not, divided into categories of when death 
occurred (during TB or after TB).  A large proportion of co-infected patients who died during the 
first year since commencement of TB treatment were not receiving ART (85%, 
(765+584) / (906+688)).  Overall patients presented with a low CD4 cell count; the median CD4 
cell count was 74 cells/µl (IQR: 29-140 cells/µl) for patients who died during the first year of TB 
treatment, compared to a median CD4 cell count of 121 cells/µl (IQR: 58-198 cells/µl) for 
patients who survived the first year of TB treatment.  Overall, women accounted for 46.8% 
((414+332) / (906+688)) of the deaths recorded during the first year of TB treatment. 
Of patients who died during TB treatment, 6.1% (55 / 906) of deaths occurred in the group who 
started ART within the first two months of TB treatment, and 9.5% (86 / 906) of deaths occurred 
in the group who started ART after two months of TB treatment (Table 44).  Interestingly, in the 
group who died after TB treatment completion but within one year since TB treatment 
commenced, only 2.2% (15 / 688) of patients died who received ART during the first two 
months of TB treatment, whereas 12.9%  (89 / 688) of patients died who started ART after two 
months of TB treatment but during the TB episode.  A large proportion of patients who died 
during the six months after completing TB treatment (62%, 430 / 688), had a successful TB 
outcome registered.  Migration seemed to be more prevalent among those who died after TB 
treatment (data not shown), with higher rates of transfer (12%, 82 / 688) and moved (17%, 
113 / 668) reported, compared with the overall population which had a transfer rate of 6.5% and 
moved of 5.8%  (Table 42). 
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Table 44: Baseline characteristics for co-infected HIV-TB patients with no deaths recorded during first year 
of TB treatment (survivors), deaths during TB treatment and deaths after TB treatment but within one year 
since TB treatment commenced. 
 Survived first 
year since TB 
treatment 
commenced  
Died during TB 
treatment a   
Died after TB 
treatment 
completion but 
within a year 
of starting TB 
treatment b 
Combined 
(All three 
groups) 
p value c 
 
n (%) n (%) n (%) N (%) 
 Number of patients 7 682 (82.8) 906 (9.8) 688 (7.4) 9 276 (100) 
 
Women 3 295 (42.9) 414 (45.7) 332 (48.3) 4 041 (43.6) 0.717 
TB duration (median, IQR), 
days 186 (181-215) 92 (43-149) 183 (88-193) 184 (172-210) <0.001 
Median CD4 cell count 
closest to starting TB 
treatment, cells/µl (median, 
IQR) 
121 (58-198) 64 (28-111) 74 (29-140) 105 (49-184) <0.001 
CD4 cell count closest to 
starting TB treatment per 
category, cells/µl      
0.010 
0-24 340 (9.6) 151 (23.1) 88 (22.6) 579 (12.6) 
 25-49 416 (11.8) 112 (17.2) 52 (13.4) 580 (12.7) 
 50-99 737 (20.8) 190 (29.1) 94 (24.2) 1 021 (22.3) 
 100-199 1 178 (33.3) 140 (21.4) 99 (25.5) 1 417 (30.9) 
 200-349 548 (15.5) 41 (6.3) 38 (9.8) 627 (13.7) 
 350-> 320 (9) 19 (2.9) 18 (4.6) 357 (7.8) 
 Type of TB 
    
0.601 
Pulmonary 5 795 (75.4) 666 (73.6) 518 (75.3) 6 979 (75.3) 
 
Extra-pulomonary 1 662 (21.6) 215 (23.8) 147 (21.4) 2 024 (21.8) 
 
Both types of TB 225 (2.9) 24 (2.7) 23 (3.3) 272 (2.9) 
 
New or Retreatment case 
    
0.001 
New case 6 433 (83.7) 742 (81.9) 611 (88.8) 7 786 (83.9) 
 
Retreat case 1 249 (16.3) 164 (18.1) 77 (11.2) 1 490 (16.1) 
 
Sputum smear results 
    
<0.001 
Smear positive 4 103 (53.4) 357 (39.4) 332 (48.3) 4 792 (51.7) 
 
Smear negative 2 346 (30.5) 326 (36) 204 (29.7) 2 876 (31) 
 
No evidence of smear 1 233 (16.1) 223 (24.6) 152 (22.1) 1 608 (17.3) 
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 Survived first 
year since TB 
treatment 
commenced  
Died during TB 
treatment a   
Died after TB 
treatment 
completion but 
within a year 
of starting TB 
treatment b 
Combined 
(All three 
groups) 
p value c 
 
n (%) n (%) n (%) N (%) 
 ART category 
    
<0.001 
Patients never started ART 
or started ART after 
completion of TB treatment 
episode 
5 926 (77.1) 765 (84.4) 584 (84.9) 7 275 (78.4) 
 
Starting ART during the 
first 61 days of TB 
treatment 
397 (5.2) 55 (6.1) 15 (2.2) 467 (5) 
 
Starting ART after 61 days 
of TB treatment but before 
TB treatment episode is 
completed 
1 359 86 (9.5) 89 (12.9) 1 534 (16.5) 
 
a Death information from ETR and HIV database 
b Death information from HIV database 
c Comparing three death categories (survived first year after TB treatment started, died during TB treatment, died after 
TB but within one year of TB diagnosis) with Pearson’s chi-squared test for categorical variables and one-way 
ANOVA for continuous variables. 
 
5.2. Effect of ART on TB treatment outcomes in co-infected patients 
Table 45 shows the effect of ART initiated either during the first two months of TB treatment or 
later (>2 months) during TB treatment, compared to ART not being provided during TB 
treatment, on death (during and after TB treatment but within one year of TB commencement) 
and other non-fatal TB treatment outcomes.   The adjusted models show a significant reduction 
in death when ART is administered during TB treatment.  In a model considering deaths reported 
by ETR alone, ART initiated within the first two months of TB treatment was associated with 
reducing the hazard of death by 50% (OR 0.50 CI: 0.35-0.73), while ART initiated after two 
months of TB treatment, the hazard of dying during TB treatment was reduced by 76% (OR 0.24 
CI: 0.18-0.32).  The adjusted risk of dying during the first year of TB treatment was decreased by 
66% (OR 0.34 CI: 0.26-0.44) when ART was administered during the first two months of TB 
treatment, and by 71% (OR 0.29 CI: 0.23-0.37) when administered after two months of TB 
treatment. 
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It was shown in Table 41 that patients who started ART during the first two months of TB 
treatment had a lower median CD4 cell count (73 cells/µl IQR: 32-138 cells/µl) compared to 
patients who started ART after two months of TB treatment (92 cells/µl IQR: 44-155 cells/µl).  
The overall low median CD4 cell count together with the gradient in odds ratios for early and 
late ART from the logistic regression models (Table 45), suggest that starting ART later during 
the course of TB treatment is more effective than starting ART early, which is consistent with 
survivor bias expected of this observational cohort. 
Table 45 further shows that ART initiated during (after two months of) TB treatment improved 
cured (OR 1.68 CI: 1.42-2.0), completed (OR 3.32 CI: 2.78-3.95), and successful (OR 4.09 
CI: 3.28-5.11) TB treatment outcomes.  Undesirable outcomes like defaulted (OR 0.60 CI: 0.44-
0.82) and failed (OR 0.73 CI: 0.41-1.30) are less likely to occur with concomitant ART and TB 
treatment. 
Table 45: Odds ratios of each TB treatment outcome comparing patients who did not receive ART during 
their TB treatment, with those who received ART early (first 2 months of TB treatment) or later (between 
2 months and end of TB treatment): logistic regression models 
  
 CRUDE a  ADJUSTED b 
Outcome variable Explanatory 
variable 
Reference 
category: 
No ART 
during first 
year of TB 
treatment 
OR 95% CI OR 95% CI 
Number of patients with 
death registered as their 
outcome on the TB register c 
Early ART f 1 1.20 0.81-1.76 0.50 0.35-0.73 
Late ART g 1 0.45 0.35-0.58 0.24 0.18-0.32 
Number of patients who died 
during TB treatment  (TB 
register supplemented by 
information from the HIV 
programme database) d 
Early ART 1 1.17 0.82-1.68 0.49 0.35-0.68 
Late ART 1 0.52 0.43-0.63 0.28 0.22-0.35 
Number of patients known 
to have died during the first 
year after TB treatment was 
started (information drawn 
from both TB register and 
HIV programme database) e 
Early ART 1 0.77 0.57-1.05 0.34 0.26-0.44 
Late ART 1 0.55 0.44-0.68 0.29 0.23-0.37 
Cured 
Cured 
Early ART 1 0.64 0.46-0.89 1.06 0.77-1.46 
Late ART 1 1.12 0.96-1.31 1.68 1.42-2.0 
Completed 
Completed 
Early ART 1 1.61 1.33-1.95 1.80 1.40-2.30 
Late ART 1 1.81 1.58-2.07 3.32 2.78-3.95 
150 
Success 
Success 
Early ART 1 1.08 0.84-1.41 1.84 1.41-2.41 
Late ART 1 2.71 2.23-3.30 4.09 3.28-5.11 
Moved 
Moved 
Early ART 1 0.62 0.35-1.08 0.40 0.24-0.69 
Late ART 1 0.06 0.02-0.14 0.04 0.02-0.10 
Failed 
Failed 
Early ART 1 0.67 0.27-1.64 0.96 0.36-2.59 
Late ART 1 0.65 0.38-1.11 0.73 0.41-1.30 
Defaulted 
Defaulted 
Early ART 1 0.98 0.72-1.33 1.09 0.80-1.50 
Late ART 1 0.56 0.42-0.75 0.60 0.44-0.82 
OR: Odds ratio;  CI: Confidence interval 
a Crude odds ratio adjusted for district and intra-cluster correlation of outcomes 
b Also adjusted for district, year when TB treatment started, sex, age, baseline CD4, timing of CD4, anatomical 
site of TB, sputum smear results, new or retreatment case of TB and intra-clinic correlation 
c Death during TB episode; Death source: TB register 
d Death during TB episode; Death source: TB register and HIV database 
e Death during first year on TB treatment; Death source: TB register and HIV database  
f Early ART – ART started during first two months of TB treatment 
g Late ART – ART started after the first two months of TB treatment but before TB episode was completed 
Table 46 and Table 47 display odds ratios from adjusted logistic regression models on the effect 
of ART for patients who died during the first year since commencement of TB treatment 
(includes patient who died during TB treatment and those who died after completion of TB 
treatment, Table 46), and patients who died during TB treatment (excludes patients who died 
after TB treatment completed, Table 47).  Factors associated with a greater odds of death are 
patients older than 50 years  (OR 1.39 CI: 1.14-1.69 (Table 46); OR 1.46 CI: 1.18-1.8 
(Table 47)), and patients with a CD4 cell count less than 100 cells/µl, but particularly severely 
immuno-compromised patients with a CD4 cell count less than 25 cells/µl (OR 3.64 
CI: 2.92-4.55 (Table 46);  OR 3.20 CI: 2.61-3.93 (Table 47)). 
Retreatment TB cases had a 40% higher odds of death during TB treatment compared to patients 
diagnosed with a new TB episode, OR 1.40 CI: 1.2-1.62 (Table 47), however this hazard 
declines after completion of TB treatment (OR 0.88 CI: 0.99-1.12, Table 46).  A missing CD4 
cell count or a CD4 taken more than 30 days after diagnosis of TB treatment was not associated 
with an increased odds of death, however patients with no smear result had an increased odds of 
death (OR 1.31 CI: 1.11-1.54 (Table 46); OR 1.25 CI: 1.00-1.57 (Table 47)).  Patients with 
smear positive sputum results (OR 0.74 CI: 0.62-0.88, Table 46) or extra-pulmonary TB 
(OR 0.82  CI: 0.69-0.97, Table 46) were associated with better survival. 
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Table 46: Multivariable model for the effect of ART and baseline covariates on patients who died during the 
first year of TB treatment, includes patients who died during TB treatment and patients who died after 
completion of TB treatment. 
Reference category Explanatory 
variable 
OR P>|t| 95% CI 
Fezile Dabi District Lejweleputswa 
District 
0.93 0.677 0.66 1.31 
Motheo District 1.24 0.220 0.88 1.75 
Thabo Mofutsanyane 1.20 0.258 0.87 1.66 
Xhariep District 1.15 0.402 0.83 1.59 
Year when TB treatment 
was started:  
2006 
2004 0.58 <0.001 0.43 0.77 
2005 0.95 0.545 0.80 1.12 
2007 1.05 0.643 0.84 1.32 
2008 1.07 0.501 0.88 1.29 
Women Men 1.10 0.134 0.97 1.24 
Age category:  
30-39 years 
 
<20 0.67 0.181 0.37 1.20 
20-29 0.96 0.618 0.84 1.11 
40-49 1.05 0.529 0.91 1.21 
>50 1.39 0.001 1.14 1.69 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl  
CD4 0-24 3.20 <0.001 2.61 3.93 
CD4 25-49 1.81 <0.001 1.50 2.19 
CD4 50-99 1.66 <0.001 1.42 1.94 
CD4 200-349 0.67 0.002 0.52 0.86 
CD4 350-2000 0.58 0.001 0.42 0.80 
CD4 test date during the 
period one year preceding 
TB diagnosis and 30 days 
there after 
CD4 test date after 
30 days of TB 
treatment 
0.70 0.003 0.56 0.89 
CD4 missing 0.36 <0.001 0.29 0.46 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.82 0.020 0.69 0.97 
Both types of TB 0.97 0.886 0.62 1.50 
TB Smear results: Smear 
negative 
Smear positive 0.74 0.001 0.62 0.88 
No smear results 1.31 0.001 1.11 1.54 
Treatment case:  New case Retreatment case 0.99 0.909 0.88 1.12 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during 
first two months of 
TB treatment 
0.34 <0.001 0.26 0.44 
Started ART between 
two months and end 
of TB treatment 
0.29 <0.001 0.23 0.37 
No valid South African ID 
number 
Valid South African 
ID number 
1.63 0.013 1.11 2.41 
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Reference category Explanatory 
variable 
OR P>|t| 95% CI 
OR:  Odds ratio; CI:  Confidence interval 
Died during first year of TB treatment; Death source: TB Register and HIV database 
Also adjusted for intra-clinic correlation 
 
Table 47: Multivariable model for the effect of ART and baseline covariates on patients who died during TB 
treatment. a  
Reference category Explanatory variable OR P>|t| 95% CI 
Fezile Dabi District 
 
Lejweleputswa 0.88 0.467 0.63 1.23 
Motheo 1.27 0.098 0.96 1.69 
Thabo Mofutsanyane 1.50 0.003 1.15 1.97 
Xhariep 1.54 <0.001 1.24 1.91 
Year when TB treatment 
was started: 2006  
2004 0.64 0.005 0.46 0.87 
2005 1.01 0.947 0.77 1.33 
2007 1.08 0.582 0.82 1.41 
2008 0.97 0.804 0.78 1.21 
Women Men 1.01 0.845 0.88 1.16 
Age category:  
30-39 years 
<20 0.87 0.693 0.44 1.73 
20-29 0.95 0.575 0.78 1.15 
40-49 1.13 0.145 0.96 1.34 
>50 1.46 <0.001 1.18 1.80 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl   
CD4 0-24 3.64 <0.001 2.92 4.55 
CD4 25-49 2.25 <0.001 1.73 2.94 
CD4 50-99 1.89 <0.001 1.54 2.31 
CD4 200-349 0.55 0.002 0.37 0.80 
CD4 350-2000 0.40 <0.001 0.26 0.61 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 30 
days of TB treatment 
0.64 <0.001 0.51 0.80 
CD4 missing 0.29 <0.001 0.23 0.36 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.89 0.306 0.72 1.11 
Both types of TB 0.88 0.652 0.51 1.52 
Smear results:  
Smear negative 
Smear positive 0.66 <0.001 0.55 0.80 
No smear results 1.25 0.049 1.00 1.57 
Treatment case:  
New case 
Retreatment case 1.40 <0.001 1.20 1.62 
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Reference category Explanatory variable OR P>|t| 95% CI 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 
0.49 <0.001 0.35 0.68 
Started ART between 
two months and end of 
TB treatment 
0.28 <0.001 0.22 0.35 
No valid South African 
ID number 
Valid South African ID 
number 
0.78 0.168 0.55 1.11 
OR: Odds ratio; CI: Confidence interval 
a Died during TB treatment; Death source: TB Register and HIV database 
b Also adjusted for intra-clinic correlation 
Table 48 displays a summary of adjusted logistic regression models for the effect of ART on 
non-fatal TB treatment outcomes.  Patients who received ART after two months of TB treatment 
(late ART), had a 1.7 times better odds of being cured (OR 1.67 CI: 1.42-2.0), a 3.3 times better 
odds of completing TB treatment (OR 3.32 CI: 2.78-3.95), and a 4 times better odds of a 
successful treatment outcome (OR 4.09 CI: 3.28-5.11) compared to not being on ART during TB 
treatment.  The first two years (2004 and 2005) were associated with better TB treatment 
outcomes for cured, completed and success compared to 2006, while 2007 and 2008 were 
associated with poorer outcomes.  Although not significant, men were more at risk of failing 
(OR 1.36 CI: 0.96-1.92) and defaulting (OR 1.15 CI: 0.98-1.34) compared to women. 
Patients older than fifty years were associated with an 18% odds of not being cured (OR 0.82 
CI: 0.68-0.99) and the odds of defaulting almost doubled (OR 1.73 CI: 0.99-3.01) for patients 
younger than 20 years old compared to patients between 30 and 39 years old (Table 48).  
Immuno-compromised patients (CD4 cell count less than 100 cells/µl) had a lower odds of being 
cured, completing TB treatment or a successful TB treatment outcome (ORs between 0.45 and 
0.84), while patients with a CD4 cell count above 200 were associated with better cured, 
completed and successful TB outcomes compared to patients with a CD4 cell count between 
100-199 cells/µl (ORs between 1.12 and 1.57).  Patients who failed treatment were four times 
more likely to fail if they were smear positive compared to smear negative patients (OR 3.95 
CI: 1.62-9.63). 
Subgroup analyses were done to evaluate the effect of ART on TB outcomes (cured, completed, 
successful, failed) for patients who survived TB treatment (excluding all deceased patients), and 
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found a similar gradient in odds ratios for starting ART early and starting ART after two months 
of TB treatment.  Logistic regression models for subgroup analyses are provided in Appendix A. 
Table 49 shows a summary of logistic regression models evaluating the effect of ART on TB 
treatment outcomes, when the two ART categories were combined (ART initiated within two 
months of TB treatment and ART initiated after two months of TB treatment).  The trends are 
very similar as discussed for Table 46 and Table 48.  Overall, the odds of death during the first 
year since commencement of TB treatment was reduced by 70% (OR 0.30 CI: 0.25-0.38), and 
ART was associated with improved favourable outcomes: cured (OR 1.52 CI: 1.27-1.83), 
completed (OR 2.84 CI: 2.37-3.42), success (OR 3.25 CI: 2.62-4.06). 
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Table 48: A summary (odds ratio and confidence interval) of multivariable regression models for the effect of ART and baseline covariates on other TB 
treatment outcomes.  Individual detailed tables are provided for TB outcomes listed in this table.  See Table 50 to Table 55. 
    Cured Completed Success Failed Defaulted Moved 
Reference category Explanatory 
variable 
OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Fezile Dabi District Lejweleputswa 0.88 (0.69-1.14) 1.19 (0.76-1.86) 1.34 (0.95-1.90) 0.42 (0.16-1.09) 0.83 (0.53-1.30) 0.80 (0.41-1.54) 
Motheo 0.50 (0.39-0.64) 1.57 (1.03-2.39) 1.41 (0.99-2.02) 0.79 (0.35-1.79) 0.80 (0.51-1.23) 0.40 (0.24-0.67) 
Thabo 
Mofutsanyane 
0.95 (0.75-1.19) 1.46 (0.93-2.28) 1.64 (1.15-2.33) 0.66 (0.28-1.53) 0.63 (0.43-0.93) 0.25 (0.14-0.44) 
Xhariep 0.40 (0.28-0.58) 1.41 (0.89-2.24) 1.45 (0.99-2.12) 0.63 (0.26-1.53) 1.02 (0.63-1.65) 0.05 (0.02-0.13) 
Year when TB 
treatment was 
started:  
2006 
2004 1.05 (0.88-1.26) 1.75 (1.32-2.32) 1.41 (1.13-1.75) 1.05 (0.55-2.03) 1.15 (0.81-1.61) 0.35 (0.21-0.58) 
2005 1.11 (0.96-1.28) 1.54 (1.18-2.01) 1.33 (1.08-1.62) 1.24 (0.71-2.18) 0.94 (0.76-1.17) 0.24 (0.16-0.35) 
2007 0.74 (0.61-0.88) 0.81 (0.65-1.01) 0.80 (0.67-0.95) 1.76 (0.98-3.14) 1.19 (1.0-1.43) 1.20 (0.86-1.65) 
2008 0.79 (0.66-0.94) 0.85 (0.69-1.05) 0.92 (0.77-1.10) 1.02 (0.61-1.70) 1.10 (0.92-1.31) 1.09 (0.75-1.58) 
Women Men 0.96 (0.86-1.07) 1.12 (1.0-1.25) 0.95 (0.84-1.06) 1.36 (0.96-1.92) 1.15 (0.98-1.34) 0.88 (0.72-1.07) 
Age category:  
30-39 years 
<20 1.12 (0.68-1.87) 0.82 (0.44-1.55) 0.80 (0.47-1.36) 1.19 (0.25-5.61) 1.73 (0.99-3.01) 0.89 (0.38-2.11) 
20-29 0.99 (0.87-1.14) 0.95 (0.84-1.07) 0.93 (0.82-1.04) 0.89 (0.61-1.29) 1.08 (0.90-1.30) 1.34 (1.07-1.68) 
40-49 1.02 (0.90-1.15) 0.91 (0.78-1.06) 1.03 (0.94-1.14) 0.78 (0.50-1.23) 0.84 (0.72-0.99) 1.05 (0.88-1.26) 
>50 0.82 (0.68-0.99) 0.96 (0.79-1.17) 0.89 (0.76-1.05) 1.01 (0.54-1.87) 0.84 (0.67-1.06) 1.07 (0.76-1.52) 
CD4 cell count 
closest to starting 
TB treatment:  
100-199 cells/µl   
CD4 0-24 0.65 (0.52-0.81) 0.52 (0.39-0.70) 0.45 (0.36-0.56) 1.44 (0.58-3.58) 1.04 (0.73-1.46) 1.28 (0.87-1.88) 
CD4 25-49 0.79 (0.65-0.96) 0.75 (0.59-0.95) 0.65 (0.55-0.78) 1.16 (0.54-2.48) 1.03 (0.77-1.36) 1.10 (0.76-1.60) 
CD4 50-99 0.84 (0.71-0.99) 0.84 (0.67-1.04) 0.75 (0.63-0.89) 1.20 (0.59-2.44) 0.90 (0.70-1.16) 1.13 (0.81-1.57) 
CD4 200-349 1.12 (0.91-1.37) 1.33 (1.05-1.69) 1.33 (1.06-1.69) 1.10 (0.50-2.41) 0.88 (0.64-1.22) 0.91 (0.62-1.33) 
CD4 350-2000 1.29 (1.04-1.59) 1.51 (1.11-2.06) 1.57 (1.20-2.07) 1.36 (0.65-2.85) 0.81 (0.54-1.21) 0.71 (0.41-1.24) 
CD4 test date 
during the period 
one year preceding 
TB diagnosis and 
30 days there after 
CD4 test date after 
30 days of TB 
treatment 
1.39 (1.21-1.60) 0.85 (0.67-1.08) 1.03 (0.83-1.29) 1.53 (0.7-3.38) 1.67 (1.2-2.31) 0.75 (0.47-1.20) 
CD4 missing 1.67 (1.42-1.96) 1.41 (1.21-1.64) 1.60 (1.32-1.96) 1.48 (1.0-2.18) 1.44 (1.18-1.76) 0.76 (0.57-1.02) 
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    Cured Completed Success Failed Defaulted Moved 
Reference category Explanatory 
variable 
OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Anatomical 
classification of TB:  
Pulmonary 
Extra-pulmonary 0.01 (0-0.01) 1.27 (1.09-1.49) 1.20 (1.03-1.40) 0.26 (0.07-0.99) 0.93 (0.73-1.18) 0.88 (0.70-1.09) 
Both TB types 0.65 (0.47-0.91) 1.41 (1.07-1.86) 1.12 (0.88-1.42) 0.93 (0.36-2.44) 0.94 (0.68-1.3) 1.16 (0.57-2.38) 
Smear results:  
Smear negative 
Smear positive  0.02 (0.02-0.03) 1.19 (1.04-1.37) 3.95 (1.62-9.63) 0.90 (0.71-1.13) 0.87 (0.65-1.17) 
No smear results  0.43 (0.35-0.53) 0.44 (0.35-0.54) 0.83 (0.31-2.23) 1.38 (1.11-1.71) 4.80 (3.16-7.30) 
Treatment case: 
New case 
Retreatment case 0.64 (0.56-0.72) 0.99 (0.83-1.19) 0.79 (0.70-0.89) 1.43 (0.86-2.37) 1.16 (0.99-1.35) 0.74 (0.56-0.98) 
ART use:  
Did not receive ART 
during TB 
treatment episode 
Started ART during 
first two months of 
TB treatment 
1.06 (0.77-1.46) 1.80 (1.40-2.30) 1.84 (1.41-2.41) 0.96 (0.36-2.59) 1.09 (0.80-1.50) 0.40 (0.24-0.69) 
Started ART 
between two 
months and end of 
TB treatment 
1.68 (1.42-2.0) 3.32 (2.78-3.95) 4.09 (3.28-5.11) 0.73 (0.41-1.30) 0.60 (0.44-0.82) 0.04 (0.02-0.10) 
No valid South 
African ID number 
Valid SA ID 
number 
1.15 (1.01-1.31) 1.16 (0.98-1.37) 1.25 (1.08-1.43) 0.96 (0.55-1.67) 0.72 (0.58-0.91) 1.19 (0.84-1.69) 
OR: odds ratio;  CI: Confidence interval 
Also adjusted for intra-clinic correlation 
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Table 49: A summary (odds ratio and confidence interval) of multivariable regression models for the effect of ART and baseline covariates on other TB 
treatment outcomes.  ART coded as a binary variable, ART received during TB treatment or not. 
    Died a Cured Completed Success Failed Defaulted Moved 
Reference category  Explanatory 
variable 
OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Fezile Dabi 
District 
Lejweleputswa 0.93  
(0.67-1.31) 
0.88  
(0.69-1.15) 
1.18  
(0.76-1.85) 
1.33  
(0.95-1.9) 
0.42  
(0.17-1.10) 
0.83  
(0.54-1.31) 
0.81  
(0.42-1.56) 
Motheo 1.24  
(0.88-1.75) 
0.51  
(0.40-0.65) 
1.58  
(1.04-2.41) 
1.42  
(1.0-2.03) 
0.79  
(0.35-1.79) 
0.79  
(0.52-1.23) 
0.40  
(0.24-0.68) 
Thabo 
Mofutsanyane 
1.20  
(0.88-1.67) 
0.95  
(0.76-1.19) 
1.45  
(0.93-2.29) 
1.63  
(1.15-2.33) 
0.66  
(0.29-1.54) 
0.63  
(0.44-0.93) 
0.25  
(0.14-0.45) 
Xhariep 1.15  
(0.83-1.60) 
0.40  
(0.28-0.59) 
1.40  
(0.89-2.24) 
1.45  
(1.0-2.12) 
0.63  
(0.27-1.53) 
1.02  
(0.63-1.65) 
0.05  
(0.02-0.14) 
Year when TB 
treatment was 
started:  
2006 
2004 0.58  
(0.44-0.77) 
1.05  
(0.88-1.27) 
1.73  
(1.31-2.3) 
1.40  
(1.13-1.75) 
1.06  
(0.55-2.04) 
1.15  
(0.82-1.63) 
0.35  
(0.22-0.58) 
2005 0.95  
(0.81-1.13) 
1.11  
(0.96-1.28) 
1.53  
(1.18-2.01) 
1.33  
(1.09-1.63) 
1.24  
(0.71-2.19) 
0.94  
(0.76-1.18) 
0.24  
(0.17-0.36) 
2007 1.05  
(0.85-1.32) 
0.73  
(0.62-0.88) 
0.81  
(0.65-1.01) 
0.80  
(0.67-0.96) 
1.76  
(0.99-3.15) 
1.2  
(1.01-1.44) 
1.19  
(0.87-1.66) 
2008 1.07  
(0.89-1.30) 
0.78  
(0.66-0.93) 
0.84  
(0.69-1.04) 
0.91  
(0.76-1.09) 
1.03  
(0.62-1.71) 
1.11  
(0.94-1.33) 
1.10  
(0.76-1.61) 
Women Men 1.10  (0.98-1.24) 
0.96  
(0.87-1.07) 
1.12  
(1.01-1.25) 
0.95  
(0.85-1.07) 
1.36  
(0.97-1.92) 
1.15  
(0.98-1.35) 
0.88  
(0.72-1.07) 
Age category:  
30-39 years 
<20 0.67  
(0.38-1.21) 
1.12  
(0.68-1.85) 
0.82  
(0.44-1.55) 
0.79  
(0.47-1.35) 
1.20  
(0.26-5.65) 
1.74  
(1.01-3.02) 
0.88  
(0.38-2.10) 
20-29 0.97  
(0.84-1.12) 
0.99  
(0.87-1.14) 
0.95  
(0.85-1.07) 
0.92  
(0.83-1.04) 
0.89  
(0.62-1.30) 
1.09  
(0.91-1.31) 
1.35  
(1.09-1.70) 
40-49 1.05  
(0.91-1.21) 
1.03  
(0.91-1.16) 
0.91  
(0.79-1.07) 
1.04  
(0.95-1.15) 
0.78  
(0.50-1.23) 
0.84  
(0.72-0.99) 
1.04  
(0.88-1.25) 
>50 1.38  
(1.14-1.69) 
0.82  
(0.69-1.0) 
0.97  
(0.80-1.19) 
0.90  
(0.77-1.06) 
1.01  
(0.55-1.88) 
0.84  
(0.67-1.06) 
1.07  
(0.77-1.52) 
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    Died a Cured Completed Success Failed Defaulted Moved 
Reference category  Explanatory 
variable 
OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
CD4 cell count 
closest to starting 
TB treatment:  
100-199 cells/µl 
CD4 0-24 3.21  
(2.62-3.95) 
0.64  
(0.52-0.80) 
0.51  
(0.39-0.69) 
0.44  
(0.36-0.55) 
1.44  
(0.58-3.60) 
1.05  
(0.75-1.49) 
1.31  
(0.90-1.91) 
CD4 25-49 1.82  
(1.51-2.20) 
0.78  
(0.65-0.96) 
0.75  
(0.60-0.95) 
0.65  
(0.55-0.78) 
1.16  
(0.55-2.49) 
1.03  
(0.78-1.38) 
1.10  
(0.76-1.61) 
CD4 50-99 1.66  
(1.43-1.95) 
0.83  
(0.71-0.99) 
0.83  
(0.67-1.04) 
0.74  
(0.63-0.89) 
1.20  
(0.60-2.44) 
0.91  
(0.71-1.17) 
1.13  
(0.82-1.59) 
CD4 200-349 0.67  
(0.53-0.86) 
1.11  
(0.91-1.37) 
1.33  
(1.05-1.69) 
1.33  
(1.06-1.68) 
1.10  
(0.50-2.42) 
0.89  
(0.65-1.22) 
0.91  
(0.63-1.33) 
CD4 350-2000 0.58  
(0.43-0.80) 
1.28  
(1.04-1.59) 
1.50  
(1.11-2.05) 
1.57  
(1.20-2.06) 
1.36  
(0.65-2.85) 
0.81  
(0.55-1.22) 
0.71  
(0.41-1.24) 
CD4 test date 
during the period 
one year preceding 
TB diagnosis and 
30 days there after 
CD4 test date 
after 30 days of 
TB treatment 
 
0.70  
(0.56-0.89) 
1.45  
(1.25-1.69) 
0.89  
(0.71-1.13) 
1.09  
(0.88-1.37) 
1.50  
(0.7-3.22) 
1.59  
(1.15-2.2) 
0.71  
(0.44-1.14) 
CD4 missing 0.36  
(0.29-0.46) 
1.69  
(1.44-1.99) 
1.42  
(1.23-1.66) 
1.62  
(1.34-1.98) 
1.46  
(1.01-2.15) 
1.42  
(1.17-1.73) 
0.75  
(0.57-1.01) 
Anatomical 
classification of 
TB:  
Pulmonary 
Extra-
pulmonary 
0.82  
(0.69-0.97) 
0.01  
(0.01-0.02) 
1.28  
(1.09-1.50) 
1.20  
(1.04-1.41) 
0.26  
(0.07-1.0) 
0.93  
(0.74-1.18) 
0.87  
(0.7-1.09) 
Both TB types 0.97  
(0.63-1.51) 
0.65  
(0.47-0.91) 
1.4 0  
(1.07-1.84) 
1.11  
(0.88-1.41) 
0.94  
(0.36-2.44) 
0.95  
(0.69-1.31) 
1.18  
(0.59-2.42) 
Smear results:  
Smear negative 
Smear positive 0.74  
(0.63-0.88) 
 0.02  
(0.02-0.03) 
1.20  
(1.05-1.39) 
3.94  
(1.62-9.65) 
0.89  
(0.71-1.12) 
0.86  
(0.64-1.16) 
No smear 
results 
1.31  
(1.12-1.55) 
 0.43  
(0.35-0.54) 
0.44  
(0.36-0.55) 
0.83  
(0.32-2.23) 
1.37  
(1.12-1.70) 
4.75  
(3.10-7.28) 
Treatment case: 
New case 
Retreatment 
case 
0.99  
(0.89-1.12) 
0.64  
(0.57-0.73) 
0.99  
(0.83-1.2) 
0.79  
(0.71-0.89) 
1.43  
(0.87-2.36) 
1.15  
(0.99-1.36) 
0.74  
(0.57-0.99) 
ART use:  
Did not receive 
ART during TB 
treatment episode 
Started ART 
during TB 
treatment 
0.30  
(0.25-0.38) 
1.52  
(1.27-1.83) 
2.84  
(2.37-3.42) 
3.25  
(2.62-4.06) 
0.77  
(0.44-1.37) 
0.71  
(0.55-0.92) 
0.13  
(0.09-0.21) 
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    Died a Cured Completed Success Failed Defaulted Moved 
Reference category  Explanatory 
variable 
OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
No valid South 
African ID 
number 
Valid SA ID 
number 
1.63  
(1.11-2.41) 
1.15  
(1.02-1.32) 
1.17  
(0.99-1.39) 
1.26  
(1.10-1.45) 
0.96  
(0.55-1.67) 
0.72  
(0.58-0.90) 
1.17  
(0.83-1.67) 
OR: odds ratio;  CI: Confidence interval 
a Died – patients who died within one year of TB treatment diagnosis, either during TB treatment or thereafter. 
Also adjusted for intra-clinic correlation 
 
160 
5.3. Summary of results 
A large proportion of co-infected patients were eligible for ART at time of starting TB 
treatment, yet only 1 484 / 4 581 (41%) received ART during treatment, and for most it was 
after two months of TB treatment, despite guideline changes in 2006 recommending earlier 
ART (PALSA PLUS 2006 edition).  Patients who did not receive any ART during their TB 
treatment had the highest percentage of deaths during the first year 1 350 / 7 275 (18.6%), 
followed by patients who started ART early during their treatment 70 / 467 (15%) and lastly 
patients who started ART later during their TB treatment 174 / 1 534 (11.3%).  Surprisingly, 
for patients not receiving ART during TB treatment the percentage of deaths during the first 
year increased from 10.4% (114 / 1 098 patients registered) in 2004 to 23.4 % (476 / 2 031 
patients registered) in 2008, despite better access to ART (Uebel KE et al. 2010), change in 
policy to start ART earlier (NDOH NSP 2007-2011), and a shift towards integrated TB and 
HIV services (Data by year not shown).   
Almost as many patients who died during TB treatment (9.8%) died in the six month period 
immediately after TB treatment was completed (7.4%).  A large proportion of these patients 
who died soon after TB treatment was successfully completed, had not yet started ART.  For 
them migration may in part explain failure to start ART as high rates of moved and 
transferred out outcomes were reported. 
Treatment success in co-infected HIV TB patients worsened during the study period (80% in 
2004, 71% in 2008) and was lower than the WHO proposed target of 85% (WHO guidelines, 
2011).  Deaths in this co-infected group increased from 4.8% in 2004 to 9.6% in 2008.  The 
proportion of TB patients co-infected with HIV increased from 12.2% to 30.5% over the 
study period and could possibly have an impact on the quality of service facilities can provide 
due to the patient load (Table 42).  Even though this dataset is a sub-sample of the patients in 
the ETR, the total number of records in the ETR increased from 8.2% (16 395 / 199 998) in 
2003 to 16.1% (32 299 / 199 998) in 2008, confirming the increasing caseload.  TB remains a 
challenging public health problem although more healthcare resources have been made 
available (Uebel KE et al., 2010).  
In summary, ART was extremely effective in reducing the odds of death (either during TB 
treatment or thereafter but within one year of TB diagnosis), and improving favourable TB 
outcomes (cured, completed, success).  Results from this observational cohort of co-infected 
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patients suggest that starting ART after two months of TB treatment is more effective than 
starting ART early during TB treatment but this is likely due to survivor bias and a small 
sample size for patients starting ART early (5%, 467 / 9 276).  Severely immuno-
compromised patients were probably prioritised to start ART early and more likely to die 
during treatment, and ‘healthier’ patients were more likely to start ART later during TB 
treatment with a better chance of survival, contributing to immortal bias (Sterne JA et al., 
2009; Levesque LE et al., 2010). 
Patients registered as retreatment cases were more at risk of unfavourable outcomes, they had 
a higher odds of death, failing or defaulting and were less likely to be cured, to complete 
treatment or to have a successful TB treatment outcomes.  Overall being male and older than 
50 years were identified as a risk factor for most of the TB treatment outcomes. 
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Table 50: Multivariable regression model for the effect of ART and baseline covariates on cured. 
Reference category Explanatory variable OR P>|t| 95% Confidence 
Interval 
Fezile Dabi District Lejweleputswa 0.88 0.347 0.69 1.14 
Motheo 0.50 <0.001 0.39 0.64 
Thabo Mofutsanyane 0.95 0.634 0.75 1.19 
Xhariep 0.40 <0.001 0.28 0.58 
Year when TB treatment 
was started:  
2006 
2004 1.05 0.585 0.88 1.26 
2005 1.11 0.165 0.96 1.28 
2007 0.74 0.001 0.61 0.88 
2008 0.79 0.008 0.66 0.94 
Women Men 0.96 0.47 0.86 1.07 
Age category:  
30-39 years 
<20 1.12 0.648 0.68 1.87 
20-29 0.99 0.934 0.87 1.14 
40-49 1.02 0.737 0.90 1.15 
>50 0.82 0.038 0.68 0.99 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 0.65 <0.001 0.52 0.81 
CD4 25-49 0.79 0.018 0.65 0.96 
CD4 50-99 0.84 0.043 0.71 0.99 
CD4 200-349 1.12 0.295 0.91 1.37 
CD4 350-2000 1.29 0.02 1.04 1.59 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 30 
days of TB treatment 
 1.39 <0.001 1.21 1.60 
CD4 missing 1.67 <0.001 1.42 1.96 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.01 <0.001 0.00 0.01 
Both TB types 0.65 0.012 0.47 0.91 
Treatment case: 
New case 
Retreatment case 
0.64 <0.001 0.56 0.72 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 1.06 0.74 0.77 1.46 
Started ART between 
two months and end of 
TB treatment 1.68 <0.001 1.42 2.00 
No valid South African 
ID number 
Valid South African ID 
number 1.15 0.036 1.01 1.31 
Also adjusted for intra-clinic correlation 
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Table 51: Multivariable regression model for the effect of ART and baseline covariates on completed TB 
outcome. 
Reference category Explanatory variable OR P>|t| 95% Confidence 
Interval 
Fezile Dabi District Lejweleputswa 1.19 0.454 0.76 1.86 
Motheo 1.57 0.036 1.03 2.39 
Thabo Mofutsanyane 1.46 0.097 0.93 2.28 
Xhariep 1.41 0.147 0.89 2.24 
Year when TB treatment 
was started:  
2006 
2004 1.75 <0.001 1.32 2.32 
2005 1.54 0.001 1.18 2.01 
2007 0.81 0.06 0.65 1.01 
2008 0.85 0.133 0.69 1.05 
Women Men 1.12 0.043 1.00 1.25 
Age category:  
30-39 years 
<20 0.82 0.542 0.44 1.55 
20-29 0.95 0.39 0.84 1.07 
40-49 0.91 0.205 0.78 1.06 
>50 0.96 0.687 0.79 1.17 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 0.52 <0.001 0.39 0.70 
CD4 25-49 0.75 0.018 0.59 0.95 
CD4 50-99 0.84 0.111 0.67 1.04 
CD4 200-349 1.33 0.019 1.05 1.69 
CD4 350-2000 1.51 0.009 1.11 2.06 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 30 
days of TB treatment 0.85 0.177 0.67 1.08 
CD4 missing 1.41 <0.001 1.21 1.64 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 1.27 0.003 1.09 1.49 
Both TB types 1.41 0.016 1.07 1.86 
Smear results:  
Smear negative 
Smear positive 0.02 <0.001 0.02 0.03 
No smear results 0.43 <0.001 0.35 0.53 
Treatment case: 
New case 
Retreatment case 
0.99 0.93 0.83 1.19 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 1.80 <0.001 1.40 2.30 
Started ART between 
two months and end of 
TB treatment 3.32 <0.001 2.78 3.95 
No valid South African 
ID number 
Valid South African ID 
number 1.16 0.085 0.98 1.37 
Also adjusted for intra-clinic correlation 
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Table 52: Multivariable regression model for the effect of ART and baseline covariates on successful TB 
outcome.  Cured and completed are combined for successful treatment outcomes. 
Reference category Explanatory variable OR P>|t| 95% Confidence 
Interval 
Fezile Dabi District Lejweleputswa 1.34 0.099 0.95 1.90 
Motheo 1.41 0.057 0.99 2.02 
Thabo Mofutsanyane 1.64 0.006 1.15 2.33 
Xhariep 1.45 0.054 0.99 2.12 
Year when TB treatment 
was started:  
2006 
2004 1.41 0.002 1.13 1.75 
2005 1.33 0.006 1.08 1.62 
2007 0.80 0.013 0.67 0.95 
2008 0.92 0.361 0.77 1.10 
Women Men 0.95 0.359 0.84 1.06 
Age category:  
30-39 years 
<20 0.80 0.409 0.47 1.36 
20-29 0.93 0.212 0.82 1.04 
40-49 1.03 0.534 0.94 1.14 
>50 0.89 0.159 0.76 1.05 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 0.45 <0.001 0.36 0.56 
CD4 25-49 0.65 <0.001 0.55 0.78 
CD4 50-99 0.75 0.001 0.63 0.89 
CD4 200-349 1.33 0.016 1.06 1.69 
CD4 350-2000 1.57 0.001 1.20 2.07 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 30 
days of TB treatment 1.03 0.79 0.83 1.29 
CD4 missing 1.60 <0.001 1.32 1.96 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 1.20 0.02 1.03 1.40 
Both TB types 1.12 0.35 0.88 1.42 
Smear results:  
Smear negative 
Smear positive 1.19 0.014 1.04 1.37 
No smear results 0.44 <0.001 0.35 0.54 
Treatment case: 
New case 
Retreatment case 
0.79 <0.001 0.70 0.89 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 1.84 <0.001 1.41 2.41 
Started ART between 
two months and end of 
TB treatment 4.09 <0.001 3.28 5.11 
No valid South African 
ID number 
Valid South African ID 
number 1.25 0.002 1.08 1.43 
Also adjusted for intra-clinic correlation 
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Table 53: Multivariable regression model for the effect of ART and baseline covariates on failed TB 
outcome. 
Reference category Explanatory variable OR P>|t| 95% Confidence 
Interval 
Fezile Dabi District Lejweleputswa 0.42 0.076 0.16 1.09 
Motheo 0.79 0.573 0.35 1.79 
Thabo Mofutsanyane 0.66 0.332 0.28 1.53 
Xhariep 0.63 0.31 0.26 1.53 
Year when TB treatment 
was started:  
2006 
2004 1.05 0.879 0.55 2.03 
2005 1.24 0.454 0.71 2.18 
2007 1.76 0.057 0.98 3.14 
2008 1.02 0.934 0.61 1.70 
Women Men 1.36 0.082 0.96 1.92 
Age category:  
30-39 years 
<20 1.19 0.824 0.25 5.61 
20-29 0.89 0.534 0.61 1.29 
40-49 0.78 0.286 0.50 1.23 
>50 1.01 0.978 0.54 1.87 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 1.44 0.431 0.58 3.58 
CD4 25-49 1.16 0.697 0.54 2.48 
CD4 50-99 1.20 0.613 0.59 2.44 
CD4 200-349 1.10 0.82 0.50 2.41 
CD4 350-2000 1.36 0.419 0.65 2.85 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 30 
days of TB treatment 1.53 0.288 0.70 3.38 
CD4 missing 1.48 0.051 1.00 2.18 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.26 0.048 0.07 0.99 
Both TB types 0.93 0.887 0.36 2.44 
Smear results:  
Smear negative 
Smear positive 3.95 0.002 1.62 9.63 
No smear results 0.83 0.714 0.31 2.23 
Treatment case: 
New case 
Retreatment case 
1.43 0.168 0.86 2.37 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 0.96 0.937 0.36 2.59 
Started ART between 
two months and end of 
TB treatment 0.73 0.285 0.41 1.30 
No valid South African 
ID number 
Valid South African ID 
number 0.96 0.874 0.55 1.67 
Also adjusted for intra-clinic correlation 
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Table 54: Multivariable regression model for the effect of ART and baseline covariates on defaulted TB 
outcome. 
Reference category Explanatory variable OR P>|t| 95%  Confidence 
Interval 
Fezile Dabi District Lejweleputswa 0.83 0.419 0.53 1.30 
Motheo 0.80 0.309 0.51 1.23 
Thabo Mofutsanyane 0.63 0.018 0.43 0.93 
Xhariep 1.02 0.942 0.63 1.65 
Year when TB treatment 
was started:  
2006  
2004 1.15 0.437 0.81 1.61 
2005 0.94 0.594 0.76 1.17 
2007 1.19 0.049 1.00 1.43 
2008 1.10 0.285 0.92 1.31 
Women Men 1.15 0.094 0.98 1.34 
Age category:  
30-39 years 
<20 1.73 0.054 0.99 3.01 
20-29 1.08 0.405 0.90 1.30 
40-49 0.84 0.039 0.72 0.99 
>50 0.84 0.137 0.67 1.06 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 1.04 0.838 0.73 1.46 
CD4 25-49 1.03 0.853 0.77 1.36 
CD4 50-99 0.90 0.424 0.70 1.16 
CD4 200-349 0.88 0.444 0.64 1.22 
CD4 350-2000 0.81 0.295 0.54 1.21 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 30 
days of TB treatment 
1.67 0.002 1.20 2.31 
CD4 missing 1.44 <0.001 1.18 1.76 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.93 0.539 0.73 1.18 
Both TB types 0.94 0.715 0.68 1.30 
Smear results:  
Smear negative 
Smear positive 0.90 0.345 0.71 1.13 
No smear results 1.38 0.003 1.11 1.71 
Treatment case: 
 New case 
Retreatment case 1.16 0.073 0.99 1.35 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 
1.09 0.583 0.80 1.50 
Started ART between 
two months and end of 
TB treatment 
0.60 0.001 0.44 0.82 
No valid South African 
ID number 
Valid South African ID 
number 
0.72 0.005 0.58 0.91 
Also adjusted for intra-clinic correlation 
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Table 55: Multivariable regression model for the effect of ART and baseline covariates on moved TB 
outcome. 
Reference category Explanatory variable OR P>|t| 95% Confidence 
Interval 
Fezile Dabi District Lejweleputswa 0.80 0.502 0.41 1.54 
Motheo 0.40 0.001 0.24 0.67 
Thabo Mofutsanyane 0.25 <0.001 0.14 0.44 
Xhariep 0.05 <0.001 0.02 0.13 
Year when TB treatment 
was started:  
2006 
2004 0.35 <0.001 0.21 0.58 
2005 0.24 <0.001 0.16 0.35 
2007 1.20 0.279 0.86 1.65 
2008 1.09 0.664 0.75 1.58 
Women Men 0.88 0.199 0.72 1.07 
Age category:  
30-39 years 
<20 0.89 0.792 0.38 2.11 
20-29 1.34 0.01 1.07 1.68 
40-49 1.05 0.587 0.88 1.26 
>50 1.07 0.69 0.76 1.52 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 1.28 0.213 0.87 1.88 
CD4 25-49 1.10 0.619 0.76 1.60 
CD4 50-99 1.13 0.482 0.81 1.57 
CD4 200-349 0.91 0.618 0.62 1.33 
CD4 350-2000 0.71 0.228 0.41 1.24 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 
30 days of TB treatment 
0.75 0.228 0.47 1.20 
CD4 missing 0.76 0.065 0.57 1.02 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.88 0.241 0.70 1.09 
Both TB types 1.16 0.684 0.57 2.38 
Smear results:  
Smear negative 
Smear positive 0.87 0.365 0.65 1.17 
No smear results 4.80 <0.001 3.16 7.30 
Treatment case: 
New case 
Retreatment case 0.74 0.035 0.56 0.98 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 
0.40 0.001 0.24 0.69 
Started ART between 
two months and end of 
TB treatment 
0.04 <0.001 0.02 0.10 
No valid South African 
ID number 
Valid South African ID 
number 
1.19 0.323 0.84 1.69 
Also adjusted for intra-clinic correlation 
 
168 
6. DISCUSSION 
6.1. Main findings 
This thesis reports on a series of cohort studies carried out among patients infected with HIV 
and receiving public sector HIV and TB healthcare in the Free State province of South Africa 
between 2004 and 2010.  Each study was aimed at estimating the effectiveness of ART by 
comparing health outcomes between patients receiving ART and those not receiving ART, 
while adjusting for other prognostic variables.  For patients who started ART after the start of 
cohort follow-up, this included comparing outcomes before and after ART was initiated, 
except for the study of TB treatment outcomes in which patients who ever received ART 
during treatment were compared with those who never did.  All of these studies showed that 
ART, provided at large scale, up to six years after public sector ART was implemented, was 
effective at preventing TB in patients with HIV, and at preventing death in co-infected HIV-
TB patients. 
The main findings are summarised in Table 56. 
Table 56: Summary of the best estimates of effects of ART in each study 
Study population Aim - Estimated effect 
of ART on: 
Statistical model  Primary result 
All HIV positive 
patients; 
TB data sources – ETR 
and HIV programme  
Time to first occurrence 
of TB  
Competing risks regression 
model SHR 0.64, CI: 0.61-0.67 
TB incidence rate, 
accounting for multiple 
episodes of TB 
Poisson regression model IRR 0.66, CI: 0.64-0.69 
HIV-TB co-infected 
patients;  
TB data sources – ETR 
and HIV programme 
Time to death  
Marginal structural model  HR 0.53, CI:0.47-0.61 
Cox proportional hazard 
model HR 0.47, CI:0.39-0.56 
HIV-TB co-infected 
patients;  
TB source – ETR only 
TB outcomes: 
death during first year 
of TB diagnosis 
Logistic regression model 
Treatment success: 
OR 3.25  CI: 2.61-4.05 
Died during TB treatment: 
OR 0.33  CI: 0.26-0.42 
Died during first year: 
OR 0.30  CI: 0.24-0.38 
ETR: electronic TB register; SHR: sub-hazard ratio; IRR: Incidence rate ratio; HR: Hazard ratio; OR: odds ratio 
They show that, in people with HIV, ART was associated with a 36% lower hazard of a first 
TB episode and a 34% lower TB incidence rate.  In co-infected HIV-TB patients ART was 
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associated with roughly halving of the hazard of death. Among patients on the ETR, receipt 
of ART was associated with a 67-70% reduction in mortality between 2004 and 2008. 
6.2. Effect of ART on incidence of TB 
In this resource-limited, public health programme setting in the Free State province, the 
overall incidence of TB in this HIV positive population was 6.68 / 100 person years (py), 
with an incidence rate of 8.95 / 100 py for patients who did not receive ART and 
4.86 / 100 py for patients who received ART.  These rates are similar to a study compiling 
data from eight Sub-Saharan African HIV programmes with 10.5 / 100 py during no-ART 
period and 5.4 / 100 py during ART (Nicholas S et al., 2011) but slightly higher than reported 
from other studies in Africa.   Van Rie and colleagues (2009) reported a TB incidence rate of 
4.2 / 100 py for TB patients on ART at a clinic in Thembalethu, while Hermans and 
colleagues (2009) found a 2.65 / 100 py rate for patients on ART at a clinic in Uganda. 
Multivariable adjustment for the most important prognostic features showed that ART was 
independently associated with reducing the hazard of developing TB in this HIV positive 
population.  Although the Cox regression model indicated that ART was more effective (53% 
risk reduction) than the competing risks regression (CRR) model (36% risk reduction), the 
CRR model is probably the more accurate model since it accounted for death as a competing 
risk.  The Cox regression model made no use of the pertinent information that death was a 
reason for censorship of follow-up. When censorship of follow-up is due to a competing risk 
– such as when death makes incident TB impossible – Cox regression estimates of the effects 
of covariates - such as ART - on survival may be biased.  These CRR results are similar to 
the results of our earlier study of the Free State HIV programme cohort between 2004 and 
2005, using a marginal structural model which appropriately adjusted for time-varying 
covariates (HR for time to TB: 0.61 CI: 0.46-0.81) (Fairall LR et al., 2008).  Taken together, 
these results suggest that other studies of TB incidence estimates using Cox regression may 
have overestimated ART effectiveness. 
The most recent systematic review and meta-analysis of the effect of ART on TB incidence 
in a range of  0 to >350 cells/µl CD4 categories (Suthar AB et al., 2012b), reported an overall 
effect estimate of 65% hazard reduction (HR 0.35 CI: 0.28-0.44), which is higher than this 
study’s competing risk and Cox models’ effect estimates (36% and 53% respectively).  Other 
studies have also reported a greater impact of ART on TB incidence but differences in study 
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designs and statistical methods could partly explain the differences.  A single South African 
facility participating in a randomised controlled trial before ART was made publically 
available was used to estimated the effect of ART with a Poisson regression model, resulting 
in an adjusted rate ratio of 0.19 CI: 0.09-0.38 (Badri M et al., 2002).  Golub and co-workers 
(2007) reported on a multi facility study done in Brazil, which had a low overall TB 
incidence rate of 2.28 / 100 py and a TB incidence rate of 1.90 / 100 py for patients on ART.  
They reported an adjusted RH (relative hazard) of 0.41 (p<0.001) for patients receiving ART 
vs. no-ART, but stated that an underreporting of TB (due to death) could have biased their 
results.    Underreporting of TB can occur when patients appear to be lost to follow-up on an 
HIV treatment programme, while attending a TB treatment programme (and 
defaulted/transferred/died) and not being counted as a TB case when data from a 
non-integrated HIV setting is reported on. 
The present study provided original estimates of the effectiveness of ART in preventing TB 
in different strata, defined according to CD4 level at the start of follow up. It showed that 
ART effectiveness was similar and significant among patients with CD4<350 cells/µl at 
baseline, but had no significant effect among patients with CD4>350 cells/µl at baseline. 
Although the review by Suthar and colleagues suggested that ART was less effective with 
increasing baseline CD4 levels, this was not significantly different (Suthar AB et al., 2012b). 
In contrast, a recent cohort study by the HIV-Causal Collaboration (2012) from facilities in 
America and Europe, showed that ART was not effective in patients with baseline 
CD4<50 cells/µl at baseline, but was highly effective at higher levels, including 
CD4>350 cells/µl. 
The effect of ART on multiple TB episodes was estimated with a Poisson regression model 
and showed that ART was less effective in preventing multiple TB episodes (IRR 0.66, 
CI: 0.64-0.69) than in preventing the first episode, in the total population. However it was 
highly effective in preventing multiple episodes in patients with CD4<200 cells/µl 
(IRR 0.32-0.48).  The surprising finding that, in patients with CD4>200 cells/µl, the IRRs for 
ART were 1.39 and 4.34, suggest that these patients might have had indications for ART 
other than depressed CD4 counts, which were associated with higher TB risks. 
This study also showed that a history of TB significantly increased the hazard of TB; this is 
keeping with previous studies reporting the influence of previous TB (Golub JE et al., 2007, 
Moore D et al., 2007, Van Rie A et al., 2011, Nicholas S et al., 2011).  
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In summary, this study provides evidence that ART reduces TB infection in people with HIV.  
As people infected with TB are liable to infect others in the population, ART is therefore an 
important part of the overall TB control strategy in South Africa, directly of benefit to people 
with HIV. 
6.3. Effect of ART on mortality 
In this public health programme, with constrained resources, the hazard of death was halved 
for HIV positive patients receiving ART compared to those not receiving ART.  The survival 
benefit persisted for patients with very low CD4 cell counts.  Most patients had advanced 
immune-suppression, which is consistent with other studies done in Sub-Saharan Africa 
(Lawn SD et al., 2006; Moore D et al., 2007; Westreich D et al., 2009; Worodia W et al., 
2012).  The primary analysis used marginal structural models to optimise adjustment for 
time-varying as well as baseline values of CD4 cell count, weight, and cotrimoxazole 
prescription, using inverse probability of treatment weighting.  A comparison of weighted 
and un-weighted models that accounted for time varying covariates (Table 31) suggests that 
un-weighted models underestimated the effect of ART on death, that is, 37% hazard 
reduction with un-weighted model vs. 47% hazard reduction with MSM.  Although MSM 
and Cox models had similar results there was one slight discrepancy: with MSM the 
effectiveness of ART was not significantly different at different baseline CD4 levels, whereas 
with Cox models ART had no significant effect at CD4 levels above 200 cells/µl.  This 
discrepancy may be due to MSM being able to adjust for time-varying CD4 levels as well as 
for baseline CD4 levels. 
These results, which appropriately controlled for confounding, found ART to be much less 
effective in preventing deaths than did two studies from Thailand (Sanguangwongese N et al., 
2007; Akksilp S et al., 2007).  The Thailand studies used public health system surveillance 
data to compare survival between co-infected HIV-TB patients receiving ART or not.  After 
controlling for confounders (CD4, cotrimoxazole treatment, type and location of TB, type of 
facility), patients treated with ART had one sixth the hazard of death compared to TB patients 
not receiving ART (Sanguangwongese N et al., 2007; Akksilp S et al., 2007).  However, 
these studies’ patients were only followed for the duration of TB treatment and not thereafter 
like this study and 41% of patients had missing CD4 results (Akksilp S et al., 2007). 
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Another study from Thailand (Manosuthi W et al., 2006), which followed patients after TB 
treatment commenced, showed that the hazard of death in TB patients was 20 times higher 
for patients who did not receive ART than for patients who received ART.  Fifty percent of 
patients not receiving ART died within one year of TB diagnosis.  A major difference 
between that study and the study presented in this thesis was that their patients were 
categorised in either an ART group or no-ART group, whereas with this analyses follow-up 
time was divided into no-ART and ART follow-up, appropriately accounting for time at risk 
of death with or without ART.  Also, in the latter Thai study CD4 counts were missing for 
more than 50% of the patients and were therefore not adjusted for in primary analysis.  A 
secondary analysis limited to patients with available CD4 counts showed that CD4 was not 
identified as a risk factor for mortality, which is surprising (Manosuthi W et al., 2006).  
These Thai results are likely to be biased by systematic differences between patients who did 
and did not receive ART.  Other possible reasons for these different effect measures could 
also be due to differences in host susceptibility, pathogen virulence, or intensity of TB 
transmission (Sanguangwongese N et al., 2007). 
There is little other direct evidence of the effectiveness ART on mortality in HIV-TB patients. 
Most of the other studies reporting on associations between ART and mortality in co-infected 
patients, were randomised controlled trials investigating the optimal timing of ART initiation, 
that is, comparing mortality in co-infected patients starting ART either earlier or later during 
TB treatment (Abdool Karim SA et al., 2010; Velasco M et al., 2009).  Showing that 
initiating ART earlier in TB treatment reduced mortality, these trials provide the most 
rigorous evidence available that ART is effective.  However, they are unable to estimate the 
absolute effectiveness of ART compared to no ART. 
In the primary MSM of the effect of cotrimoxazole on mortality, it was surprising that 
cotrimoxazole appeared to have no effect at all.  However, in the MSMs in which the inverse 
probability of treatment weights were truncated, cotrimoxazole was weakly associated with  
reduced mortality (HRs 0.81 and 0.83).  The latter estimates are more likely to be correct, 
because MSMs are recognised as being at risk of bias by extremely large weights resulting 
from extremely low cumulative probabilities of treatment in a small number of observations, 
in which case truncated weights are recommended (Cole & Hernan, 2008).  In the Cox 
models, cotrimoxazole was associated with greater effects on mortality (HRs 0.56 - 0.65) 
than in the MSMs.  However, the Cox models of cotrimoxazole effectiveness did not account 
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for the precise date on which cotrimoxazole was started; they only accounted for whether a 
patient received cotrimoxazole at all when on ART or not on ART.  In contrast, all the 
analyses of ART effectiveness, and the MSM of cotrimoxazole effectiveness did account for 
the precise date on which cotrimoxazole started and so are more likely to be accurate. 
6.4. Effect of ART on TB treatment outcomes 
The third study was of 9 276 co-infected HIV-TB patients whose TB treatment outcomes 
were recorded in the provincial ETR, as required by the South African national TB 
programme and WHO.  In addition to death during treatment, the most important  treatment 
outcomes were “cure” (conversion from positive to negative sputum smear) and treatment 
completion.  As many HIV- infected TB patients are sputum negative at the start of TB 
treatment, and so thus cannot be “cured” as defined, the composite outcome of cure or 
completion – defined as “success” – is thus important.  In this HIV positive study population 
73.9% of patients had a successful treatment outcome, and 8.3% died during treatment.  
These results are similar to results from European cohorts (Faustini A et al., 2005; Falcon D 
et al., 2005), but mortality was lower than in two other studies from Taiwan and Italy, which 
reported death rates of 21.6% (Yen YF et al., 2012) and 14.6% (Girardi E et al., 2012) 
respectively.  For HIV-negative patients mortality for TB patients is usually in the order of 
3.6% (Mugusi FM et al., 2009).  Cohort and research setting differences are most probably 
the main reason for variations seen in TB outcomes, such as the proportion of intravenous 
drug users, migrants, elderly patients, which  differed between the cohorts. 
In this study logistic regression models were used to estimate the effect of ART on TB 
treatment outcomes while controlling for confounders.  Unlike the studies with time to TB 
and time to death as outcomes, these analyses did not account for how long it took to attain 
each outcome, but only which outcomes were recorded at the end of treatment, or whether 
death occurred within a year of starting TB treatment.  The study showed that ART was 
significantly and independently associated with lower odds of unfavourable outcomes (death, 
treatment failure, default) and higher odds of favourable outcomes (cure, completion and 
success).  This is in line with other studies which also reported that the use of ART was 
associated with a reduction in the risk of death (Girardi E et al., 2012; Kwan C et al., 2011; 
Boulle A et al., 2010). 
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Internationally there is limited evidence of the effect of ART on TB treatment outcomes other 
than death.  Studies by Yen and colleagues (2012) and by others (Obuku EA et al., 2012; 
Muniyande M et al., 2007) reported strong associations between unemployment and lower 
education levels with unfavourable TB treatment outcomes.  Although not recorded in our 
data, these factors could also be of importance and applicable to the Free State population 
which has an unemployment rate of 38.9% (South African Government information).   
Studies have shown that patients with better socioeconomic status are likely to receive 
additional diagnostic procedures and superior treatment (Younis MZ et al., 2005) as well as 
patients with a better education (Berisha M et al., 2009; Lu SH et al., 2009). 
In this study population only 20.5% of patients started ART during their TB treatment 
episode, that is, 5.0% during initiation phase (early ART) and 16.5% during continuation 
phase (late ART).  In these analyses, ART started after two months of TB treatment appeared 
to be more effective than ART started earlier, which is the opposite of what randomised trials 
have shown (Naidoo K et al., 2013; Velasco M et al., 2012).  The reason for this discrepancy 
in the present study could be because the comparison of patients who started ART early or 
late is subject to “immortal time bias” (Sterne JA et al., 2009; Levesque LE et al., 2010).  
That is, TB patients would only be able to start ART later if they had not already died earlier, 
and those who did not die earlier would tend to be healthier at the start TB treatment than 
those who died earlier.  The adjustment for baseline prognostic variables would have gone 
some way toward avoiding this bias, but would be unlikely to avoid it altogether.  
An important finding for this study population was the high mortality (7.4% of patients who 
died during the first year, 118 / 1 594) between completion of TB treatment and a year after 
TB treatment started, even in people who successfully complete TB treatment.  This is 
consistent with previously published studies but mainly in cohorts not receiving ART 
(Mugusi FM et al., 2009; Harries AD et al., 2001).  These deaths after successful TB 
completion could be caused by HIV-related causes other than TB.  The presence of TB in 
HIV positive patients is known to accelerate the progression of HIV disease due to an 
activation of the immune system, which subsequently enhances viral replication.  Patients 
with low CD4 counts and increased viral loads are more susceptible to opportunistic 
infections which may cause death (Freudenberg N et al., 2006; Mugusi FM et al., 2009; 
Geldmacher C et al., 2010).  High rates of transfer and movement elsewhere were seen for 
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this sub-population who died after treatment compared to the overall population, which 
suggests that they moved back to their home towns to be taken care of by family. 
In terms of other risk factors, this study’s results showed that advanced age (Farah MG et al., 
2005; Falzon D et al., 2005; Yen FE et al., 2010), history of TB, positive smears (Tessema B 
et al., 2009), lower weight and CD4 cell counts were risk factors for unfavourable outcomes 
of TB treatment.  Male sex was associated with unfavourable TB outcomes which confirmed 
the results of another report (Falzon D et al., 2005), but contradicts the results of other studies 
(Pablos-Mendez A et al., 1996; Silva DR et al., 2010). 
In summary, this study shows that receipt of ART during TB treatment greatly improves all 
treatment outcomes. 
6.5. Strengths and limitations of this research 
Compared with previous studies from dedicated non-government organisations and research- 
supported ART services in South Africa (Bekker LG et al., 2006; Coetzee D et al., 2004) and 
elsewhere (Tessema B et al., 2009; Lee JJ et al., 2009; Silva DR et al., 2010), this study 
investigated a large heterogeneous province-wide population of HIV positive and co-infected 
HIV-TB patients, representing diverse geographical and clinical settings and exposed to all 
inefficiencies of real-world healthcare services (Sanguanwongse N et al., 2007).  It is thus 
unusually representative of the impact of ART applied across a health system, making the 
research findings generalisable to a wide variety of settings (D’Agostino RB et al., 2007).  
The studies also showed variation in care in a national programme which is typically a 
function of when patients present themselves at clinics.  Ingle SM et al., reported in 2010b 
that facility-level characteristics rather than patient-level characteristics were associated with 
the odds of starting ART treatment across facilities in the Free State Province.    
Ideally, evidence of ART effectiveness would come from randomised controlled trials 
comparing ART with placebo.  However these would not be ethically possible because of the 
known effectiveness of ART, based on the long history of randomised trials comparing single 
ART drugs with placebo, dual ART with single ART and triple ART with dual ART, as well 
as clinical and public health experience of ART.  The fact that so many patients had to wait 
so long to initiate ART, while unfortunate, provided powerful comparative evidence of risks 
associated with not receiving ART. 
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The present studies aimed to make optimal use of all available data and to avoid the biases, 
which are a continual problem with observational studies of treatment effectiveness.  The 
main methodological problem is that people receiving ART tend to be systematically 
different from those not receiving ART, both because of the indications for initiating 
treatment and because of the effects of ART after treatment.  The fact that, for most patients, 
the most important prognostic factors were recorded at their time of registration with the HIV 
programme and periodically thereafter made it possible to adjust statistically for these 
differences. 
The relative completeness of personal identifiers such as first name, surname, address, sex, 
and DOB on both datasets supported a robust data linkage procedure between the two public 
sector programmes without a unique patient identifier in the majority of TB records.  The 
opportunity to combine patient information from five large scale databases (ART, TB, 
laboratory, hospital, death population register) made it possible to establish an integrated 
research platform to address several research questions about this cohort. 
The strict and standardised systems for ART and TB data collection helped in decreasing 
recording errors and information bias, as patient data was captured from clinical records and 
registers completed and kept on site by the ART and TB facilities.  Although underreporting 
of HIV information on the TB register, and of TB status information on the HIV programme 
was seen, the linked dataset provided a more accurate status of co-morbidity.  Also, due to 
the high percentage of available South African ID numbers for the HIV programme patients, 
active follow-up of survival through data linkage with the death population register was 
possible and helped to avoid survivor bias.   
Patients co-infected with TB were identified from both the HIV programme and provincial 
TB register to overcome non-reported TB episodes for HIV patients who defaulted from the 
HIV programme while attending a TB facility, or were not screened for TB during a HIV 
visit, or a visit form was not captured on the HIV system (missing information), or were not 
scheduled for a HIV visit during the time of TB due to a high CD4 cell count, which required 
less regular visits to the HIV programme. 
The studies of effect of ART on TB incidence, and on time to death in co-infected patients 
used relatively sophisticated cohort study designs, compared to most previous African studies, 
to optimally use data on person-time at risk and on time-varying treatment and prognostic 
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variables.  This made it possible to include the experience of the majority of patients before 
and after they started ART, as well as that of the minority of patients who never received 
ART or who were already receiving it at the time of enrolment with the HIV programme.  
The large sample sizes provided ample statistical power to adjust a wide range of prognostic 
variables and to provide precise effectiveness estimates. 
A key limitation of these studies, other than their observational design, was missing data 
about prognostic variables, especially CD4 counts. Between 13% and 50% CD4 counts were 
missing, depending on the time point for CD4 cell counts used for various analyses.  CD4 cell 
counts recorded close to enrolment were missing for about 13%-18% of patients, and CD4 
cell counts closest to the date when TB treatment was started were missing for 50% of 
patients.  Body weight was another important prognostic variable, which was missing for 
16%-22% of patients.  In order not to exclude them from the primary analyses, for patients 
who had one or more missing CD4 or weight measurements, multiple imputation of missing 
CD4 counts and weights was used.  It is reassuring that the sensitivity analyses, that is, 
complete case analyses excluding patients with any missing CD4 or weight data, showed very 
similar results to the primary analyses with imputed data. 
Also, according to national policy at the time, patients with CD4>200 should not have started 
ART unless they had stage 4 AIDS. As we did not have other information on whether 
patients had stage 4 AIDS, CD4>200 was thus simultaneously a good and a bad prognostic 
indicator. Therefore the estimated risks and modification of ART effectiveness associated 
with CD4>200 should be interpreted with caution.   
Another limitation was uncertainty about whether those patients assumed to be receiving 
ART were in fact receiving it.  In the absence of accurate information about treatment 
adherence or default, all analyses assumed that patients who received ART continued to do so 
throughout follow-up.  It is likely that some patients assumed to be receiving ART were no 
longer doing so. The same applies to estimates of cotrimoxazole effectiveness.  However, if 
misclassification was non-differential then the final outcome would be to underestimate 
ART’s effectiveness.  It is also likely that for some patients the dates of initiation of ART and 
cotrimoxazole and of TB diagnosis could have been inaccurately recorded, such errors could 
have biased effectiveness estimates in either direction, but without information about such 
errors it is difficult to predict the direction of bias. 
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The exact date of TB diagnosis was not available on either the ETR or HIV programme 
database therefore the assumption was made that diagnosis and treatment was on the same 
date. This would overestimate time to TB disease, but it would not bias ART effectiveness 
estimates unless the delay from TB disease to treatment was different in people on ART than 
in people not on ART.  If the delay was shorter in people on ART than in people not on ART, 
then ART effectiveness would be underestimated, and vice versa. 
Incomplete and incorrect entries in either of the registers (ART, TB or death) would have 
limited the generalisability of the results.  The completeness of the TB register has always 
been questioned (Van Hest  NAH et al., 2006; Melosini L et al., 2012) and there is potential 
for misclassification of patients as being TB free when there is no record of the patient in the 
ETR, which was shown when patients themselves reported to be on TB treatment at an ART 
programme visit but they could not be linked to a patient record on the ETR.  Also, the 
dataset had a small proportion of patients with CD4 cell counts above 350 cells/µl and the 
relevant outcomes (death, TB), which limits the ability to look at the effect of ART in less 
immuno-suppressed patient groups and could explain differences noted from North American 
and European cohorts on the benefits of ART in patients with high CD4 cell counts.   
The deterministic data matching process was complex and to improve data linkage accuracy 
the number of rules can increase dramatically.  This data linkage process could be difficult to 
reproduce on different datasets and each dataset might need different rules to suit the data 
depending on the format of the data variables.  This limits reproducibility but the process 
developed and described in this thesis sets a platform on how to develop rules to link datasets.  
Probabilistic matching is a more automated process but requires human input to calibrate 
matching rules and weights (probabilities) for each dataset, which is time consuming, needs 
sophisticated software and  computers with extensive processing power.  A sample run was 
done with a server in Bern, Switzerland and probabilistic General Record Linkage Software 
(GRLS) but due to the large datasets and limited computing power of the servers the linkage 
process was aborted. 
In summary, these studies made exceptionally thorough efforts to avoid confounding, 
selection biases and information biases, but it remains possible that unmeasured or hidden 
factors could have influenced treatment outcomes and thus biased the effectiveness estimates.  
However, these limitations do not change the main findings: ART was highly effective but 
not as effective as it could be. 
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6.6. Recommendations for policy and research 
This thesis suggests that ART is effective at preventing death in co-infected patients even 
when provided at scale within a province-wide resource-constrained setting, supporting the 
ongoing scale-up of treatment programmes.  These findings also support recent changes in 
ART treatment polices which recognise the risk imposed by co-infection, and recommend 
ART for those HIV-infected with TB irrespective of the CD4 count (Circular H116/2012 and 
H3/2013 for Western Cape).  There is not conclusive evidence that initiating ART in patients 
with a CD4 cell count above 350 cells/µl will benefit patients (Geffen N, 2011; Suthar AB et 
al., 2012b).  A study done by South African Centre for Epidemiological Modelling and 
Analysis (SACEMA) predicts that the best threshold for starting ART is 350 cells/µl not to 
increase the population  incidence of TB (Williams BG, 2013).    
Although the optimal timing of ART initiation in co-infected patients was beyond the scope 
of this thesis, findings are consistent with current recommendations to start ART early in co-
infected HIV-TB patients, especially in those who are severely immuno-compromised 
(Naido K et al., 2013; Circular H116/2012 and H3/2013  for Western Cape). 
Mortality in co-infected patients remains unacceptably high and this thesis and suggests that 
ART may be less effective at reducing deaths compared with other reports 
(Sanguangwongese N et al., 2007; Akksilp S et al., 2007; Manosuthi W et al., 2006).  
Furthermore, linking the ETR and national death population registers showed that a sizeable 
proportion of co-infected patients die within the six months immediately after they have 
completed TB treatment, many of them despite successful TB treatment outcomes.  Currently 
there is no consensus regarding the reasons for this high mortality.  Some studies have shown 
that TB was not an independent predictor of mortality in co-infected patients, which instead 
was explained by low baseline CD4 cell counts (Lawn SD et al., 2009; Escombe AR et al. 
2008; Zacharian R et al., 2006; Westreich D et al., 2009).  Research has also shown that TB 
activates the immune system which in turn leads to an increase in the replication of the HIV 
virus, placing the patient at risk of other opportunistic infections and death.  A recent analysis 
from the IeDEA collaboration in Southern Africa showed that TB confers increased risk for 
cryptococcal disease and pnemocystis pneumonia (Fenner L et al., 2013).  Further research is 
urgently needed to elucidate the reasons for this high mortality, so that strategies can be 
devised to tackle this problem.  In the interim, it is important that care of co-infected patients 
include adequate screening for other concurrent opportunistic infections.  One important 
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development in this regard has been the introduction of routine laboratory-based screening 
for cryptococcal disease in all patients with CD4 counts below 100 (Jarvis JN et al., 2012). 
The linkage of data from the ART and TB programmes showed that patients treated in the TB 
programme were not routinely enrolled in the ART programme, despite advanced levels of 
immuno-suppression and often with fatal consequences.  Some eight years into the rollout of 
ART in South Africa’s public sector, integration of these programmes at clinic level remains 
suboptimal, despite high levels of co-infection.  In part this can be attributed to the restriction 
of ART services to selected accredited sites, in contrast to the vastly more decentralised 
model adopted by the TB programme where almost every fixed primary care facility operates 
a TB service.  A study from Cape Town showed that patients attending an integrated service 
had a 60% greater chance of starting and reduced waiting times for ART initiation 
(Kerschberger B et al., 2012).  The integration agenda must be actively pursued to ensure that 
TB patients are actively screened for HIV, eligibility for ART assessed and treatment started 
without delay.  Hopefully this will become easier as South Africa works towards making 
ART available in all its primary care facilities (NDOH National Strategic Plan 2012-2016). 
Vulnerable populations identified from this thesis include men and older patients, in keeping 
with findings from other cohorts (Cornell M et al, 2012a; Cornell M et al, 2012b; Grieg J 
et al, 2012).  Special care and strategies need to be developed to target these patient groups to 
improve their care-seeking and retention in care. 
This thesis showed that ART substantially reduces the risk of TB in HIV-infected adults and 
should form a key part of strategies to control TB in high HIV burden settings, alongside 
WHO’s collaborative activities for HIV-TB co-infections (Intensified case-finding, Izoniazid 
preventative therapy, Infection control (WHO 2012). Unfortunately izoniazid prophylaxis 
was only rarely prescribed to patients in the Free State cohort, preventing any assessment of 
its effect on TB incidence.  Reports that IPT has now been rolled to out to 373 000 South 
Africans provides some reassurance that this effective intervention is finally being adopted on 
a large scale (WHO Global TB report, 2012).  But this thesis confirmed the work of others 
which shows that the risk of TB on ART remains higher than background rates (Lawn SD et 
al., 2010).  Research on the additive effects of ART/IPT and optimal duration of IPT for the 
prevention of TB is urgently needed and results from the two randomised trials currently 
underway in South Africa and Côte d’Ivoire are awaited (Gideon HP et al., 2009; Clinical 
trial ANRS 12136 TEMPRANO). 
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These results provide further justification for the strengthening and expansion of ART in 
South Africa.  However, they also show that in this province-wide programme, ART was not 
as effective as it could be, compared with the experience of ART in high income countries, 
and of smaller scale better resourced ART programmes in South Africa.  Within this province, 
the big differences in treatment outcomes between different districts and facilities show wide 
variations in the quality of care, raising the question of what the reasons are for those 
differences, and of how the worst performing districts and facilities should be helped to 
obtain the best possible outcomes.  Future research should be targeted at finding the reasons 
why the province- and country-wide public sector ART programmes in South Africa are not 
as effective as they could be, how they could be strengthened, and at evaluating the 
effectiveness and cost-effectiveness of new interventions aimed at improving ART delivery.  
Cohort, operational research and qualitative studies are needed to understand the reasons for 
effective and ineffective ART delivery, and randomised trials, quasi-experimental and cohort 
studies are needed to evaluate innovative ways of strengthening ART.  Efforts to link clinical, 
laboratory, mortality and health system data, as in this study, would greatly enhance the 
ability to carry out such studies, especially on such a large scale.  At the same time smaller 
studies in sentinel sites which are able to ensure complete high quality data are also needed.  
In summary, this thesis demonstrated substantial and durable clinical benefits for co-infected 
HIV-TB patients who were able to access public sector treatment interventions during a 7-
year period in the Free State Province.  It advanced our current understanding by 
demonstrating that ART in HIV positive and co-infected HIV-TB patients was strongly 
associated with better TB treatment outcomes, reducing the presence of TB and improving 
survival.  It is strongly recommended that health services should be integrated such that 
patients are diagnosed earlier with HIV/TB to prevent impairment of the immune system 
which leads to poorer outcomes and to implement co-morbidity screening for this vulnerable 
population. 
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Table 1: Multivariable regression model for the effect of ART and baseline covariates on cured TB 
outcome in patients who did not die during TB treatment. 
Reference category Explanatory variable OR P>|t| 95%  Confidence 
Interval 
Fezile Dabi District Lejweleputswa 0.85 0.226 0.66 1.10 
Motheo 0.50 0.000 0.39 0.64 
Thabo Mofutsanyane 0.99 0.953 0.79 1.25 
Xhariep 0.41 0.000 0.27 0.61 
Year when TB treatment 
was started:  
2006 
2004 1.00 0.980 0.81 1.22 
2005 1.14 0.110 0.97 1.33 
2007 0.74 0.003 0.61 0.90 
2008 0.80 0.013 0.66 0.95 
Women Men 0.96 0.524 0.86 1.08 
Age category:  
30-39 years 
<20 1.13 0.653 0.67 1.90 
20-29 0.99 0.896 0.87 1.13 
40-49 1.03 0.627 0.91 1.17 
>50 0.86 0.099 0.72 1.03 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 0.82 0.085 0.65 1.03 
CD4 25-49 0.88 0.232 0.72 1.08 
CD4 50-99 0.92 0.345 0.77 1.10 
CD4 200-349 1.04 0.719 0.84 1.28 
CD4 350-2000 1.18 0.129 0.95 1.46 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 
30 days of TB treatment 
1.28 0.002 1.10 1.50 
CD4 missing 1.37 0.000 1.16 1.61 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.00 0.000 0.00 0.01 
Both TB types 0.64 0.010 0.45 0.90 
Treatment case: 
 New case 
Retreatment case 0.66 0.000 0.58 0.75 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 
0.94 0.729 0.68 1.31 
Started ART between 
two months and end of 
TB treatment 
1.39 0.000 1.17 1.65 
No valid South African 
ID number 
Valid South African ID 
number 
1.09 0.153 0.97 1.23 
Death source: Deaths registered on TB register and HIV programme database 
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Table 2: Multivariable regression model for the effect of ART and baseline covariates on completed TB 
outcome in patients who did not die during TB treatment. 
Reference category Explanatory variable OR P>|t| 95%  Confidence 
Interval 
Fezile Dabi District Lejweleputswa 1.15 0.584 0.70 1.91 
Motheo 1.93 0.008 1.19 3.13 
Thabo Mofutsanyane 1.92 0.007 1.19 3.10 
Xhariep 1.76 0.031 1.05 2.94 
Year when TB treatment 
was started:  
2006  
2004 1.60 0.002 1.19 2.13 
2005 1.62 0.002 1.20 2.19 
2007 0.75 0.014 0.60 0.94 
2008 0.77 0.022 0.61 0.96 
Women Men 1.19 0.009 1.04 1.35 
Age category:  
30-39 years 
<20 0.74 0.437 0.35 1.57 
20-29 0.91 0.162 0.80 1.04 
40-49 0.96 0.690 0.80 1.16 
>50 1.09 0.493 0.86 1.38 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 0.82 0.262 0.57 1.17 
CD4 25-49 0.94 0.656 0.70 1.26 
CD4 50-99 0.99 0.963 0.77 1.29 
CD4 200-349 1.18 0.240 0.89 1.56 
CD4 350-2000 1.36 0.081 0.96 1.93 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 
30 days of TB treatment 
0.72 0.009 0.56 0.92 
CD4 missing 0.99 0.928 0.85 1.16 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 1.30 0.008 1.07 1.57 
Both TB types 1.27 0.198 0.88 1.84 
Smear results:  
Smear negative 
Smear positive 0.01 0.000 0.01 0.02 
No smear results 0.34 0.000 0.26 0.45 
Treatment case: 
New case 
Retreatment case 1.10 0.385 0.88 1.38 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 
1.56 0.004 1.15 2.10 
Started ART between 
two months and end of 
TB treatment 
2.74 0.000 2.24 3.34 
No valid South African 
ID number 
Valid South African ID 
number 
1.15 0.197 0.93 1.44 
Death source: Deaths registered on TB register and HIV programme database 
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Table 3: Multivariable regression model for the effect of ART and baseline covariates on successful TB 
outcome in patients who did not die during TB treatment. 
Reference category Explanatory variable OR P>|t| 95%  Confidence 
Interval 
Fezile Dabi District Lejweleputswa 1.38 0.100 0.94 2.02 
Motheo 1.71 0.007 1.16 2.52 
Thabo Mofutsanyane 2.31 0.000 1.56 3.41 
Xhariep 1.97 0.005 1.22 3.16 
Year when TB treatment 
was started:  
2006 
2004 1.30 0.065 0.98 1.72 
2005 1.49 0.001 1.17 1.90 
2007 0.76 0.006 0.62 0.92 
2008 0.88 0.222 0.72 1.08 
Women Men 0.94 0.419 0.82 1.09 
Age category:  
30-39 years 
<20 0.69 0.209 0.38 1.23 
20-29 0.88 0.039 0.78 0.99 
40-49 1.10 0.094 0.98 1.24 
>50 1.03 0.781 0.84 1.26 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 0.66 0.005 0.50 0.88 
CD4 25-49 0.81 0.089 0.64 1.03 
CD4 50-99 0.91 0.372 0.73 1.13 
CD4 200-349 1.16 0.309 0.87 1.53 
CD4 350-2000 1.34 0.057 0.99 1.82 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 
30 days of TB treatment 
0.79 0.072 0.61 1.02 
CD4 missing 1.03 0.805 0.82 1.30 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 1.24 0.020 1.03 1.49 
Both TB types 1.10 0.544 0.81 1.50 
Smear results:  
Smear negative 
Smear positive 1.03 0.752 0.88 1.20 
No smear results 0.35 0.000 0.27 0.46 
Treatment case: 
 New case 
Retreatment case 0.85 0.032 0.73 0.99 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 
1.59 0.006 1.14 2.21 
Started ART between 
two months and end of 
TB treatment 
3.86 0.000 2.89 5.14 
No valid South African 
ID number 
Valid South African ID 
number 
1.19 0.025 1.02 1.39 
Death source: Deaths registered on TB register and HIV programme database 
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Table 4: Multivariable regression model for the effect of ART and baseline covariates on failed TB 
outcome in patients who did not die during TB treatment. 
Reference category Explanatory variable OR P>|t| 95% Confidence 
Interval 
Fezile Dabi District Lejweleputswa 0.42 0.068 0.16 1.07 
Motheo 0.80 0.587 0.36 1.79 
Thabo Mofutsanyane 0.67 0.343 0.29 1.54 
Xhariep 0.65 0.337 0.27 1.57 
Year when TB treatment 
was started:  
2006 
2004 1.04 0.895 0.55 2.00 
2005 1.27 0.402 0.73 2.23 
2007 1.79 0.044 1.02 3.17 
2008 1.03 0.908 0.62 1.71 
Women Men 1.35 0.091 0.95 1.90 
Age category:  
30-39 years 
<20 1.17 0.847 0.25 5.52 
20-29 0.87 0.475 0.60 1.27 
40-49 0.78 0.278 0.49 1.22 
>50 1.04 0.891 0.56 1.95 
CD4 cell count closest to 
starting TB treatment:  
100-199 cells/µl 
CD4 0-24 1.66 0.269 0.67 4.10 
CD4 25-49 1.25 0.564 0.58 2.70 
CD4 50-99 1.27 0.501 0.63 2.59 
CD4 200-349 1.06 0.886 0.48 2.33 
CD4 350-2000 1.30 0.489 0.62 2.71 
CD4 test date during the 
period one year 
preceding TB diagnosis 
and 30 days there after 
CD4 test date after 
30 days of TB treatment 
1.40 0.395 0.64 3.06 
CD4 missing 1.28 0.221 0.86 1.92 
Anatomical classification 
of TB: Pulmonary 
Extra-pulmonary 0.26 0.047 0.07 0.98 
Both TB types 0.93 0.891 0.36 2.45 
Smear results:  
Smear negative 
Smear positive 3.80 0.003 1.56 9.26 
No smear results 0.88 0.794 0.33 2.35 
Treatment case: 
New case 
Retreatment case 1.48 0.134 0.89 2.46 
ART use:  
Did not receive ART 
during TB treatment 
episode 
Started ART during first 
two months of TB 
treatment 
0.89 0.819 0.32 2.46 
Started ART between 
two months and end of 
TB treatment 
0.65 0.156 0.36 1.18 
No valid South African 
ID number 
Valid South African ID 
number 
0.93 0.790 0.53 1.63 
Death source: Deaths registered on TB register and HIV programme database 
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APPENDIX B: 
HIV PROGRAMME CLINICAL VISIT FORMS 
